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ABSTRACT

[Background and Purpose] Nasopharyngeal carcinoma (NPC) is a serious health
problem in southern China. The continuing struggle to control tumor gives constant
impetus to efforts to refine the various available treatment modalities. It has been
widely recognized that only a well developed and disciplined quality assurance (QA)
program can achieve a high degree of accuracy and reliability in radiation treatment
of cancer patients. The main purpose of the present study is to introduce a new metal
oxide semiconductor field effect transistor (MOSFET) dosimetry system as a QA tool
for intensity modulated radiation therapy (IMRT) and high dose rate (HDR)
brachytherapy.

[Materials and Methods]

A comprehensive set of experiments has been

performed to characterize the performance of the new miniature MOSFET detector,
including the reproducibility, linearity, energy response, angular dependence, etc. The
feasibility and efficiency of this MOSFET detector in absolute dose rate
measurements for the HDR

192

Ir source and in accurate skin dose assessments for the

IMRT treatment are explored, respectively. The new MOSFET detectors are then used
in vivo to monitor the treatment delivery for both HDR intracavitary brachytherapy
and serial tomotherapy IMRT. The preliminary results of in vivo measurements are
presented.

[Results]

The MOSFET detector, with a 5 V gate bias, shows a good dose linearity

i

(R2=1), small angular effect (<2%) and flat energy response in high energy photon
and electron fields. It can provide dose accuracy within measurement uncertainty for
applied doses above 20 cGy and within ±1 mV for small doses less than 10 cGy.

The MOSFET dosimetry system, after proper calibration and correction, is
applied to verify the dosimetric accuracy of HDR brachytherapy treatment plan.
Results show the phantom verification method using MOSFET detectors is reliable
and also very sensitive to errors such as source position inaccuracies, data transfer
errors and source strength discrepancies.

The miniature MOSFET detector has a minimal but highly reproducible intrinsic
buildup of 7 mg/cm2 corresponding to the requirement of personal surface dose
equivalent Hp (0.07). Phantom measurements demonstrate that the MOSFET detector
agrees well with the Attix chamber and the EBT Gafchromic® film in terms of
surface and buildup region dose measurements, even for oblique incident beams. In
our anthropomorphic phantom investigation, an overestimation of up to 8.5% in
surface dose calculations has been found for a commercial treatment planning system
(TPS). Similar trend has also been observed through in vivo patient dosimetry during
IMRT treatments.

From 2007 till now, a total of 70 in vivo measurements in 11 NPC patients
receiving HDR intracavitary brachytherapy have been performed at Sun Yat-sen
University Cancer Center (SYSUCC), China using the new MOSFET dosimetry
system. Results indicate good agreement between theory and experiment. Less than
ii

±7% deviation from the planned dose is measured in all patients.

Another in vivo dosimetry practice with miniature MOSFET detectors has also
been conducted at SYSUCC for serial tomotherapy IMRT. The mean difference
between 48 MOSFET measured doses and their calculated values for 8 NPC patients
is 3.33%, ranging from -2.2% to 7.89%. More than 90% of the total measurements are
less than 5% deviation from the planned doses.

[Conclusions]

The miniature MOSFET detector, due to its small physical size, ease

of use and real time readout, provides a useful QA tool not only for routine in vivo
dosimetry, but also for more advanced techniques such as IMRT and HDR
brachytherapy. The dosimetry methods we presented here are universal and can also
be applied to other cancer treatments receiving radiotherapy.
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PREFACE

Nasopharyngeal carcinoma has always presented a challenge to the radiation
oncologist because of the complex shape of the target structures and the organs at risk
close by. Over the past several years, a large number of advanced techniques such as
IMRT and CT-based HDR brachytherapy have been introduced to help achieve a
better therapeutic ratio. To date, more than 6000 patients have been treated at
SYSUCC using either IMRT or HDR brachytherapy.

The rapid implementation of advanced techniques has placed stress on the quality
assurance issues, especially for large cancer centers. The current QA programs have
been questioned for not providing adequately or cost-effectively safeguards against
treatment delivery errors that have the potential to degrade the expected therapeutic
ratio or in extreme cases, to cause significant injury to the patient undergoing
radiotherapy. There is thus a high demand for a well developed and disciplined QA
protocol that can offer another line of security for radiation treatment of cancer
patients.

In late 2004, a research project was initiated under the bilateral collaboration
between Center for Medical Radiation Physics (CMRP), University of Wollongong
and SYSUCC, with efforts to develop an in vivo dosimetry method with MOSFET
detectors for routine QA of IMRT and HDR brachytherapy. At that time, the
MOSFET detector was relatively new in radiation therapy, and we hope we can share

v

our experience in MOSFET design and application through this work in order to
ensure the potential benefits of technological advances.

Chapter 1 of this thesis gives an introduction to the current status and challenges
relating to dosimetry and QA of IMRT and HDR brachytherapy, with special focus on
NPC. The main objectives of this project have been outlined.

Chapter 2 is a systematic review that is an extension of Chapter one. The theory
of the MOSFET detector, including the basic structure and working principle, has
been introduced. The MOSFET performance and several different MOSFET designs
currently available are reviewed. The potential applications of the MOSFET detector
in radiotherapy and radiation protection fields are also discussed.

Chapter 3 - Chapter 8 are the main experimental part of this thesis. As the in vivo
MOSFET dosimetry practice starts from the calibration procedure, Chapter 3 provides
a general guideline for calibration process. The reference ionization chambers used
and the related IAEA dosimetry protocols for external beam radiation therapy using
high energy photon and electron beams are briefly introduced in this chapter.

Chapter 4 presents a comprehensive investigation concerning the physical
performance of some commercial MOSFET detectors. The advantages and
disadvantages of these detectors are analyzed, from which the common technical
requirements are proposed for the new generation MOSFET design.

Through Chapter 5 to Chapter 8, a new miniature MOSFET detector designed
vi

utilizing a novel packaging technology has been introduced. The dosimetric
performance of this new detector, such as the reproducibility, linearity and angular
dependence, is characterized for HDR brachytherapy in Chapter 5. Following these
assessments, a practical dose verification method for CT-based HDR treatment
planning has been developed in this chapter.

The advantages of new packaging technology in detector design have been
evaluated in Chapter 6 to provide an accurate skin dosimeter for radiotherapy and
radiation protection purposes. The experience of in vivo skin dosimetry with these
MOSFET detectors in a pre-clinical study using the anthropomorphic phantom and in
clinical practice is also reported.

Chapter 7 and Chapter 8 explore the feasibility of real time in vivo dosimetry
using miniature MOSFET detectors as a safeguard against treatment delivery errors
for HDR intracavitary brachytherapy and serial tomotherapy IMRT, respectively. The
methodology and preliminary results of in vivo measurements are presented.

Chapter 9 gives a summary of this project. Future research to refine MOSFET
dosimetry and extend its applications is suggested at the end of this chapter.
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CHAPTER 1
Introduction: Current Status and Challenges

1.1.

Introduction
Radiation therapy has a long history as a treatment option for most kinds of

cancer. The primary objective of a radiotherapeutic procedure is to deliver the highest
possible dose to the cancer-bearing tissues while at the same time minimizing the
radiation exposure to the surrounding normal tissues, in particular, the organs at risk.
Driven by this goal, many advanced techniques have been put into use such as IMRT
and HDR brachytherapy.

However, the application of advanced techniques necessitates a high degree of
quality assurance for safe and effective radiation treatment of cancer patients. During
the past few years, a number of significant radiation therapy errors have been reported
(Peiffert et al 2007, Bogdanich 2010). It has been suggested that the errors could
result from the introduction of, and increasing dependence upon, advanced
technologies (Fraass et al 1998, Ibbott 2010). The publication of the American
Association of Medical Physicists in Medicine (AAPM) Report No.13 (1984) has
indicated that the possible sources of treatment error include tumor localization, lack
of patient immobilization, field placement, human errors in calibration, dose
calculation, daily patient setup, and equipment-related problems. Subsequent
publications (e.g. AAPM 1994, AAPM 1998, and AAPM 2003) present a series of
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comprehensive QA programs for radiation oncology practice in IMRT and HDR
brachytherapy.

There have been wide spread concern that current QA practices and protocols are
inadequate in keeping pace with the rapid implementation of new and advanced
radiotherapy techniques (Saw et al 2008). The International Commission on Radiation
Units and Measurements (ICRU) has recommended an overall accuracy of ±5% in the
delivery of absorbed dose (1976). This level of accuracy is by no means easy to attain
if considering all uncertainties involved in the dose delivery to the patient.

In vivo dosimetry is one notable method that can directly monitor the radiation
dose delivered to the patient during radiotherapy, thus providing insight into the
accuracy and precision of the treatment delivery, detection of systematic errors and
helps in the prevention of radiation accidents. A well-devised in vivo dosimetry
program may offer additional safeguards without significantly extending treatment
delivery time (AAPM 2005). A variety of dosimeters, including thermoluminescent
dosimeters (TLD), semiconductor diodes, and new detectors such as MOSFETs are
currently available for in vivo dosimetry.

The current status and challenges relating to dosimetry and QA of IMRT and
HDR brachytherapy are described in the sections below, with special focus on
nasopharyngeal carcinoma.
1.2.

Nasopharyngeal Carcinoma

1.2.1.

Basic concepts
2

Nasopharyngeal carcinoma is a poorly differentiated carcinoma that may appear
at any site in the upper respiratory tract, but most frequently, in the lateral wall of the
nasopharynx with a predilection for the fossa of Rosenmüller. The tumor may involve
the mucosa or grow predominantly in the submucosa, spreading by direct extension
into neighboring structures. Since the nasopharynx has a rich supply of lymphatics,
cervical lymph-node involvement occurs early in the disease. Also, it has been
confirmed that the incidence of distant metastases has no relationship to the stage of
the primary tumor but correlates strongly with cervical lymph-node involvement
(Clifford et al 2004).

NPC is a major threaten to human life in southern China. It may occur at any age,
with incidence rates as high as 25-50 per 100,000 annually (Clifton et al 2001).
Although the exact cause of NPC is unknown, genetic predisposition, environmental
factors, and Epstein-Barr virus (EBV) all have been associated with the pathogenesis
of this tumor (Clifford et al 2004).

1.2.2.

Radiotherapy management

Unlike other cancers of the head and neck region where surgery is preferred,
radiotherapy is the mainstay of treatment for NPC with chemotherapy used in
advanced cases (Clifford et al 2004). Radiotherapy is administered to the primary
tumor as well as involved lymph nodes and lymph nodes at risk of disease in the neck.
Usually radiation doses of 6500 to 7000 cGy are directed at the primary lesion and the
upper echelon lymph nodes. If clinically positive, lower cervical nodes are included in
3

the field. Also, prophylactic treatment of clinically negative lower cervical nodes with
5000 cGy may be considered. Because of the juxtaposition of the tumor volume to a
number of critical structures (i.e., optic nerve, chiasm, temporal lobe, brain stem,
spinal cord, etc), meticulous treatment planning is essential so that the dose to critical
structures dose not exceed organ tolerance.

1.2.3.

Treatment outcomes and survival

Historically, survival is good only for early-stage NPC patients who have both
early primary tumors (T1 and T2) and minimal neck disease (N0 and N1) (Clifton et
al 2001, Clifford et al 2004, Maalej et al 2007). Unfortunately, many patients present
with locally advanced disease. Even with the introduction of combined modality
therapy, control rates have remained approximately 62-73% and 44-50% for T3 and
T4 lesions, respectively (Vikram et al 1985, Perez et al 1992, Lee et al 1993). Failure
at the primary site has been the major pattern of treatment failure in NPC (Bedwinek
et al 1980, Lee et al 1993, Clifford et al 2004). Some dose escalation trials have
revealed that higher doses of radiation might improve therapeutic results, yet the
nasopharynx is surrounded by critical, dose-limiting normal tissues (Wolden et al
2006, Fiorino et al 2007). Obviously, any advances in radiotherapy technology that
may provide the potential to deliver higher radiation doses with increased precision
and safety will hold the promise of improved local control.
1.3.

Intensity Modulated Radiation Therapy

1.3.1.

Technical advances in treatment management
4

Conventionally, initial radiotherapy fields are often treated with two parallel
opposed lateral fields that encompass the nasopharynx and upper cervical nodes. The
lower cervical nodes are treated with an anterior field, which abuts the upper lateral
fields superiorly. Thereafter, the primary site receives a boost, delivering a dose
totaled up to 65-70 Gy. Because shielding of critical normal structures is necessary,
conventional techniques may be impossible to properly cover tumors that extend into
the retropharynx and clivus. This may lead to poor local control for those with locally
advanced NPC (Wolden et al 2001).

Three-dimensional (3D) conformal radiotherapy techniques can be used to spare
more critical structures next to the nasopharynx. However, Wolden and his associates
(2001) stated that 3D conformal boost did not show improvement in local control
rates compared to conventional methods. Because of a lack of major benefit with
conventional 3D treatment planning used only during the boost phase of treatment for
NPC, they proposed to use intensity modulated radiation therapy (IMRT) to deliver
the entire course of radiation (Wolden et al 2006).

IMRT has recently gained popularity in the treatment of NPC. As a state of the
art technique, IMRT can use multiple non-uniform beams whose fluence profiles are
modulated in two dimensions so as to achieve a uniform high dose region that closely
conforms to the tumor target in three dimensions while sparing the surrounding
normal tissues, especially the organs at risk. In contrast to the experience-based,
trial-and-error approach common to conventional treatment planning, IMRT is
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inherently related to the inverse method of treatment design. These advantages have
made IMRT the most efficient technology in the following cases (Nutting et al 2000,
Galvin 2003):
(1) Tumor in sites with complex anatomy;
(2) Irregular shaped tumors;
(3) Tumors adjacent to radiation sensitive normal structures;
(4) Small volume or high dose treatments.

Clearly, the nasopharynx is one of the sites where IMRT can play a major role in
improving the therapeutic ratio.

1.3.2.

Clinical applications of IMRT

Xia et al (2000) compared IMRT treatment plans with conventional treatment
plans for a case of locally advanced NPC and concluded that IMRT could provide
improved tumor target coverage with significantly better sparing of sensitive normal
tissue structures. The quantitative superiority of IMRT over traditional conformal
techniques has now been widely substantiated (Wolden et al 2001, Lu et al 2004,
Wolden et al 2006).

In comparison with the primary NPC, local recurrent NPC that has received
previous full-dose radiotherapy presents a great challenge to subsequent treatment
options since additional radiotherapy, especially with conventional techniques, could
cause significant undesirable complications and side effects. Lu et al (2004) explored
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the feasibility of IMRT as a re-treatment option for recurrent NPC after initial
radiotherapy failed. Their results demonstrated that IMRT was able to offer a safe
treatment option for recurrent NPC, with acceptable radiation-induced toxicity and
encouraging tumor control.

In a brief, IMRT is ideal for NPC treatment since it can potentially improve
local-regional control, reduce side effects and improve quality of life.

1.3.3.

Dosimetric accuracy of treatment delivery

In recent years, the rapid development of IMRT technology has significantly
changed the traditional way in which radiation therapy is planned and delivered. The
hardware and software become so complex that the successful delivery of IMRT
requires a reliance on a series of factors that are unprecedented in radiation therapy
(e.g. the treatment planning system software, its data and algorithms, the information
transfer process, and the linear accelerator calibration and operation). Errors anywhere
in the process may lead to catastrophic mistakes (AAPM 2003, Low et al 2005).
Keeping in mind that the improvement of tumor control is attributed not only to the
administration of higher radiation doses, but also to improvements in technical
accuracy, careful implementation of QA protocols is essential for IMRT to ensure that
it can perform to its full potential.

Unfortunately, an accurate, thorough evaluation of the IMRT dose distribution is
currently not possible due to the limitation of the available technology (Van Esch et al
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2002, Low et al 2005). The direct phantom measurement is the only widely adopted
method for checking the delivered dose distribution against the results of the
treatment planning system (TPS). Typically, this dosimetric process involves the
registration of the computed tomography (CT) images for the phantom used and then
the creation of a special “hybrid phantom plan” using the treatment delivery
parameters that are selected for the patient plan. The phantom is subsequently
irradiated and the measured dose is compared with the calculated dose distribution.
Such a measurement can mirror treatment errors that might otherwise go unnoticed
and facilitate the improvement of precision and safety for IMRT treatment.

1.3.4.

Methodology of IMRT phantom verification

In current practice, ionization chamber is still the most reliable tool commonly
used for absolute absorbed dose verification in the phantom. However, due to a finite
size of the chamber’s active volume, the ionization chamber-based point dose
measurement needs to be considered as a volume-averaging value. Moreover,
Bouchard et al (2004) has pointed out that despite the fact that clinical efforts are
always made to locate the ionization chamber in a relatively homogeneous
accumulated IMRT field, residual fluence perturbation effects on the chamber
resulting from lateral electronic disequilibrium of small IMRT beamlets should not be
neglected. For these reasons, there is an intuitive tendency to selecting small-volume
ionization chamber for IMRT dose verification. This, on the other hand, will provoke
other unwanted effects such as leakage or significant polarity effects, especially in
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penumbra areas (Bouchard et al 2004). Therefore, the selection of a suitable
ionization chamber for IMRT QA is crucial. In general, ionization chamber with an
active volume of about 0.1 cm3 is a good compromise and is often recommended for
IMRT dose measurement (Low et al 2005).

Opposite to the ionization chamber that can provide only one data point for each
irradiation, radiographic film is de facto an ideal dosimeter to validate the planar dose
distribution (Zhu et al 2002, Childress et al 2002, Ju et al 2002). Nevertheless, there
has been some debate as to the accuracy of radiographic film owing to its
overresponse to low energy photons because of the non-tissue equivalent ingredient of
silver atoms in the emulsion (Ju et al 2002, Yeo et al 2004). A “filtration method” has
thus been introduced to prevent the scattered low-energy photons from reaching the
film and causing overresponse (Yeo et al 2004). While Yeo et al (2004) has stated
that the use of filters of a uniform thickness works well for various x-ray energies, the
optimal filter thickness, in theory, is variable over depth, field size, energy, and
orientation of filter relative to film. Consequently, it is worthwhile to further
investigate the applicability of filtration method to different conditions.

Recently a new type of film, namely radiochromic film, is also available in
radiotherapy dosimetry. The characteristics of this film have been widely reported in
the literature (Chiu-Tsao et al 2004, Chiu-Tsao et al 2005, Dini et al 2005). It is
recognized that dosimetry with radiochromic films has a few advantages over
traditional radiographic films, such as elimination of the need for film possessing,
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near tissue equivalence for higher energy (>100 keV) photons and electrons, and
insensitivity to ambient conditions. Some of the disadvantages of using radiochromic
films are:
(1) Radiochromic films are generally less sensitive than silver based films;
(2) Dose response often exhibits non-linear characteristics at higher doses;
(3) Radiochromic films require several hours to self-develop after irradiation to be
sufficiently stabilized for evaluation.

1.3.5.

Main limitations and future work

Even with immediate attention to those dosimetric challenges, the use of phantom
plan irradiation has some significant drawbacks (Low et al 2005):
(1) The locations of critical structures are not typically identified on the phantom
plan, leading to the difficulty in interpreting dose errors with respect to anatomic
location;
(2) Although phantom measurement can use the same irradiated fluence as in
treatment, the dose distribution is not the same as in the patient owing to the
difference between the patient and phantom geometries.

Therefore, in addition to the standard clinical procedure of initial dose delivery
testing via point measurements and filmed dose distributions, in vivo dosimetry has
been recommended by WHO publication (1988) as a useful method to verify the
radiation dose delivered during treatments. Unfortunately, current dosimeters
available for in vivo dosimetry such as thermoluminescent dosimetry (TLD) and
10

silicon diodes all have their drawbacks (Kron et al 1996, Wilkins et al 1997, ESTRO
2001) and can not fully satisfy the increasing clinical demands. As a result, there is an
urgent need for introduction of new dosimeters that can offer sufficient accuracy for
in vivo measurement.
1.4.

High Dose Rate Brachytherapy

1.4.1.

General aspects

The word “Brachytherapy” is derived from the Greek word "brachios" meaning
short and refers to a form of treatment whereby sealed radioactive sources are placed
within or close to tumor tissues. According to the dose rate, brachytherapy can be
characterized as follows (AAPM 1997, Meertens et al 2002):
(1) Low dose rate (LDR) brachytherapy: 0.4-2 Gy/h;
(2) Medium dose rate (MDR) brachytherapy: 2-12 Gy/h;
(3) High dose rate (HDR) brachytherapy: >12 Gy/h.

Among them, HDR is a technically advanced form of brachytherapy. Modern
HDR unit is usually equipped with a single, tiny, highly radioactive source of 192Ir that
can be delivered with millimeter precision under computer guidance to each
prescribed “dwell” position. The radiation dose distribution is determined by the
dwell positions the source stops at and the length of time it dwells there. The ability to
vary the dwell times, likely to have an unlimited choice of source strengths, is
possible only with HDR. Hence, HDR brachytherapy can provide greater degrees of
freedom to produce a dose distribution that best conforms to the clinical goals.
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1.4.2.

The advantages of HDR brachytherapy

In short, the basic radiation oncology principle is to deliver the highest possible
dose to the cancer-bearing tissues while keeping the dose delivered to the surrounding
normal tissues as low as possible, so as to achieve the best therapeutic ratio. This
principle helps better understand the advantages of HDR brachytherapy as part of
multi-modality approach to cancer management.

The main advantages of HDR brachytherapy include (Thomadsen et al 1997,
AAPM 1998, IAEA 2001):
(1) HDR brachytherapy can deliver a highly localized radiation dose to a small tumor
volume by introducing the radioactive source into “the heart of the tumor”.
Meanwhile, the rapid fall-off of radiation dose can effectively spare more of the
normal tissues. This offers an alternative method for dose escalation trials to improve
local tumor control.
(2) The dose distribution of HDR brachytherapy can be manipulated by selecting
appropriate source dwell positions as well as source dwell times, allowing better
optimization of the isodose distributions to the shape of the treatment volume. In a
sense, HDR brachytherapy may be regarded as the ultimate form of conformal
radiotherapy.
(3) In IMRT delivery, the internal organ motion may present a great challenge due to
the fact that it may cause insufficient dose coverage of tumor target. To avoid missing
target, additional margin needs to be considered, which may somewhat counteract the
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otherwise highly conformal dose distributions. However, the chances of geographical
miss due to patient movement in HDR brachytherapy are reduced, since the
radioactive source is located within the tumor tissues.
(4) The overall duration of HDR brachytherapy is usually short, compared with
external beam radiotherapy. This allows for treatment to be delivered in the outpatient
setting, which may reduce the costs and is also more convenient for the patients.
(5) The introduction of HDR brachytherapy with remote afterloading techniques has
eliminated the exposure risks to staff, providing better radiation protection for all
health care workers.

Based on these advantages, HDR brachytherapy alone, or in conjunction with
external beam radiotherapy, has been currently used in the treatment of primary and
recurrent NPC. The clinical outcomes have been well documented (Chang et al 1996,
Slevin et al 1997, Syed et al 2000).

1.4.3.

Safe delivery of HDR treatment

Offsetting these merits, misadministration of HDR units is subject to serious
accidents. Users should keep in mind that HDR carries with it the potential for serious
errors. This is mainly due to its unforgiving nature that HDR brachytherapy combines
many complex elements in a procedure often carried out quickly and with little
opportunity for correction (AAPM 1998).

1.4.3.1. Technical difficulty due to relatively complicated treatment system

13

To ensure that the stepping source can be driven to the designated dwell positions,
stopping for the correct dwell times requires a series of safety interlocks. This makes
the HDR units more complicated and difficult to operate. Also, the implementation of
HDR brachytherapy with advanced TPS increases the need for accurate dosimetric,
anatomic and geometric information. Understanding the whole processes behind these
actions and functions thus becomes increasingly difficult.

1.4.3.2. Compressed time frame for a large fraction dose

Usually, the whole HDR treatment proceeds very quickly. This makes it
extremely difficult for users to verify each treatment in such a short time. Potential
errors in the treatment plan or treatment unit operation overlooked by quality reviews
likely will be executed before detection. Since HDR brachytherapy can deliver a large
dose in a single fraction, any mistakes may lead to serious complications.

Obviously, HDR brachytherapy, from the physical and dosimetric point of view,
requires a much stricter QA protocol over teletherapy. Only a well developed and
disciplined QA program stands between a safe practice and disaster.

1.4.4.

Quality assurance issues

Many authors contribute to the quality management for HDR brachytherapy (),
and the AAPM TG No.59 report (AAPM 1998) addresses this issue in detail.
However, most of these efforts are either focused on the mechanical checks, or
concentrated on the treatment procedure supervision, likely to reduce the potential for
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machine malfunctions and human errors. Little dosimetric practice has been
emphasized, especially for the treatment plan. Hence, new questions arise:

(1) Even though current treatment planning in HDR brachytherapy can calculate
radiation dose distribution in three dimensions, it is rather primitive compared with
teletherapy. For example, no inhomogeneity correction for the patient’s tissues is
taken into account in brachytherapy treatment plans. This may take a risk of
significant underdosage to breast tumors, owing to the lack of scattering medium, the
attenuation by the contrast medium and the low density of lung (Ye et al 2004).
Similar dose errors should also occur in NPC treatments because the anatomical
location of nasopharynx is surrounded by air cavity and bone structure. Therefore a
major concern is whether dosimetry surveys should be included in the system
commissioning to indicate such intrinsic system limitations.

(2) Taking full advantage of stepping source remote afterloading technology that
allows the treatment time at each active dwell position to be independently
programmed, current treatment planning in HDR brachytherapy possesses powerful
engine for dose calculation and optimization. In general, such greater degrees of
freedom in optimization of radiation dose distribution helps achieve better clinical
outcomes. However, this flexibility creates a number of quality assurance problems
(AAPM 1998). As a result, a frequently asked question is how to verify the dosimetric
accuracy of computerized treatment planning prior to the HDR treatment.

(3) With the technical advances, the hardware and software of HDR brachytherapy
15

become increasingly complex so that understanding the detailed workings of these
systems and their potential limitations becomes more difficult. This may cause an
environment that treatment errors are prone to occur. It has been pointed out that
mistakes can happen even though all the QA checks recommended to be routinely
performed are carried out as they were intended (Alecu et al 1997, Alecu et al 1999).
Hence an important issue is how to develop a method that can monitor the HDR
delivery during treatment so as to be the last line of defense against erroneous
treatment.

Obviously, dosimetric practice is a good solution for preceding questions. Several
studies have demonstrated in vivo dosimetry helps increase the opportunity of
detecting and correcting treatment errors, thus improving the quality assurance and
patient safety (Brezovich et al 2000, Ricke et al 2005, Das et al 2007).

1.4.5.

Technical difficulties in dose measurements

Nevertheless, dose measurements in the vicinity of the HDR

192

Ir source are

usually problematic, mainly due to the facts that:

1.4.5.1. Energy dependence

The

192

Ir brachytherapy source has a very complex spectrum. It contains

approximately 24 photon lines with energies ranging from 9 to over 1000 keV. Two
strong L x-ray lines (9.00 and 9.44 keV) which are almost completely attenuated by
the source encapsulation are removed, resulting in an air kerma weighted average
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energy of 397 keV (Stump et al 2002, Baltas et al 2007). In this energy range, most
dosimeters designed for high energy photons & electrons present obvious energy
dependence.

1.4.5.2. The extremely steep dose gradient near the source

Basically, the absorbed dose to tissue varies as a function of the distance to the
192

Ir source following the inverse square law from 1 cm to the first 5 cm, where the

scatter mostly compensates for the absorption. This yields an extremely steep dose
gradient near the source (Baltas et al 2007). Thus, small uncertainties in experiment
setup will be significantly amplified, leading to unacceptable errors in dose
measurements close to the source. Also the rapid falloff of radiation dose across the
detector volume results in a non-uniform electron distribution, which makes precise
dosimetry a great challenge.

Addressing the above mentioned issues, future work should endeavor to explore
suitable in vivo dosimeters and dosimetric methodologies for measurement in the
vicinity of the

192

Ir source so as to provide direct proof for evaluation and

optimization of treatment plans.

1.5.

In Vivo Dosimetry

1.5.1.

The application of in vivo dosimetry
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The rapid development of advanced treatment techniques places higher demands
on the independent verification of the dose delivered to the patient. As mentioned
everywhere, in vivo dosimetry is an essential element in the QA program used in
today’s radiotherapy department. The following are the main applications of in vivo
dosimetry (WHO 1998):
(1) Verification of particular technique that is first used in clinic. It is advisable to
measure and document the doses actually received by the first few patients to be
treated, even having taken precautions from phantom measurements;
(2) Verification of prescribed dose to individual patients, especially for the cases
where the treatment planning system is less accurate such as in total body irradiation
(TBI) and in the build-up region;
(3) Verification that the dose to a shielded structure is acceptably low. For example,
monitor the eye dose during a treatment of a tumor in the head and neck region. Many
radiotherapy departments have routinely implemented such measurements.

To date, the usefulness of in vivo dosimetry as a standard QA method has been
generally recognized. Some in vivo dosimetry systems are now commercially
available. However, these systems are not mature enough and users should handle
them with caution. For accurate in vivo dosimetry, the physical characteristics of each
system should be well understood so as to utilize them properly and efficiently.

1.5.2.

Current in vivo dosimetric practice

The methods most commonly used for in vivo dosimetry are thermoluminescent
18

dosimetry and the use of semiconductor diodes.

1.5.2.1. TLD dosimetry

TLD is a relatively old dosimetric technique that was first used some 100 years
ago (Kron 1995). One of the most important features for TLD is its flexibility due to a
whole variety of TLD materials and physical forms available. Today, TLD is widely
used for in vivo dose measurements in total skin irradiation (Weaver et al 1995), total
body irradiation (Palkosková et al 2002), brachytherapy (Brezovich et al 2000), and
verification of dose delivery (Banjade et al 2003).

In a pilot study, Brezovich et al (2000) investigated the feasibility of using TLD
measurements in urethra to estimate the discrepancy in HDR treatments for prostate
cancer. They developed an array of liF TLD rods with small dimensions that was able
to be inserted into the urethral (Foley) catheter during the treatment. The measured
doses were then compared to the treatment plan. Their preliminary result
demonstrates that such a method is capable of detecting errors of major clinical
significance.

However, the use of TLD for clinical dose evaluation has several limitations:
(1) TLD does not allow an immediate response due to its characteristics of integral
dosimetry.
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(2) The use of TLD is time consuming. Obtaining moderate accuracy (5%) of dose
determination with the routine use of TLD is quite tedious because of the complicated
annealing, handling, and calibration procedures.

1.5.2.2. Semiconductor dosimetry

Semiconductor diodes play an important role for in vivo dosimetry, due to their
advantages of high sensitivity, good spatial resolution, real time readout and simple
instrumentation.

In one study, Alecu et al (1999) introduced an energy compensated silicon diode
for an in vivo dosimetry program designed both for measuring the rectal dose and for
avoiding misadministration in gynecological intracavitary implants. They calculated
the value for the “20% reading” (i.e. the dose delivered to the diode by the initial 20%
of the total dwell time), and use it as a safety interlock. If the 20% readings are
outside an established tolerance range, the treatment is stopped and rechecked. They
concluded that the in vivo measurement of the dose actually delivered to rectal points
during one treatment fraction enables one to adjust the treatment parameters for the
following fractions accordingly.

In another study, in vivo dosimetry with p-type diodes was used for routine QA in
IMRT (Higgins et al 2003). They required that every accessible field, both static and
dynamic, be verified with a diode measurement on the central axis or at a specified
point within the first two treatment days. Although the uncertainties in the diode
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measurements were relatively large (±10%), they stated that the potential problems
for IMRT treatment would remain unknown without such real in vivo measurements
of IMRT fields that were used to treat the patients. By using such direct in vivo
method to verify the clinical dose delivered, they have instituted a uniform startup
procedure for all patients while simplifying their IMRT QA process.

While diode semiconductors are preferred for in vivo dosimetry in many cases,
one would be aware of a number of limitations concerning their use (AAPM 2005):
(1) The diode signal depends on the photon energy, due to the relatively higher
atomic number of silicon (Z=14) compared to soft tissue (Z≈7).
(2) The diode signal is dose rate dependent. This may be particularly of concern in
pulsed radiation beams generated by linear accelerators.
(3) The diode signal is influenced by temperature, in particular for in vivo dosimetry
where the diodes are in contact with the patient and not in temperature equilibrium.
(4) The diode is subject to radiation damage. This represents the main limitation of
silicon diodes.

In conclusion, current dosimetric techniques are not fully competent for in vivo
dosimetry. This gives constant impetus to efforts to develop new dosimetric
methodologies for in vivo measurement.

1.5.2.3. Metal oxide semiconductor field effect transistor
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Recently, a new development of dosimetric techniques is the introduction of
MOSFET detectors for use in radiotherapy. The basic principle of the MOSFET
detector is that the radiation-induced threshold voltage shift, which is proportional to
the absorbed radiation dose, can be measured under constant current conditions. A
detailed review on MOSFET dosimetry will be presented later in this work.

The main advantages of MOSFET detectors are their extremely small physical
size, instant readout and permanent storage of total dose after irradiation. These
provide a potentially useful tool for in vivo dosimetry. Several studys have revealed
the feasibility of MOSFET detectors for use in external beam radiotherapy, such as
IMRT (Chuang et al 2002), image guide radiotherapy (Rowbottom et al 2004), and
total body irradiation (Scalchi et al 1998, Best et al 2005). The potential use of
MOSFET detectors in HDR brachytherapy are also under investigation (Zilio et al
2006, Kinhikar et al 2006).

Currently, there are some different types of MOSFET dosimetry systems
commercially available, including the real time “clinical semiconductor dosimetry
system” (CSDS) developed at the Center for Medical Radiation Physics (CMRP),
University of Wollongong. The developed system, including newly designed
MOSFET detectors and microprocessor based reader, is capable of reading ten
MOSFETs sequentially online in a short time. The results are sent directly to
computer via a RS232 link, and the control software and internal microprocessor
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corrects for any drift of the MOSFET threshold voltage due to slow border state
induced by radiation or thermal effects (Rosenfeld et al 2001).

For accurate in vivo dosimetry, the features of each MOSFET detector should be
well understood so as to utilize them properly and efficiently. At present, most
experiments with MOSFET detectors are limited to the phantom study. There are no
guidelines to assist clinical physicists in performing reliable in vivo dose verification
using MOSFETs. Clearly, it is high time to systematically investigate the physical and
clinical characteristics of the MOSFET detector, and this task runs through all this
work.
1.6.

Brief Summary
NPC has a very high incidence rates in China, and Canton is the most affected

area. This permits an in-depth study for NPC.

Currently, radiation therapy is still the mainstay of treatment for NPC. One of the
major tasks for modern radiotherapy is to improve the accuracy of daily radiation
treatment. Many groups now dedicate to this task, including the Center for Medical
Radiation Physics, University of Wollongong. Herein we present a new MOSFET
dosimetry system that has a good potential for advanced dosimetry in high energy
photon & electron fields as well as in medium energy gamma ray (i.e.
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Ir source)

fields. The main purpose of this work is:
(1) To fully investigate the physical performance of MOSFET detectors
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(2) To explore the feasibility and efficiency of MOSFET detectors in routine QA of
IMRT
(3) To extend the use of MOSFET detectors in HDR brachytherapy, providing a
useful tool for dosimetric verification of HDR treatments
(4) To establish practical guidelines for the implementation of MOSFET dosimetry
in radiotherapy
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CHAPTER 2
MOSFET Dosimetry：Literature Review

2.1.

Introduction
The MOSFET detector was originally designed to monitor the effects of radiation

on equipment flown in space. It was first initiated by Dr. Andrew Holmes-Sieldle in
1978, when a radiation-sensitive field effect transistor (RADFET) was applied in the
satellite Geos-II (Holmes-Siedle 1994). Since then MOSFET dosimetry was widely
used in space technology, contributing to our understanding of the space radiation
environment. Dr. Andrew Holmes-Sieldle was later received The 2001 Radiation
Effects Awards, Nuclear & Plasma Sciences Society (NPCC) for his leading role in the
field of radiation dosimetry.
While the MOSFET detector has a long history of application in space dosimetry,
it is relatively new in clinical radiotherapy. The literature herein aims to outline the
recent achievements of MOSFET dosimetry in modern radiotherapy. The theory of the
MOSFET detector, including the basic structure and working principle, was firstly
reviewed. The MOSFET performance and several different MOSFET designs
currently available were then introduced. The potential use of MOSFET detectors in
radiotherapy applications was further discussed.

2.2.

The Basic Principle

2.2.1.

The MOSFET structure

A typical MOSFET consists of a source (S), a drain (D), a metal gate (G) and a
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semiconductor substrate (SB). The portion of the semiconductor immediately under
the gate connecting the source and the drain is called the channel region. Depending
on the type of charge carriers conducting the channel current, the MOSFET can be
classified as either a p-channel (hole conduction) or an n-channel (electron conduction)
device (Crawford 1967, Soubra et al 1994).
Take a p-channel MOSFET as an example (see Figure 2.1). The p-channel
MOSFET is built on a negatively doped (n type) silicon substrate. Two terminals of
the source and the drain are situated on top of a positively doped (p type) silicon
region. The third terminal of the metal (or poly-crystalline) gate covers the region
between the source and the drain, but is separated from the n type substrate by an
insulating silicon dioxide layer.

Figure 2.1 Schematic diagram of a typical p-type MOSFET.

When the gate voltage (VG) is set to zero, the source-drain current is limited by
only a minimal amount of reverse saturation current from the two back-to-back p-n
junctions. The device is therefore in its “off” state. When a small negative VG is
applied to the gate, the majority carriers (electrons in this case) in the channel
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underneath the gate oxide will be depleted, due to the electric field from the negative
gate charge. This depletion region acts as an insulator, and the generated source-drain
current is negligible. When a sufficiently large negative VG is applied to the gate,
however, a significant number of minority carriers (holes in this case) will be attracted
to the oxide-silicon interface from both the bulk of the silicon substrate and the source
and the drain regions. Once a sufficient concentration of holes has accumulated there,
a conduction channel is formed, allowing an appreciable amount of current to flow
between the source and the drain (Ids). The device is now in its “on” state. Herein, the
minimum gate voltage required to initiate the appreciable current flow (Ids) is defined
as the device threshold voltage (VTH).
The structure of an n-channel MOSFET is similar, except for a change in the
voltage polarity and in the sign of the charge carriers.

2.2.2. The principle operation of MOSFET detector
The principle operation of MOSFET dosimetry is based on the generation of
electron-hole pairs in the silicon dioxide (SiO2) due to the incident ionizing radiation.
In general, the energy required to produce an electron-hole pair in SiO2 is about 18 eV
(Rosenfeld 2002).
When the radiation impinges on the MOSFET detector, it knocks the negative
electrons out of the atoms in the SiO2 layer leaving behind positively charged holes.
The generated electrons, whose mobility in SiO2 at room temperature is about 4
orders of magnitude greater than holes, quickly move toward the gate electrode. The
holes that escape initial recombination, on the other hand, are relatively immobile and
remain behind, near their point of generation (Crawford 1967, Soubra et al 1994).
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Over a period of about 1 second at room temperature, the holes undergo a
stochastic hopping transport in the direction of the Si-SiO2 interface where they are
arrested in the long-term trapping sites within the oxide, causing a positive charge
buildup (QT). This residual positive charge QT will effectively change the current in
the channel as it is physically located very close to the channel. Accordingly, to ensure
a given constant current flow through the channel necessitates a corresponding
negative shift in the threshold voltage (ΔVTH) at the gate (see Figure 2.2).

Figure 2.2 The threshold voltage shift before and after the irradiation.

The threshold voltage shift ΔVTH, in theory, is proportional to the total quantity of
trapped charges which is proportional to the radiation dose deposited in the oxide
layer. In practice, this threshold voltage shift ΔVTH is most commonly determined by
maintaining a constant current (e.g. 50 μA) between the source and the drain, and
measuring the required gate bias before and after exposure (Metcalfe et al 1997).
When electron-hole pairs are generated within the SiO2, some fraction of
electrons and holes will recombine depending on the applied field and the energy and
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the kind of incident particle. Therefore, a positive gate bias is usually applied during
irradiation to suppress the immediate electron-hole recombination, which in turn
significantly increases the hole trapping efficiency. As a consequence, the response of
the MOSFET detector becomes more linear and sensitive.
Since the positive charges (holes) in the oxide traps which cause the negative
voltage shift (ΔVTH) can persist for years, the MOSFET detectors have the ability to
permanently store the accumulated dose data.

2.3.

MOSFET Performance

2.3.1.

Standards for an ideal dosimeter

From a physics point of view, a radiation-sensitive dosimeter along with its reader
constitutes a dosimetry system that is able to measure, either directly or indirectly, the
dosimetric quantities such as exposure, absorbed dose and other related quantities of
ionizing radiation. In order to be useful, the dosimeter must exhibit a number of
desirable properties, defined below. The MOSFET performance, discussed in the
following sections, has to be compared with these characteristics.
1) Accuracy and Precision
In radiotherapy dosimetry, the uncertainty associated with the measurement is
often characterized in terms of accuracy and precision.
The accuracy is the most important features for dosimeters. It is a parameter that
describes the proximity of the expectation value of a measured quantity to its true
value. The accuracy of dosimetry measurements may be affected by both systematic
and the stochastic errors. Although repeated measurements may not eliminate
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systematic errors, it can effectively reduce stochastic errors.
The precision specifies the reproducibility of the measurements under similar
conditions and can be estimated from the data obtained in repeated measurements.
Usually the precision of dosimetry measurements is expressed as 1 or 2 standard
deviations of the fluctuations of the measurement scores around the mean. High
precision is always associated with a small standard deviation of the measurements.
Ideally, a dosimeter should be both accurate and precise, with measurements all
close to and tightly clustered around the known value. It is not possible to reliably
achieve the accuracy in individual measurements without the precision and vice versa.
2) Linearity
The reading of the dosimeter should be linearly proportional to the measured
quantity. However, beyond a certain dose range the dosimeter may present a
non-linear behavior, depending on the type of the dosimeter and its physical
characteristics. In general, the non-linear response can be corrected for to expand the
use of the dosimeter over a wider dose range.
3) Dose rate dependence
An ideal dosimeter should be independent of the dose rate, meaning that the
response of a dosimetry system at two different dose rates should remain constant. In
reality, dose rate may influence the dosimeter readings and therefore the appropriate
corrections are necessary. This is particularly important for pulsed beams like linear
accelerators that deliver very high doses in very short pulses.
4) Energy dependence
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The energy dependence is an important characteristic of a dosimetry system.
Ideally, the energy response of a dosimetry system should be flat over a wide range of
radiation qualities.
In practice, the dosimetry systems are usually calibrated at a specified radiation
beam quality (e.g. Co-60), and are used over a much wider energy range. Since no
dosimeter is water or tissue equivalent for all radiation beam qualities, the variation of
the response of the dosimetry system with radiation energy should be taken into
consideration.
5) Directional dependence
The response variation of a dosimeter with the angle of incidence of radiation is
defined as the directional (or angular) dependence of the dosimetry system.

An ideal dosimeter should have an isotropic response over a full 360 degrees.
However, the dosimeter may exhibit a directional dependence to some extent in reality,
due to its constructional details, physical size, and the energy of the incident radiation.
For the purpose of accuracy, users should understand this feature and during the
measurement try to keep the dosimeter in the same geometry as that in which it is
calibrated to avoid the influence of directional dependence.
6) Spatial resolution and physical size
The dosimeter should allow the determination of the dose in a very small volume
(point dose). This is particularly important for measurement in a rapid dose fall-off
region. Hence, a “point dosimeter” with minimal physical size is ardently anticipated.
However, in practice this is very difficult to achieve since small dosimeter volume is
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usually associated with a poor signal to noise ratio. As a result, compromises must be
made in dosimetric practice.
7) Readout convenience
For practical reasons, the dosimeter should be easy to handle. In general,
direct-reading dosimeters are much more convenient than passive ones that are read
after due processing following the exposure. Also, the dosimeter that can measure
both the integral dose and the differential dose rate is most expected.
Clearly, none of dosimeters can satisfy all the characteristics above mentioned.
The choice of a suitable dosimetry system thus becomes most important, taking into
account the requirements of the measurement situation.

2.3.2.

Performance characteristics of MOSFET detector

1) Accuracy and Precision

It was observed that the overall accuracy of MOSFET measurements was
dominated by reproducibility as a function of the applied dose (Scalchi et al 2005,
Ehringfeld et al 2005). According to the manufacturer’s specification, in high energy
photon & electron fields the error range for a widely used commercial MOSFET
detector (TN-502RDI, Thomson and Nielson Electronics Ltd 2001) with bias
sensitivity set to “standard” was less than 8% for doses between 0.2 and 1Gy, less
than 3% in the dose range from 1 to 2 Gy, and less than 2% for doses higher than 2 Gy.
As for x-rays in the kV range, a similar dose-dependent error range was also presented
(Ehringfeld et al 2005).
However, the quoted accuracy of MOSFET measurement in low dose range may
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mainly rely on different MOSFET sensitivity settings. Cheung et al (2005)
investigated a new MOSFET dosimetry system in high sensitivity mode and found it
was able to provide an adequate dose assessment at low dose levels with an accuracy
of less than 10%, 5% and 2.5% within the 95% confidence interval for 2, 5 and 10
cGy applied dose, respectively. This level of accuracy is comparable to the Attix
ionization chamber used at these dose levels.

2) Dose linearity

When irradiated, the MOSFET detector can work either in a passive mode
without a bias voltage on the gate or in an active mode with a positive gate bias
voltage.
The passive mode has the advantage that there is no requirement for additional
bias supply during the measurement. The dosimetry system may thus become more
portable and easier to use for in vivo dosimetry. However, in the passive mode the
dose response of the MOSFET detector is basically sub-linear (Rosenfeld 2002). Only
a limited dose range can be utilized for measurement. Take a commercial OneDoseTM
MOSFET detector (Sicel Technologies, Inc, USA) as an example. It is particularly
designed for single use, with a recommended dose upper limit within only 5 Gy
(Halvorsen 2005).
In the active mode, the hole trapping efficiency has been increased and many
studies have demonstrated that the MOSFET detector is linear with the applied dose
over a wide dose range (Butson et al 1996, Metcalfe et al 1997). At higher dose levels,
the MOSFET detector will exhibit a nonlinear response. The main reason for this
phenomenon is the buildup of the positive charges (holes) in the oxide traps which
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effectively reduces the magnitude of the electric field produced by the positive gate
bias during the irradiation. The reduced fields in the oxide, in turn, lead to an
enhanced electron-hole recombination and thus diminish the voltage shift measured
(Boesch et al 1976). A new reading equipment with higher bias voltage can be used to
extend the detector’s dose linear region, until the hole traps near the Si-SiO2 interface
are saturated. At this amount no change in threshold voltage is observed and the
MOSFET can no longer be used as a dosimeter.

3) Dose rate dependence

Unlike semiconductor diodes which are dose rate dependent, MOSFET detectors
are reported to be dose rate independent (Scalchi et al 1998). This is one of the major
advantages of MOSFET detectors over diodes, especially for measurements in pulsed
radiation beams.

4) Energy dependence

The MOSFET detector has a relatively flat energy response in high energy photon
& electron radiation fields (Gladstone et al 1994, Ramani et al 1997). However, it is
advisable to measure using MOSFET detectors in the same beam quality as that in
which they are calibrated.

The MOSFET detectors, on the other hand, are well known to have a nonlinear
response in the low energy range. At energies below 300 keV, the MOSFET response
primarily shows a significant increase with the decrease of photon energy. It attains a
maximum value at about 40 keV that depends on packaging and then falls down
rapidly. The observed sensitivity enhancement is theoretically explained on the basis
of a dominant contribution from the photoelectric effect in SiO2 in comparison with
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tissue, while the reduced sensitivity in the extreme low-energy range (70eV-20keV)
has been attributed to the increasing recombination of electron-hole pairs in the
silicon oxide with decreasing photon energy ((Kron et al 1998)).

A simple model is thus proposed to describe the variation of MOSFET response R
with energy E, based on the assumption that the detector response at low energies is
reduced exponentially while at medium energies, as already indicated, is mainly
governed by the photoelectric effect (Kron et al 1998). For materials with low atomic
number, the cross section for photoelectric effect is approximately inversely
proportional to the cube of the photon energy. Consequently, one can write
R (E) =｛1 – exp[ –α1 ( E – E1 )]｝[ 1 + α2 / ( E – E2 )3 ]

Eq2.1

where α1 and α2 are two fitting parameters which determine the importance of
exponential fall-off at low energies and inverse cubic fall-off at medium energies,
respectively. The other two fitting parameters, E1 and E2, allow for an energy shift for
the two components. The maximum MOSFET response aforementioned depends on
all four parameters.

The energy dependence of the MOSFET detector may be modified through
special packaging (Rosenfeld et al 1995). With adequate filtration added to the
MOSFET, uniform response was reported for photon energies above 80 keV (Soubra
et al 1994).
5) Directional dependence
In some early designs, the MOSFET detector may present an obvious angular
dependence when comparing the detector response of the round side with the flat side
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(Scalchi et al 1998). Therefore, the same side of the MOSFET detector used for the
calibration needs to be faced up to the incident beams during the measurement to
avoid the influence of angular dependence.
To date, with improved packaging, the angular dependence of MOSFET detectors
has been effectively reduced. The newly designed MOSFET detectors with the
angular dependence within about 2-3% over a full 360 degrees are widely available
(Chuang et al 2002, Zilio et al 2006). This offers a great flexibility for measurement
in a complex geometry where the incident beams comes from different directions.
6) Spatial resolution and physical size
The major advantage of MOSFET detector is its extremely small physical size.
The active area of a common MOSFET detector is about 0.2×0.2 mm2, and the active
volume thickness is only about 1 μm.
The small physical size of MOSFET detector was utilized to develop a promising
“edge-on” scanning system for assessing dose distributions in radiotherapy with high
spatial resolution in real time (Rosenfeld et al 1999, Kaplan et al 2000, and Kron et al
2002). They mounted the MOSFET detector on an in-air beam-scanning device with
the edge of the detector area pointing toward the radiation source. In this
configuration, the spatial resolution of the MOSFET dosimetry system is limited only
by the thickness of the gate oxide and it can thus be estimated to be better than 0.1
mm.
7) Readout convenience
The radiation-induced threshold voltage shift of the MOSFET detector can be
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directly read out by a portable reader. In a new advanced design, the MOSFET
dosimetry system is connected to a personal computer (PC) via an RS232 link
(Rosenfeld et al 2001). With the aid of control software, the system allows reading ten
MOSFETs simultaneously at a near real-time data acquisition mode (1 second
intervals). This provides a way of measuring the accumulated dose of ionization in
real time using a small, solid-state device.

2.3.3.

Some concerns about MOSFET performance

1) Silicon dioxide layer

The silicon dioxide layer is the active volume of the MOSFET detector. In
general, a typical MOSFET detector has an active area of 0.2×0.2 mm2 with the oxide
thickness of about 200-800 Å (Soubra et al 1994). MOSFET detectors are also
available with gate oxide of thickness 1.5 μm thermally grown and up to 2.5 μm
thermal/deposited oxide (Rosenfeld 2002).

Theoretically, increasing the gate oxide thickness will increase the number of
electron-hole pairs generated within the oxide and hence increase the MOSFET
sensitivity. From a physics point of view, a relatively thick gate oxide is preferred in
order to maximize the MOSFET sensitivity to ionizing radiation. However, growth of
extremely thick oxide layers (>1μm) requires growth times of more than 100 hours at
temperatures of 1000 ℃ (Soubra et al 1994). Obviously, these oxidation times are not
feasible. In addition, thick oxide will tend to be highly stressed leading to dislocations
at the Si-SiO2 interface. This may result in fast surface states and threshold instability
(Klausmann et al 1989, Soubra et al 1994).

2) Radiation induced interface states
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The irradiation of MOSFET detectors will not only cause a positive charge
buildup QT in the oxide as already mentioned above, but also increase the trap density
at the SiO2-Si interface (Scofield et al 1991). Although the former mechanism
generally dominates over other radiation-induced phenomena, the latter defect will
lead to a further increase in the threshold voltage, in absolute value, for both n- and
p-channel MOSFET device. Therefore, the measured threshold voltage shift ΔVTH, in
principle, should be the sum of two contributions, ΔVOX and ΔVIT, which are related to
the hole trapping in the silicon dioxide and to the charge state of the interface traps
respectively.

Today, many experiments have revealed that the number of traps created directly
by radiation is negligible and the interface traps buildup, in fact, is due to the creation
of electron-hole pairs and the subsequent transport of holes in the oxide (McLean et al
1980, Winokur et al 1989, Dasgupta et al 2000). Consequently, the radiation-induced
interface states increase is a slower phenomenon than the buildup of positive charge in
the oxide. Since only the positive charge trapped in the SiO2 which gives origin to the
negative threshold voltage shift ΔVOX is proportional to the radiation dose deposited in
the oxide, the slow interface states will cause some instability during the MOSFET
readout and affect the accuracy of dose measurements if special measures have not
been undertaken (Rosenfeld 2002).

3) Data acquisition and analysis techniques

Most developed MOSFET dosimetry systems can only operate in an integral
mode. This limits the application of MOSFET dosimetry in situations where the
radiation fluence varies as a function of time. Also, lack of capability to provide
corrections in readout circuits for intrinsic and extrinsic drifts in MOSFET signals due
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to ion diffusion and electron tunneling may lead to a large uncertainty especially for
low dose rate, long time scale measurements (Gladstone et al 1994). For practical
purposes, it is recommended to read the MOSFET signal during the first 15 minutes
after irradiation due to fading effect (Ehringfeld et al 2005). To avoid “creep-up”
phenomenon during consecutive readings, a second readout was suggested to be taken
at a time interval beyond 1 minute after the first read cycle (Ramani et al 1997).

Driven by the increasing demands for advanced dosimetry in radiotherapy,
Gladstone et al (1991) presented an automatic data collection and analysis system for
use with MOSFET detectors, which was able to acquire and process measurement
data on-line by interrogating the MOSFET signal in small time intervals during the
irradiation. This near real time dosimetry system included a personal PC fitted with
digital-to-analog and analog-to-digital converter boards. A single-chip programmable
current supply was used to power the MOSFET detectors. The threshold voltage of
the MOSFET detector was extracted from the linear regression of the square root of
the current versus the gate voltage obtained by applying a current ramp of 0-100 μA to
the MOSFET in 40 steps during the irradiation. By using multiple data sampling
during the current ramp coupled with the high resolution 16-bit analog-to-digital
converter board, this automatic data collection and analysis system decreased the
uncertainty in individual threshold voltage readings to ±2 mV (Gladstone et al 1994).

Moreover, various signal drifts that occurred in time during and after irradiation
were corrected by using deconvolution methods in this system (Gladstone et al 1991).
To acquire the drift function, the MOSFET detector was exposed to the high dose rate
irradiation for a short time period. Its signal variation was then recorded, under the
same bias voltage, as a function of time after the irradiation. Once the drift function
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was obtained for the MOSFET, it was used to predict and correct for signal drifts
occurring during long time, low dose rate irradiations supposing that the functional
form of the signal drift remained constant and was proportional in magnitude to the
dose received. With such corrections, the MOSFET detector can be read either during
or immediately after irradiation.

4) MOSFET Packaging

It has been proved that the package of MOSFET detectors plays a very important
role in the energy dependence of the device. A dose enhancement of up to a factor of
18 has been observed if materials with high effective atomic numbers are used in the
packaging (Bruker et al 1995, Rosenfeld et al 1995).

Rosenfeld et al (1995) investigated the package effect for different MOSFET
encapsulation configurations over a wide energy range. In high energy bremsstrahlung
radiation fields, they analyzed the dose enhancement effect for a TO-18 packaged
MOSFET, a semi-encapsulated MOSFET and an unencapsulated (or “bare”)
MOSFET in surface dose measurements. They found that the encapsulated MOSFET
and the semi-encapsulated MOSFET yielded an overestimation of the dose by 4 times
and 2.5 times, respectively, relative to the Attix plane-parallel ionization chamber. The
“bare” MOSFET, however, was in good agreement with the Attix chamber to better
than 1% for the entire build-up region. Therefore, it is recommended to measure
surface tissue doses using the “bare” MOSFET in high energy bremsstrahlung beams
where other encapsulation configurations would yield errors in excess of 100% due to
photon induced build up from the kovar can.

As for tissue dosimetry in low energy ranges between 50 kV and 250 kV, they
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observed that the package effect became more complicated, depending on different
irradiation conditions. In free air geometry, the TO-18 encapsulated MOSFETs
yielded a maximum dose enhancement of 9-10 times relative to the tissue dose, while
the “bare” and the polyethylene capped MOSFETs showed a maximum response of
5-5.5 times for the lowest testing energy. When changing the irradiation conditions
from free air geometry to being on the surface of a solid water phantom, the dose
enhancement was much less for the TO-18 encapsulation than the polyethylene
package and the “bare” MOSFETs. This is mainly due to the contribution of
backscattered electrons and low energy photons which were attenuated by the kovar
can but registered by the bare and the polyethylene covered MOSFETs. Obviously, the
packaging required will depend very strongly on the application for which the
dosimetry system is intended. Simply optimizing the MOSFET energy response for
tissue kerma equivalence in free air geometry will not guarantee a tissue equivalent
response for the same device on the surface dose measurement.

5) Temperature effect

For in vivo application, it is essential to evaluate possible temperature effects on
the MOSFET detector since it is attached to the patient’s body (37 ℃) during the
measurement. Current research revealed that the temperature dependence of the
detector signal was small (about 0.3% per ℃) for p-MOSFETs in the temperature
range between 22 and 40 ℃ (Ehringfeld et al 2005). Changing the temperature in the
range between ±60 ℃during the irradiation for n-MOSFETs (Litovchenko et al 1990)
and between 0 to 80 ℃ for dual p-MOSFETs (Soubra et al 1994) did not change the
sensitivity of the detector.

6) Finite lifetime
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The major limitation of MOSFET detectors was their finite lifetime. This is
mainly due to the saturation of the hole traps near the Si-SiO2 interface with the
accumulated dose. At this amount no change in threshold voltage is observed and the
MOSFET can no longer be used as a dosimeter (Jornet et al 2004).

Current MOSFET detector can be used up to 20,000 mV in threshold voltage
change. The associated maximum measured dose depends on the type and sensitivity
of the MOSFET being used. Kelleher et al (1994) reported that the accumulated
charge could be annealed under 150 ℃, and the MOSFET detector thus became
reusable. However, this technique was not mature enough to be widely implemented
and further methods should be explored to expand MOSFET lifetime.

2.4.

Clinical MOSFET Designs

2.4.1.

OneDoseTM MOSFET detector

A new design MOSFET dosimetry system (OneDoseTM, Sicel Technologies,
Morrisville, NC – distributed by Med-Tec, Orange City, IA) has recently been
introduced for in vivo patient dosimetry (Halvorsen 2005). The efficient system
consists of a wireless handheld reader and self-adhesive MOSFET detectors
particularly designed for one-time use. The MOSFET is a 300×50 μm p-channel
enhancement-mode device with a nominal 400 nm gate oxide thickness. It is
fabricated on a 0.05 mm thick polyimide base and encapsulated with epoxy. This
yields an inherent buildup thickness of about 1.2 mm water equivalent for 6 MV
photons.
The OneDoseTM MOSFET detector works in a passive mode and thus no
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additional bias supply is required during measurement. It is intended for use with
high-energy photons and electrons for integrated doses from 1 to 500 cGy. The
detector is pre-calibrated by the manufacturer in a 60Co irradiation under 2 cm of solid
water buildup. The associated calibration coefficients are stored in an on-board
memory chip and are used by the reader to calculate the absorbed dose based on the
threshold voltage shift of the MOSFET detector.
The OneDoseTM MOSFET detector can be easily adhered to the patient’s skin and
thus provides great convenience for routine in vivo surface dose measurement.
Recently, its application in TBI has been explored (Best et al 2005). Also the potential
use of OneDoseTM MOSFET detectors in HDR brachytherapy has been investigated
(Kinhikar et al 2006).

2.4.2.

Dual bias dual MOSFET design

In using a MOSFET as a dosimeter, care should be taken to its limitations. The
single MOSFET detector is subject to the influence of temperature. The published
data demonstrated that 1 ℃ change in ambient temperature can shift VTH by as much
as 4-5 mV for a MOSFET with gate oxide thickness approximate for use as a sensor
(Thomson et al 1990). Also, the response of the single MOSFET detector (ΔVTH) as a
function of the accumulated dose will exhibit a nonlinear region at high dose levels.
To overcome the above shortcomings, a new design of dual bias dual MOSFET was
introduced (Soubra et al 1994).
The dual bias and dual MOSFET design consists of two identical MOSFETs
fabricated on the same silicon chip. The principle of operation of each of the
MOSFETs in the dual dosimeter is similar to that of the single MOSFET. Upon
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irradiation these two identical MOSFETs will operate at two different positive gate
biases and each of the sensors thus will produce a threshold voltage shift whose
magnitude increases when the positive gate bias is raised. The measured difference
between the threshold voltage shifts of the two sensors (ΔVTH1 - ΔVTH2), is
representative of the absorbed dose and the magnitude of this difference per unit dose
(i.e., sensitivity) will be shown to be constant and independent of the total absorbed
dose. The measurement shows such a dual bias dual MOSFET design will result in
sensitivity reproducibility better than ±3% over a range in dose of 100 Gy and at a
dose per fraction greater than 20×10-2 Gy.

Also, since the response to temperature of each individual MOSFET is identical,
the incorporation of the dual MOSFETs in the dosimeter will give minimal
temperature effects.

2.4.3.

Miniature MOSFET linear array

The most advantage of MOSFET detectors over semiconductors and TLDs is that
they can be manufactured in a very small physical size as well as can provide real
time reading. This characteristic has been utilized to develop some special miniature
MOSFET detectors for real-time in vivo dosimetry.
Gladstone et al (1994) introduced a prototype miniature MOSFET probe to
measure, in vivo, the total accumulated dose and dose rate as a function of time after
internal administration of long range beta particle radiolabeled antibodies and in
external high energy photon and electron beams. The probe has overall dimensions of
1.6 mm diameter and 3.5 cm length, which could be inserted into a standard 16 gauge
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flexi-needle during the measurement. The good physical characteristics revealed that
this miniature MOSFET radiation detector probe, combined with an automatic data
collection and analysis system, might potentially offer a unique tool for direct
measurement of dose rates and total delivered doses to critical locations possible in
real time during radiotherapy.
Recently, a miniature MOSFET linear array was further developed as a probe
particularly for measuring the dose distribution from the location of the tumor to the
position of the anal verge during the external beam radiotherapy treatment of an anal
carcinoma (Price et al 2004). In this new design, four miniature MOSFET detectors
and an integral diode were fabricated on the same silicon chip. The chip was 1 mm
square and was connected to the corresponding substrate bond-pads via conductive
bumps to form the so-called Flip-Chip interconnection. A chain of ten or more
MOSFETs was then put into an intracavity catheter for in vivo measurement. The
preliminary results demonstrated that such a probe provided a promising candidate for
on-line in vivo dosimetry in the rectum, esophagus and vagina during external beam
radiotherapy. However, the external dimensions of the probe should be further
reduced in future development in order to permit its use in brachytherapy catheters.

2.4.4.

An implantable MOSFET detector

A novel design of an implantable wireless MOSFET detector has recently been
presented for use in external beam radiotherapy (Scarantino et al 2004). In this pilot
study, a thick oxide MOSFET was fabricated on a ceramic circuit board and the entire
structure was hermetically sealed in a glass tube so that body fluids would not enter
the capsule and affect device properties. When the detector was permanently
implanted in the body, a telemetric reading device was used to inductively couple
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power into the capsule via an antenna. Hence a fixed bias current was applied to the
MOSFET prior to and after each measurement. The resulting analog voltages were
digitally encoded, and were then transmitted out via backscatter modulation to the
external reader, where they were further converted to the equivalent doses using the
third-order fit parameters generated during the calibration procedure. Although the
effective communication distance of the current reading device was only about 15 cm,
it could be extended in future to allow placement of the detector anywhere in the
body.

The advent of a fully implantable MOSFET detector enables verification of the
planning dose in vivo at the site of the tumor. However, this newly designed MOSFET
has now been tested only in animal, and preliminary clinical testing is still underway.
Therefore, further clinical outcomes are expected so as to build up confidence with
this new technique.

2.5.

Clinical Application of MOSFET Detector

2.5.1.

Potential use in high energy photon & electron fields

1) The surface dose & entrance dose measurement

Theoretically, dose deposited at the surface (surface dose) and in the buildup
region (entrance dose) has two main contributors (Butson et al 1996). One is
in-phantom scatter due to photon interactions with phantom material and subsequent
generation of secondary electrons which deposit energy along their path. The other
one is electron contamination which derives from electrons produced outside of the
phantom but incident on the phantom to deposit their dose. In practice, in vivo surface
dose measurement represents a greater technical challenge because the epidermal
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layer of the skin is only approximately 0.07 mm thick and the radiosensitive basal
layer lies at this depth (ICRP 1975).

At present, accurate measurement of surface and skin dose is possible with the
introduction of MOSFET detectors (Butson et al 1996, Quach et al 2000, Scalchi et al
2005). However, care should be taken when using commercial MOSFETs to measure
the skin dose, because the encapsulation of these MOSFETs yields an intrinsic build
up which will lead to a wrong surface dose. As observed by Butson et al (1996), the
totally encapsulated MOSFET with nickel casing overestimated the percentage
surface dose to 65% of Dmax for a 10×10 cm2 open field at 100 cm source-surface
distance (SSD) for 6 MV x-rays. They subsequently removed the MOSFET casing
and found that the unencapsulated MOSFET was able to produce a percentage surface
dose well agreed with previous published data. This observation has been proved by
Rosenfeld (2002) and hence the unencapsulated MOSFETs with minimal buildup
were suggested for surface dose measurement.

2) Routine verification of planning dose
Currently, direct phantom measurement is still the only way widely implemented
to verify IMRT treatments. Due to the small physical size, the MOSFET detector can
be regarded as a “point detector” and thus is preferred in phantom measurement. In a
recent study, a comprehensive set of investigations including the stability, linearity,
energy effect and angular dependence have been conducted for a commercially
available MOSFET detector (TN502RD) to evaluate its feasibility and efficiency in
routine IMRT dosimetry (Chuang et al 2002). The TN502RD detector is a dual bias
dual MOSFET device. During IMRT phantom verification, 3 to 5 MOSFET detectors
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were used to measure multiple point doses at different locations. Also, ionization
chamber measurements were performed in this study for comparison. The preliminary
results showed that the agreement between the dose measured by the MOSFET and
that calculated by the treatment planning system was within 5% error, while the
agreement between the ionization chamber measurement and the calculation was
within 3% error. They therefore concluded that the MOSFET detectors were suitable
for routine IMRT dose verification.
Since only in vivo dosimetry can measure the actual doses received by the patients,
Marcie et al (2005) applied MOSFET detectors to verify in vivo dose delivery in
oropharynx and nasopharynx IMRT treatments. During measurements, they fixed
MOSFET detectors in a custom-made oral plate which allowed positions to be
reproduced in the mouth. Measurements were obtained during each session for a total
of 21 patients, and measured doses were then compared with calculated values. They
stated that the discrepancies between the measured and calculated means were within
±5% for 92% and 95% of the right and left sides of the oral cavity, respectively.
Comparison of these discrepancies and the discrepancies between calculated values
and measurements made on a phantom revealed that all differences were within ±5%.

3) Monitoring dose during TBI

One of the most important tasks for in vivo dosimetry is to verify individual
patient doses in the cases where the treatment planning system is less accurate. Using
MOSFET detectors to monitor the dose delivery during TBI treatment is such an
application.

Scalchi and his co-worker (1998) investigated the MOSFET midplane dosimetry
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in TBI setup. By connecting entrance MOSFETs with low-sensitivity bias supply
while keeping exit MOSFETs with high-sensitivity bias supply, a low uncertainty in
the midplane dosimetry was achieved. The correlation coefficient between the
water-equivalent midplane depth and the ratio of the exit MOSFET readout divided by
the entrance MOSFET readout was about 1. The TBI midplane dosimetry using
MOSFETs was valid also in the presence of inhomogeneous tissues such as lung
tissue. The MOSFET midplane dosimetry relevant to the anthropomorphic phantom
irradiation was in agreement with ionization chamber measurement within 2%. This
demonstrated that the MOSFET detectors were suitable for in vivo dosimetry in TBI
treatments.

4) Use of MOSFETs in electron fields

Not only can MOSFETs measure in high energy photon fields, but also they can
be used in high energy electron beams. Tao et al (2000) investigated MOSFET dose
responses to various electron beam energies and angles. Their results indicated that
the MOSFET detector was near energy independent to within 1%. Also, the MOSFET
responses correlated within 2% of the doses in different electron field sizes including
blocked or small cutout down to 4 cm. This necessitates only a nominal dose
calibration factor for field size when using MOSFETs for in vivo dosimetry under the
nominal beam conditions in the clinic.

2.5.2.

Potential use in low energy x-ray & gamma ray fields

1) In low energy x-rays

Most publications have concentrated on in vivo dose measurements with
MOSFET detectors in high energy photon & electron beams (Ramani et al 1997,
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Quach et al 2000, Jornet et al 2004, Bloemen-van et al 2006) and very few have
reported the use of MOSFETs in low energy x-rays & gamma rays (Cheung et al 2003,
Ehringfeld et al 2005). One reason for this is that the MOSFET detectors have
obvious energy dependence in low energy ranges (Kron et al 1998).

Cheung et al (2003) investigated in vivo dosimetry using n-MOSFET detectors for
radiotherapy treatment at superficial and orthovoltage x-ray energies. A total of 25
patients were measured and the results showed that the in vivo MOSFET
measurements agreed with the calculated values on average within ±5.6% over all
energies from 100 kVP to 250 kVP. They concluded that the MOSFET device was
able to provide adequate in vivo dosimetry for superficial and orthovoltage energy
treatments with the accuracy of the measurements compatible with TLD, but having
the advantage of immediate readout over TLD.

A much detailed investigations on physical performance of a commercial
p-MOSFET detector in the therapeutic x-ray ranges between 80 kV and 250 kV were
given by Ehringfeld et al (2005). Their results further confirmed that the MOSFET
detectors were suitable for in vivo dosimetry in the kV ranges, if energy-dependent
dosimetric effects were considered and corrected for.

2) In HDR brachytherapy

A more interesting aspect for MOSFET detectors is their potential use in HDR
brachytherapy. In a recent published paper, Zilio et al (2006) compared MOSFET
measured radial dose rate distributions of a HDR

192

Ir source in water with Monte

Carlo simulations for different planes perpendicular to the source axis. The
discrepancy between experimental and Monte Carlo results was within 5% for 82% of
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the points and within 10% for 95% of the points. The preliminary results revealed that
MOSFET detectors could be used for absolute dose measurement, even in the vicinity
of

192

Ir source, with appropriate calibration and correction. Similar conclusion was

also found for OneDoseTM MOSFET detectors (Kinhikar et al 2006).

However, these investigations are mainly limited to the phantom study. Further
clinical results are most anticipated. Also, the MOSFET detectors used in these
studies are relatively large in size. This necessitates new MOSFET designs with
smaller physical size that can be easily held in a brachytherapy catheter.

2.6.

Summary
The use of the MOSFET as a radiation dosimeter has lots of advantages, such as

small physical size, immediate readout and permanent storage of total dose after
irradiation. The future of MOSFET detectors in clinical dosimetry is promising.
However, keeping in mind that the MOSFET detector is just becoming available
for clinical use, current investigations can not cover the entire fields of radiotherapy
dosimetry. Therefore, the application of MOSFET detectors needs to be further
explored and MOSFETs themselves should also be improved to satisfy clinical
demands.
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CHAPTER 3
Dosimetry Protocols: Theory and Practice

3.1.

Introduction

Radiation dosimetry refers to a quantitative determination by measurement and/or
calculation of the absorbed dose or some other physically relevant quantities, for
example, air kerma at a given point of interest in a certain medium (Andreo et al
2005). It can generally be classified into two categories: absolute dosimetry and
relative dosimetry. Absolute dosimetry correlates directly with the absorbed dose in
Gy, while relative dosimetry is a comparison of dose measured at a specified point
under certain irradiation conditions with the dose given at a reference point under
reference conditions.

To find the value of a dosimetric quantity experimentally, a radiation dosimeter
along with its reader, referred to as a dosimetry system, is required. The dosimeter is a
device that can measure, either directly or indirectly, the average absorbed dose
deposited in the dosimeter’s sensitive volume by ionizing radiation (Izewska et al
2005). In order to be useful, the dosimeter should have a number of desirable
characteristics as discussed in Chapter 2. Clearly, not all dosimeters can satisfy all
those characteristics. It is advisable that the selection of a dosimeter should take into
account the requirements of the measurement situation.
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The MOSFET dosimeter is the most recent development for the dosimetry of
ionizing radiation compared with TLDs and semiconductor diodes. It possesses
excellent spatial resolution and offers very little attenuation of the beam due to its
small size, which is particularly useful for in vivo dosimetry. However, like TLDs and
diodes, the MOSFET dosimeter is also a relative dosimetry instrument. Prior to use, it
must be firstly calibrated against a reference dosimeter under reference conditions to
obtain a so-called “calibration factor”, so as to convert its raw reading to dose in
reference conditions.

Generally, clinical reference dosimetry in photon and electron beams is
performed with ionization chambers. Its working principle is based on the ionization
charge or ionization current produced by radiation in the chamber’s sensitive air
volume. Subsequent conversions are needed to transfer the measured quantity in air to
the absorbed dose in medium (usually water). Several protocols are followed in the
procedures to ensure that all centers use the same data sets in their dose determination
(IAEA 1987, IAEA 1997).

In this chapter, we will briefly introduce the reference ionization chambers and
related IAEA dosimetry protocols for external beam radiation therapy using high
energy photon and electron beams. These dosimetry equipments and protocols are
subsequently used for the calibration of MOSFET dosimeters.

3.2.

Ionization Chamber Based Dosimetry Equipments
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3.2.1.

Ionization chambers

3.2.1.1. Thimble type ionization chamber

The thimble type ionization chamber is the most frequently used dosimeter in
radiation oncology centers around the world. It is originally constructed as a
modification of the free-air chamber，thus having a gas filled cavity surrounded by a
conductive outer wall and a central collecting electrode. Figure 3.1 shows a typical
example of thimble chambers, i.e. a 0.6 cm3 Farmer type ionization chamber, which is
particularly recommended for absolute dose measurements.

Figure 3.1 A photograph of a PTW 0.6 cm3 Farmer type ionization chamber.

As it has been pointed out, for a thimble chamber to be air equivalent, the
effective atomic number of the chamber wall material and the central electrode must
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be such that the system as a whole behaves like a free-air chamber (IAEA 1987). In
practice, the most commonly used wall materials is made of graphite which has an
atomic number a little less than that of air. Such a wall would give rise to less
ionization in the air cavity than a free-air wall. To compensate for this phenomenon,
an aluminum central electrode with a relatively high atomic number of 13 is often
used to ensure that the energy response of the chamber is flat.

There are also some other requirements in the chamber construction. For example,
the chamber volume is typically between 0.1 and 1 cm3, with an internal diameter of
preferably not greater than 7 mm and an internal length of not greater than 25 mm.
This size range is a compromise between the need for sufficient sensitivity and the
ability to measure dose at a point. More construction details of various commercially
available thimble chambers are given in the IAEA Technical Reports Series No. 277
(1987) and No. 381 (1997).

It should be noted that the ionization chamber measurement can only provide a
volume-averaged reading. As a consequence, the chamber in use must be aligned in
such a way that the radiation fluence is uniform over the cross-section of the chamber.
The detailed use of the thimble chamber in photon and electron beam dosimetry will
be discussed later in this chapter.

3.2.1.2. Parallel-plate (plane-parallel) ionization chamber

The plane-parallel ionization chamber is recommended for dosimetry of electron
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beams with energies below 10 MeV, and it must be used for energies below 5 MeV.
The plane-parallel ionization chamber is also very suitable for use with energies
above 10 MeV (IAEA 1997).

The plane-parallel ionization chamber typically consists of two plane walls, one
serving as an entrance window and polarizing electrode and the other as the back wall
and collecting electrode. There is also a guard ring system which has the same
potential as the collecting electrode and creates therefore a homogenous electric field
between the two electrodes. Figure 3.2 shows a photograph of a commercially
available plane-parallel ionization chamber, a Roos® electron chamber, which is
recommended by the IAEA for high precision electron dosimetry in radiation therapy.

Figure 3.2 A photograph of a PTW plane-parallel ionization chamber.
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One of the major advantages of the plane-parallel ionization chamber for electron
beam dosimetry is its small in-scattering perturbation effects (IAEA 1997). This is
primarily due to the special chamber design in which the cavity height is required not
to exceed 2 mm, the ratio of cavity diameter and cavity height must be large (of the
order of ten), and the guard electrode should have a width not smaller than 1.5 times
the cavity height. These design characteristics, in theory, can ensure that the
plane-parallel chamber only samples the electron fluence incident through the front
window, the contribution of electrons entering through the side walls being negligible.

Some plane-parallel ionization chambers have the ability to be waterproofed. This
is convenient for calibration of electron beams in a water phantom. As for other
plane-parallel chambers designed for measurements in solid phantoms, it is advisable
to apply the chamber in a phantom of the same materials as the one the chamber is
constructed so as to avoid interface problems.

3.2.2.

Dosimetry phantoms

3.2.2.1. Phantom materials

Water is a major component of the human body. Its physical properties are
homogenous and uniform, and its beam absorption properties closely match that of
soft tissues (Metcalfe et al 1997). Therefore, water is the standard phantom material
usually recommended as the reference medium for absorbed dose measurements both
for photon and electron beams. Throughout this paper, unless otherwise mentioned,
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all clinical reference dosimetry is performed in a water phantom.

The main limitation of water as a phantom material is that the dosimeter to be
used must be waterproof or placed in a waterproof sleeve. In the past few years,
several solid phantom materials have been developed as being similar enough to
natural water that they can be used interchangeably as calibration phantoms. Figure
3.3 gives a photograph of a RW3 slab phantom (SP34, IBA Dosimetry GmbH,
Schwarzenbruck, Germany). The phantom is reported to be water-equivalent in the
energy ranges from 60Co to 25 MV photons and from 4 MeV to 25 MeV electrons. It
consists of 1 plate 1 mm thick, 2 plates each 2 mm thick, 1 plate 5 mm thick and 29
plates each 10 mm thick. This combination makes it possible to vary the measuring
depth in increments of 1 mm. Different kinds of adapter plates designed for a number
of detector types are also available.

Figure 3.3 A photograph of a 30×30×30 cm3 RW3 slab phantom.

59

3.2.2.2. Water equivalency correction

Although the solid phantom material has been verified to be suitable as water
substitute under certain conditions, it is recommended to compare the beam output
measurements in the solid phantom to those in natural water for different radiation
qualities (Christ 1995, Tello et al 1995). A water-equivalency correction factor
(WECF), defined as the ratio of the ionization readings in the water tank (Mwater) to
that in the solid material phantom (Msolid) at the same water-equivalent depth, was
thus introduced:

WECF =

M water ( z ref )
M solid ( zeq )

Eq3.1

where Zref is the reference depth in water and Zeq is the water equivalent depth in solid
material.

For high-energy photon beams, where Compton scattering dominates, the water
equivalent depth is obtained by matching the electron density of the material (ρe(s)) to
that of water (ρe(w)) (Seuntjens et al 2005):
Z eq
Z ref

=

ρ e ( w)
ρe (s)

Eq3.2

In electron beams, obtaining water equivalence needs to match both the scattering
and stopping powers (which have different dependencies on energy and atomic
number) (IAEA 1997):
Z ref = Z eq ⋅ C pl

Eq3.3
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where Cpl is the range scaling factor that convert a depth in solid material to the
equivalent depth in water so as to keep the electron spectra similar in shape at the two
positions in the two materials.

Since all solid phantoms are limited in water equivalence, the ionization chamber
readings in the solid phantom have to be corrected by the water-equivalency
correction factor in the following measurements for the purpose of accuracy.

3.3.

Calibration Protocols

3.3.1.

General considerations

The calibration of a radiation beam used for the treatment of cancer in patient is
based on rather complicated measurements that need several conversions and
corrections (Andreo et al 2005). During the past few years a number of codes of
practice, protocols and documents have been proposed with efforts to outline in detail
the methods of procedure and provide the current best values for physical interaction
coefficients and correction factors. These calibration protocols fall into two
categories:
(a) Calibration in terms of the quantity exposure or air kerma (e.g. IAEA Technical
Reports Series No. 277);
(b) Calibration in terms of absorbed dose to water (e.g. IAEA Technical Reports
Series No. 398).

For practical purposes, the introduction of absorbed dose to water based protocols
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for all radiotherapy beams of ionizing radiation will greatly simplified the calibration
procedure. However, the national standards authority of P.R.China continues the use
of in-air exposure calibration which references to the IAEA Technical Reports Series
No. 277 and No.381. To keep our physical measurements traceable to the national
standards, the IAEA dosimetry protocols based on exposure calibration coefficients
are used in this study.

3.3.2.

Reference conditions and correction factors

The IAEA Technical Reports Series No. 277 defines the reference conditions by a
set of influence quantities for which the chamber calibration factor is valid without
any further corrections. In calibrating a dosimeter as many influence quantities as
possible should be kept at reference conditions. However, clinical irradiation
conditions are always different from reference conditions. As a consequence, a
number of correction factors need to be applied for ionization chamber dosimetry in
non-reference conditions (IAEA 1987). General conditions that require corrections
are:

3.3.2.1. Temperature and pressure

If an ionization chamber is open to the ambient air, its response is affected by air
temperature and pressure. The mass of air in the chamber volume will increase as the
temperature decreases or pressure increases. This may lead to a different number of
ions for a certain dose in the active volume. Therefore, a correction factor PTP was

62

applied to the chamber reading:
PTP =

P0 × (273.2 + T )
P × (273.2 + T0 )

Eq3.4

where T and P are the temperature and air pressure during the measurement, and T0
and P0 are the reference values as stated in the calibration certificate (herein 20℃and
101.3 kPa).

3.3.2.2. Ion recombination

Even with the recommended high voltage for an ionization chamber, there are
still a certain number of ions which will recombine before reaching the electrodes.
This loss of signal is typically very small for continuous radiation but can amount to
more than 1% in pulsed radiation from a Linac (Kron 2005). The ion recombination
can be corrected using the “two-voltage” method as recommended by the IAEA
(1987).

Supposing M1 and M2 are chamber readings at two different operating bias
voltages of V1 (the normal bias voltage) and V2 (V2 is equal to 1/3 V1) for the same
irradiation conditions, the associated recombination correction factor Ps at the normal
bias voltage V1 for pulsed radiation can be obtained by
Ps = a0 + a1×(M1 / M2) + a3×(M1 / M2)2

Eq3.5

where a0, a1, a3 are 1.198, -0.8753, and 0.6773, respectively.

It should be noted that the Ps is dependent on the beam quality. The ion
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recombination effect has thus to be investigated for each radiation beam of interest
individually.

3.3.2.3. The polarity effect

Under identical irradiation conditions, the use of polarizing potentials of opposite
polarity in an ionization chamber may yield different readings. This phenomena,
referred to as the polarity effect, is particularly pronounced in the build-up region
dosimetry using plane-parallel ionization chambers.

The polarity effect can be accounted for by taking the mean value of the chamber
readings measured at both polarities of the chamber voltage. The polarity correction
factor Kp is thus given by

KP =

M− + M+
2× M−

Eq3.6

where M- is the chamber reading at the normal bias voltage and M+ is the chamber
reading at the reverse bias voltage.

Like the Ps, the Kp should also be determined for each particular measurement
situation. If the polarity effect for a given chamber is larger than 3%, the chamber
should not be used for absolute dose measurement (Andreo et al 2005).

3.3.3.

IAEA protocols for absorbed dose determination in high energy photons

According to the IAEA Technical Reports Series No.277, the Farmer type
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ionization chamber is recommended to perform the calibration in the water-equivalent
phantom at a specified reference depth such as 5 cm for lower megavoltage radiation
x-ray beams and 10 cm for higher energies (IAEA 1987).

The associated absorbed dose to water, Dw, at the effective point of measurement,
Peff, is determined by
Dw (Peff) = Mu×ND,air×(Sw,air)u×Pu×Pcel

Eq3.7

where Mu is the chamber reading corrected for temperature, pressure, humidity, ion
recombination and polarity effect.
(Sw,air)u is the restricted stopping power ratio of water relative to air.
Pu is the perturbation correction factor, allowing for non-water equivalence of
chamber wall material and air cavity.
Pcel is the correction factor for the non-air equivalence of the material in the
central electrode.
ND is the absorbed dose to air chamber factor, which can be derived by
ND,air = Nx×(W/e)×Katt×Km

Eq3.8

where Nx is the exposure calibration factor, given by the Primary Standard Dosimetry
Laboratory (PSDL) or the Secondary Standard Dosimetry Laboratory (SSDL).
(W/e) is the mean energy required to produce an ion pair in air per unit charge
and its current value for dry air is 33.97 J/C.
Katt is the correction factor for photon attenuation and scatter in the chamber
wall.
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Km is the correction factor for the non-equivalence of chamber wall and
build-up cap materials.

Note that an effective point of measurement is to be used when applying Eq3.1 to
determine the absorbed dose to water. This takes into account the spatial extent of the
air cavity by locating the point of interest Peff in front of the chamber center toward
the source to correct for the gradient of fluence within the chamber cavity. For high
energy x-rays, Peff is equal to
Peff = 0.6×r

Eq3.9

where r is the inner radius of the ionization chamber.

3.3.4.

IAEA protocols for absorbed dose determination in high energy
electrons

The introduction of an air-filled cavity into a medium irradiated by electrons will
give rise to a perturbation effect which increases with a decrease in electron energy.
The commonly used thimble chambers, previously recommended for the absorbed
dose measurements in photon beams, are reported to have a perturbation of several
percent for electron beams with energy below Ēz = 10 MeV. Therefore, plane-parallel
ionization chambers, due to their design characteristics which result in a minimal
perturbation effect, are generally recommended for measurements in electron beams
of energies below Ē0 = 10 MeV, and must be used below Ē0 = 5 MeV (IAEA 1997).

For plane-parallel ionization chambers, the effective point of measurement Peff is
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assumed to be situated at the center of the front surface of the air cavity. The absorbed
dose to water Dw,Q in the user’s beam of quality Q, when Peff is positioned at the
reference depth, is given by
Dw,Q = MQ×ND,pp,air×(Sw,air)Q×PQ

Eq4.0

where MQ is the chamber reading in the user’s beam, corrected for temperature,
pressure, humidity, ion recombination and polarity effect.
(Sw,air)Q is the stopping power ratio, water to air, in the user’s beam.
PQ is an overall perturbation factor for the plane-parallel ionization chamber.
ND,pp,air is the absorbed dose to air chamber factor for the plane-parallel
ionization chamber. Unlike the thimble type ionization chamber which has to be
periodically calibrated at PSDL or SSDL, ND,pp,air can be obtained by the user through
a cross-calibration against a reference Farmer type ionization chamber with known
ND,air traceable to the national standards at the highest available electron energy
(preferable Ē0 > 15 MeV). The ND,pp,air for the chamber to be calibrated can then be
derived from the following formula:

N Dpp,air = N Dref,air ×

ref
ref
× Pcav
× Pcelref
M ref Pwall
×
pp
pp
M pp Pwall
× Pcav
× Pcelpp

Eq4.1

where the superscripts “ref” and “pp” denote, respectively, the reference Farmer type
ionization chamber with known ND,air and the plane-parallel ionization chamber to be
calibrated.
Mref and Mpp are ratios of the two chamber readings to those of an external
monitor to take into account possible accelerator output fluctuations. They must be
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corrected for temperature, pressure, humidity, ion recombination and polarity effect.
Pwall and Pcav are correction factors that account for the non-medium
equivalence of the chamber wall material and the effects related to the air cavity,
respectively.
Pcel is the correction factor allowing for the effect of the central electrode of the
reference Farmer type ionization chamber during in-phantom measurements in high
energy electron beams.

Note that ND,ref,air used here is slightly different from Eq3.8. A correction factor
for the non-air equivalence of the material in the central electrode, Kcel, is included in
ND,air. Thus
ND,air = Nx×(W/e)×Katt×Km×Kcel

3.4.

Experiments: MOSFET Calibration

3.4.1.

Materials and methods

Eq4.2

3.4.1.1. Ionization chamber measurement

1) Absorbed dose determination in high energy photon beams

A NE-2571 0.6 cm3 Farmer type ionization chamber (Nuclear Technology Ltd.,
Reading, UK) and a NE-2670A reader (Nuclear Technology Ltd., Reading, UK) were
used as an absolute dosimetry system for calibration of MOSFET detectors in high
energy photon fields. The ionization chamber, along with the reader, has been
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calibrated at National Institute of Metrology, Beijing, P.R.China. The long term
stability of the system is within 0.5% per year, and the variation of the exposure
calibration factor Nx of the chamber is less than 2.5% between 60Co and 70 kV x-rays.

Calibration measurements were performed in a 30×30×30 cm3 water phantom.
The effective point of measurement of the ionization chamber Peff was located in the
central beam axis at reference depth of 5 cm in the phantom for Varian 600C 6 MV
x-rays and Elekta Precise 8 MV x-rays, and at the reference depth of 10 cm for Elekta
Precise 15 MV x-rays. The field size was set as 10×10 cm2 at SSD=100 cm. 100
monitor units were delivered every time and the average value of five repeated
measurements corrected for temperature, pressure, ion recombination and polarity
effect was used to calculate the absorbed dose to water at the reference depth. The
maximum dose at dmax (Dmax) was then determined by dividing the associated
percentage depth dose (PDD) data.

For all the measurements the ionization chamber and the water phantom were
preset in the linac room at least 30 minutes before measurements to reach thermal
equilibrium with the room temperature. The reader was warmed up more than 10
minutes prior to use to stabilize. The leakage current was observed for 180 seconds
and a 60-second auto-zeroing was performed to ensure that the leakage current was
much less than the real measurements. Before the first reading of each series of
measurements was taken, the ionization chamber inside the phantom was
pre-irradiated with 5 Gy to achieve charge equilibrium.
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2) Absorbed dose determination in high energy electrons

A NACP-02 plane-parallel ionization chamber (Scanditronix, IBA Dosimetry
America, Bartlett, TN) was used for MOSFET calibration in high energy electron
beams of an Elekta Precise linac ranging from 4 MeV to 21 MeV. The ionization
chamber has a small measuring volume of 0.16 cm3, with 2 mm electrode spacing and
3 mm guard ring. The absorbed dose to air chamber factor for the plane-parallel
ionization chamber ND,pp,air, as before mentioned, was obtained by intercomparison
with a NE-2571 Farmer type ionization chamber of known ND,air using Elekta 18 MeV
electron beams in a water phantom.

The effective point of measurement of the plane-parallel chamber Peff was
situated in the central axis of the beam at dmax in the water phantom with the entrance
window facing the radiation source. An electron applicator with standard applicator
size of 14×14 cm2 defined at SSD=95 cm (i.e. 14.7×14.7 cm2 at SSD=100 cm) was
selected. All the measurements were performed at SSD=100 cm and 100 monitor
units were delivered every time. Since the ion recombination and polarity effect of the
plane-parallel chamber are dependent on the beam quality, these effects were
investigated for different electron beams. In our experiment, each measurement was
repeated five times and the average value corrected for temperature, pressure, ion
recombination and polarity effect was used to calculate the absorbed dose to water.

As a comparison, the NE-2571 Farmer type ionization chamber was also used
here to measure the applied dose under the same setup conditions. The effective point
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of measurement Peff for the Farmer chamber in high energy electrons was shifted by
0.5·r toward the incident beams. The absorbed dose in water was then calculated using
Eq3.7 but with different values for (Sw,air)u, Pu, and Pcel.

3.4.1.2. MOSFET measurement

Two different MOSFET detectors were calibrated for use in high energy photon
and electron beams, including
(a) CMRP standard-size MOSFET probe, RADFET chip type TOT500 manufactured
by REM Oxford, UK.
(b) OneDoseTM MOSFET detector (Sicel Technologies, Inc, USA).
1) CMRP standard-size MOSFET detector

The RADFET dosimeter employs a TOT500 p-MOSFET device which has a
specially-grown thick gate oxide layer that can be used to measure the integrated
radiation dose and therefore constitutes the sensitive part of the device. The gate oxide
has a serpentine shape, with the source and drain regions in an interlocking finger
structure separated by the gate oxide ribbon layer, packed into a 180×270 µm2
rectangular shape (Kaplan et al 2000). The sensor chip is mounted and wire bonded to
a low-Z chip carrier and covered with the minimum possible amount of opaque epoxy
resin. The overall physical dimensions of the detector is approximately 7×2.1×1.6
mm3.

The RADFET dosimeter is connected to a CMRP reader system when it is used.
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The reader contains circuits not only for tracking and logging the threshold voltage
but also for applying gate bias as required during exposure. A positive gate bias of +5
V is used in the current version of MOSFETs. With the aid of a dedicated computer,
the system is capable of reading five probes sequentially online in a short time. The
control software, MosPlot 4.1, developed by using MATLAB 6.0 allows for the
on-line graphical presentation of the change in VTH or the increment of ΔVTH for
consecutive readouts (i.e. dose rate measurements). Various signal drifts that occurred
in time during and after irradiation can be corrected by using deconvolution methods
(Gladstone et al 1991) in this MOSFET dosimetry system (Rosenfeld et al 2001).

The MOSFET calibration was conducted in a 30×30×30 cm3 RW3 slab phantom
immediately after the ionization chamber measurements. A 1-cm thick phantom slab
with a custom-made groove on its surface was used to hold the MOSFET detector and
the connecting wires. For all calibration measurements, the MOSFET detector was
placed in the central axis of the beam at dmax in the solid phantom with the round
surface facing the beam. The field size was set as 10×10 (or standard applicator field
size as 14.7×14.7 cm2) at SSD=100 cm. To save the MOSFET lifetime, 20 monitor
units were delivered every time. The MOSFET detector was read before and after
each irradiation, and the corresponding threshold voltage shift ΔVTH was multiplied by
a factor of 5 to equal to the dose delivered to the ionization chamber. For each beam
quality, five repeated measurements were performed and the mean value was used to
calculate the calibration factor FC for the MOSFET according to the formula:
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FC (cGy / mV ) =

DW (cGy )
∆VTH (mV )

Eq4.3

2) OneDoseTM MOSFET detector

A commercial OneDoseTM MOSFET dosimetry system was also tested for use in
high energy photon and electron beams. The OneDoseTM MOSFET is a 300×50 μm
p-channel enhancement-mode device with a nominal 400 nm gate oxide thickness.
The detector is designed for single use only, making it possible to be operated in a
passive mode when irradiated. For ease of use, the OneDoseTM MOSFET detector is
pre-calibrated individually by the manufacturer using
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Co irradiation under full

build-up conditions. The resulting calibration factors are stored in a memory device
located on the chip carrier of the detector, and are later used by the reader to calculate
the applied dose based on the threshold voltage shift of the MOSFET detector. To
avoid mix-ups, each MOSFET detector has a unique serial number that can be
identified when inserted into the reader.

The OneDoseTM MOSFET was embedded in the RW3 slab phantom in the central
beam axis at dmax with the round surface facing the beam. For each beam quality, at
least two MOSFET detectors from the same calibration batch were irradiated with 100
monitor units under the same setup conditions as in CMRP MOSFET measurements.
To minimize the influence of signal drifts, the readout was made within 2 minutes
after irradiation. By using the pre-determined calibration factor and the vendor
supplied energy correction factor, the measured dose in cGy was obtained directly
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from the reader. A correction factor (CF) specified for the user’s beam quality was
thus determined with comparison to the referenced ionization chamber dosimetry:

CF =

DW , MOSFET (cGy )
DW ,Chamber (cGy )

Eq4.4

where Dw,MOSFET(cGy) and Dw,Chamber(cGy) are absorbed doses measured by the
OneDoseTM MOSFET and the ionization chamber, respectively. This correction factor
was then used to evaluate the uncertainties associated with the manufacturer’s
calibration and was applied to the following measurements in order to provide the
best accuracy.

3.4.2． Results and discussion

3.4.2.1. Calibration of MOSFETs for photon beams

Three RADFET dosimeters and a batch of OneDoseTM MOSFET detectors (Lot #:
04184) were calibrated for use in high energy photon beams.

Table 3.1 listed the parameters used to calculate the ND,air for the NE-2571 Farmer
type ionization chamber. The corresponding parameters that were required by the
Farmer type ionization chamber to determine the absorbed dose in high energy
photons were given in Table 3.2.

The required correction factors, Ps and Kp, for the NE-2571 Farmer type
ionization chamber were investigated for each beam quality and were listed in Table
3.3.
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Table 3.1 The parameters used to calculate the ND,air for the NE-2571 Farmer type ionization
chamber.

Nx a

W/e b

Katt b

Km b

Katt×Km b

1.012

33.97

0.990

0.994

0.985

Note: a was provide by National Institute of Metrology, Beijing, P.R.China; b was introduced from
IAEA Technical Reports Series No.277.

Table 3.2 The parameters required to calculate the absorbed dose in high energy photons for the
Farmer type ionization chamber.

Note:

a

E (MV)

Sw,a a

Pu a

Pcel a

PDDz b

6
8
15

1.121
1.116
1.102

0.994
0.995
0.996

1.000
1.000
1.000

85.4%
87.3%
76.2%

was introduced from IAEA Technical Reports Series No.277;

b

was the associated PDD

data at the reference depth obtained by the user using a Scanditronix Wellhofer 3D-beam
analyzing system.

The mean calibration factors for three RADFET dosimeters were 0.217±0.0097
cGy/mV for Varian 600C 6 MV beams, 0.219±0.0092 cGy/mV and 0.216±0.0096
cGy/mV for Elekta Precise 8 MV and 15 MV beams, respectively. Results showed a
standard deviation of approximately 4.4% in calibration factors among different
detectors. This may indicate that each MOSFET detector should be calibrated
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individually even they were obtained from the same calibration batch.

Table 3.3 Correction factors, Ps and Kp, for the NE-2571 Farmer type ionization chamber in high
energy photon beams.

E (MV)

Ps

Kp

6
8
15

1.0031
0.9979
1.0045

0.9997
1.0007
1.0003

Table 3.4 showed the correction factors for OneDoseTM MOSFET detectors in
different photon beams. The percentage errors related to the manufacturer’s
calibration were observed to be less than 1.5% for all tested photon beams.

Table 3.4 Correction factors for OneDoseTM MOSFET detectors in high energy photon beams. The
vendor supplied energy correction factors were applied.

Energy
(MV)
6
8
15

Delivered
(cGy)
100
100
100

Mean measured
(cGy)
99.7
99.6
101.3

Correction
factors
0.997
0.996
1.013

From the above calibration measurements, we can conclude that both RADFET
dosimeters and OneDoseTM MOSFET detectors have a relatively flat response
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variation in high energy photon beams. Even these MOSFET detectors were
calibrated in a certain beam quality (e.g. 6 MV photons), they could still be used for
measurements in other high energy photon fields with an acceptable uncertainty.
Nevertheless, it is advisable to calibrate these MOSFET detectors in the situation
where the real measurements will be performed so as to improve the accuracy of
MOSFET dosimetry.

3.4.2.2. Calibration of MOSFETs for electron beams

According to the IAEA Technical Reports Series No.381 (1997), the NACP-02
plane-parallel ionization chamber was taken as our “gold standard” for MOSFET
calibration in electron beams. As shown in Table 3.5, the well designed, well guarded
plane-parallel ionization chamber such as Scanditronix NACP-02 has a minimal ion
recombination (<±0.1%) and polarity effect (<±0.5%) under the nominal bias voltage.
This makes it very suitable for accurate dosimetry in high energy electron beams.

Table 3.6 listed the required (Sw,a)Q and PQ for absorbed dose determination in
high energy electron beams using the plane-parallel ionization chamber.

Since the Farmer type ionization chamber was still used in some hospitals to
perform routine monitor unit check for high energy electron beams, we also measured
electron beam outputs using the NE-2571 Farmer chamber for comparison purposes.
The corresponding parameters used by Eq3.7 to determine the absorbed dose in high
energy electrons for the Farmer type ionization chamber were shown in Table 3.7.
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Table 3.5 Correction factors, Ps and Kp, for the NACP-02 plane-parallel ionization chamber in
different electron beams.

E (MeV)

Ps

Kp

4

1.0010

1.0048

6

1.0006

0.9991

8

1.0006

0.9995

10

1.0006

0.9998

12

1.0005

1.0010

15

1.0010

1.0006

18

1.0010

1.0007

Table 3.6 The parameters used to calculate the absorbed dose in high energy electron beams using
the plane-parallel ionization chamber.

E (MeV)

(Sw,a)Q a

PQ a

4

1.085

1.000

6

1.069

1.000

8

1.061

1.000

10

1.051

1.000

12

1.040

1.000

15

1.016

1.000

18

1.009

1.000

Note: a was introduced from IAEA Technical Reports Series No.381 (1997).

Table 3.7 The parameters required to determine the absorbed dose in high energy electrons for the
Farmer type ionization chamber. These parameters were introduced from IAEA Technical Reports
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Series No.277.

E (MeV)

Sw,a

Pu

Pcel

4

1.086

0.948

1.008

6

1.068

0.953

1.008

8

1.056

0.956

1.008

10

1.048

0.960

1.008

12

1.034

0.964

1.008

15

1.010

0.973

1.008

18

1.003

0.981

1.008

Figure 3.4 provided a comparison between the Farmer type ionization chamber
measurements and the corresponding plane-parallel ionization chamber values in
electron beams from an Elekta Precise linac. For electron energies ranging from 6
MeV to 18 MeV, the difference between the two chamber measurements was less than
0.5%. However, when electron energy fell to 4 MeV, the difference was increased up
to more than 2.5%. This result was consistent with previous findings that the Farmer
type ionization chamber was no longer suitable for electron dosimetry with energies
less than 5 MeV and hence must be replaced by the plane-parallel ionization chamber
(IAEA 1997, Metcalfe et al 1997). As a consequence, we calibrated MOSFET
detectors with the plane-parallel ionization chamber over the full electron beam
energies for the purpose of accuracy.
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Figure 3.4 Comparison of absorbed dose measurements using plane-parallel ionization chamber vs.
Farmer type ionization chamber for Elekta Precise electron beams with energy ranging from 4
MeV up to 18 MeV.

One RADFET dosimeter was calibrated in this study for all electron beam
energies. The derived calibration factors were shown in Table3.8. The mean
calibration factor for various electron energies was calculated to be 0.218 cGy/mV,
with a coefficient of dispersion less than 1%. The RADFET dosimeter also exhibits a
minimal response variation in high energy electron beams.

Table 3.8 Calibration factors (CF) for the RADFET dosimeters in high energy electron beams.

Energy (MeV)

4

6

8

10

12

15

18

CF (cGy/mV)

0.217

0.216

0.220

0.216

0.217

0.220

0.219
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Table 3.9 showed the OneDoseTM MOSFET measurements to a fixed irradiation
of 100 cGy in different electron beams. The OneDoseTM MOSFET detectors were
pre-calibrated by the manufacturer in a 60Co irradiation. Although the vendor supplied
energy correction factors were applied, the response variation due to different beam
qualities in the user’s beams may affect the accuracy of MOSFET measurements. As
shown in the table, using only the manufacturer pre-determined calibration and
correction factors without further corrections for the user’s beam qualities, a
maximum deviation of 2% was observed. Therefore, it is essential to re-check the
MOSFET measurements in each user’s beam quality and appropriate corrections may
be needed to provide the best accuracy.

Table 3.9 Comparison of measured and delivered doses for OneDoseTM MOSFET detectors in
different electron beams. The vendor supplied energy correction factors were applied.

Energy
(MeV)
4
6
8
12
15
18

3.5

Delivered
(cGy)
100
100
100
100
100
100

Mean measured
(cGy)
99.0
102.0
101.4
101.1
99.4
100.0

Correction
factors
0.990
1.020
1.014
1.011
0.994
1.010

Summary

The MOSFET detector is a kind of relative dosimetry instrument. Prior to use, it
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must be calibrated against an ionization chamber with calibration factors traceable to
the national standards. To acquire the best accuracy, the choice of a suitable chamber
for MOSFET calibration is essential. For high energy photon beams, the Farmer type
ionization chamber is selected; while for high energy electron beams, the
plane-parallel ionization chamber is recommended.

Due to the response difference among individual detectors, each MOSFET
detector, even obtained from the same calibration batch, should be calibrated
independently. To improve the accuracy of MOSFET dosimetry, it is advisable to
calibrate the MOSFET detector in the situation where the real measurements will be
performed. Otherwise appropriate corrections should apply when irradiation
conditions differ from the calibration conditions. This is also indispensable for
OneDoseTM MOSFET detectors, although they are pre-calibrated by the manufacturer.
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CHAPTER 4
Characteristics and Performance of Commercial MOSFET Detectors

4.1.

Introduction

Modern radiotherapy requires high doses of radiation to be delivered with
increased accuracy. The ICRU has recommended an overall accuracy in tumor dose
delivery of ±5% in some treatment situations (ICRU 1976). Another investigation
indicates that an even better accuracy is needed (Brahme 1984). Considering all
uncertainties involved in the dose delivery to the patient, this is a great challenge to
present day practices.

In vivo dosimetry is known to be a useful tool in supporting the high accuracy in
tumor dose delivery expected from complex and conformal therapy techniques (WHO
1998). Among other frequently used in vivo dosimeters like TLDs and semiconductor
diodes, the MOSFET detector is also a good candidate for patient dosimetry in
external beam radiotherapy (Chuang et al 2002, Rowbottom et al 2004, Cherpak et al
2008). The MOSFET detector combines many of the advantages of both TLDs and
semiconductor diodes. It is designed as an electronic replacement for TLDs with size
advantages of TLDs and fewer correction factors compared with semiconductor
diodes. Several commercial MOSFET designs are available now (Soubra et al 1994,
Gladstone et al 1994, Rosenfeld et al 2001, Halvorsen 2005).
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We herein introduce two different MOSFET detectors: one is an active mode
MOSFET, i.e., the CMRP standard-size MOSFET probe (RADFET chip type TOT500
manufactured by REM Oxford, UK). The other is a passive mode MOSFET, i.e., the
single use OneDoseTM MOSFET detector (Sicel Technologies, Inc, USA). As it has
been discussed in Chapter 2, an ideal dosimeter should exhibit some expected features
in order to be useful. Since not all dosimeters can satisfy all those requirements, the
choice of a suitable dosimeter for a given measurement situation becomes most
important. Obviously, such a choice can only be made based on the understanding of
physical performance of the dosimeter. Therefore a detailed investigation of MOSFET
performance in high energy photon & electron fields is provided in this chapter.

In addition, the MOSFET detectors are usually calibrated against a reference
ionization chamber under the reference conditions (i.e. a 10×10 cm2 field size at the
SSD equal to 100 cm). In clinical dosimetry, however, the treatment conditions are
not limited to the reference conditions and many treatment specific parameters such as
SSD, field size and wedge angle may differ. In this chapter, the possible influence of
these treatment parameters to the MOSFET response is also evaluated and if
necessary, appropriate corrections are recommended for irradiation conditions that
differ from the reference conditions.

4.2.

Materials and Methods

4.2.1.

General characteristics
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4.2.1.1. Reproducibility

The reproducibility of the MOSFET detector，defined as the coefficient of
dispersion of repeated measurements，was investigated in Varian 600C 6 MV photons.

One RADFET dosimeter was selected for this measurement. The dosimeter was
fixed in the central beam axis at dmax in a 30×30×30 cm3 RW3 slab phantom with the
round surface facing the beam. Under the calibration conditions (i.e. 100 cm SSD, 10
×10 cm2 field size), ten equal and consecutive irradiations were delivered and the
MOSFET reproducibility S was calculated using:
n

S=

1
×
M

∑ (M − M
i =1

n −1

i

)2
× 100%

Eq4.1

where M is the average MOSFET reading for ten equal and consecutive irradiations
(n = 10).
Mi is the MOSFET reading for ith irradiation.
Since small dose was often used in MOSFET dosimetry to prolong the dosimeter’s
life span, the measurement reproducibility was evaluated with applied doses ranging
from 5 cGy up to 100 cGy for the RADFET dosimeter.

To avoid the fluctuation of the pulsed radiation beam, in particular, for small
monitor unit measurements, a NE-2571 Farmer type ionization chamber was used as a
monitor chamber during the investigation. The ionization chamber was situated under
the MOSFET detector in the phantom at the depth of 5 cm. The ratio of the MOSFET
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reading to the chamber result was used to determine the reproducibility of MOSFET
measurements at each dose level.

As for the single use OneDoseTM MOSFET detector, there was no way to perform
reproducibility tests with the same dosimeter. Different MOSFET detectors had to be
used for multiple measurements. Therefore the so-called intra-batch reproducibility
was measured here for OneDoseTM MOSFET detectors.

In our experiment, the OneDoseTM MOSFET detector was also kept in the central
beam axis at dmax in the RW3 slab phantom with the round surface facing the beam.
Five MOSFET detectors from the same calibration batch were sequentially irradiated
with 100 cGy using Varian 6 MV photons and the same calibration setup. The
corresponding coefficient of dispersion was calculated for comparison.

4.2.1.2. Energy response

The energy response of the RADFET dosimeter was studied in the following
beam qualities:
(1) Kilovoltage x-rays with energies ranging from 100 kVp to 210 kVp on a
commercial orthovoltage therapy unit (F34-I, BeiJing Medical Ltd., P.R.China).
(2) High energy photons of 6 MV (Varian 600C linac), 8 MV and 15 MV (Elekta
Precise linac).
(3) Electron beams with emerges ranging between 4 MeV and 18 MeV (Elekta
Precise linac).
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The MOSFET sensitivity, in terms of mV per cGy, was determined for the above
beam qualities. For kilovoltage x-rays, the half-value layers (HVL) for a variety of
kVp and filter combinations were measured on the day of measurement using a
NE-2571 Farmer type ionization chamber. The effective energies for each available
beam were calculated from HVL measurements by

µ effective =

0.693
HVL

Eq4.2

where µeffective is the "effective" linear attenuation coefficient of the attenuator material
for the polyenergetic beam, by means of which the effective energy was derived from
look-up tables.

An intercomparison between the RADFET dosimeter and the calibrated
ionization chamber was then performed free in air for different energies with a 6×8
cm2 applicator at SSD=50 cm. The measured quantity exposure was converted to
absorbed dose (cGy) using the F-factor (IPSM 1991):

D = 0.01 ⋅ R ⋅ N X ⋅ F

Eq4.3

where R is the instrument reading corrected for temperature, pressure, humidity, ion
recombination and polarity effect.
Nx is the exposure calibration factor appropriate to the HVL of the x-ray beam
being used. It is provided by the Primary Standard Dosimetry Laboratory (PSDL) or
the Secondary Standard Dosimetry Laboratory (SSDL).
F is the conversion factor between rontgens and rads (or cGy). Recommended
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values are given in Table 4.1.
and the MOSFET sensitivity was computed by

Sensitivity (mV / cGy ) =

∆VTH (mV )
DW (cGy )

Eq4.4

where ΔVth is the threshold voltage shift of the MOSFET detector before and after the
irradiation.

Table 4.1 Recommended values of the conversion factor, F, taken from ICRU Report 23 (1973).

HVL of x-rays

Values of F

(mmAl)
0.5

0.89

1.0

0.88

2.0

0.87

4.0

0.87

6.0

0.88

8.0

0.89

(mmCu)
0.5

0.89

1.0

0.91

1.5

0.93

2.0

0.94

3.0

0.95

4.0

0.96

In our cross-calibration practice, the MOSFET detector and the ionization
chamber were placed side by side in the beam with their long axes parallel and were
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irradiated simultaneously to ascertain the x-ray beam stability. The two dosimeters
were also swapped over to correct for any non-uniformity of the beam.

For high energy photons & electrons, the RADFET dosimeter was calibrated with
the NE-2571 Farmer type ionization chamber and the Scanditronix NACP-02 plane
parallel ionization chamber, respectively, using the method described in Chapter 3.

Moreover, a depth dose measurement was conducted with the RADFET
dosimeter in Varian 600C 6 MV photon beams. As the radiation energy spectrum
attenuates with the thickness of materials it passes through, the depth dose
dependence check exams, from another aspect, the response sensitivity of the
MOSFET detector to changes in the radiation spectrum. Using a field size of 10×10
cm2 at SSD=100 cm, the depth doses were measured in a stack of RW3 phantom slabs
from dmax up to 20 cm in 1 cm increments. To keep the MOSFET signal at a
reasonable level (about 100 mV in this case), different monitor units were delivered
for different depths. The recorded readings, corrected to a fixed irradiation of 100
monitor units, were normalized to the dmax value. The measured depth dose curve was
then compared with a known PDD acquired by a Scanditronix Wellhofer 3D-beam
analyzing system. The consistency of MOSFET measurements with ionization
chamber data was analyzed.

As a comparison, the variation of the detector response in high energy photon &
electron beams was also investigated for the OneDoseTM MOSFET detector. A
minimum of two MOSFET detectors were irradiated to a fixed dose of 100 cGy for
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each beam quality under the same calibration conditions. The average MOSFET
readings (only using the manufacturer-supplied calibration factors without energy
corrections) were compared with the delivered doses, and the relative sensitivity
variation at given photon & electron energies was thus determined.

4.2.1.3. Dose linearity and linear region

A dose linear measurement was performed to identify the useful dynamic range
of the MOSFET detectors.

The RADFET dosimeter was fixed in the central beam axis at dmax in the RW3
slab phantom with the round surface facing the incident beam. Doses ranging from 5
cGy up to 400 cGy were measured in Varian 600C 6 MV photons with the established
calibration setup. The derived MOSFET readings were plotted against the applied
doses and a best linear fit was used to estimate the expected MOSFET responses for
each given dose. The relative differences between the measured signals and their
expected values were calculated.

Referred to the manufacturer’s specification, the used R-type MOSFET has an
operating voltage range of between 9 V and 24 V with the current version of the
CMRP dosimetry system. The linearity of the MOSFET response within this voltage
range was tested by measuring the MOSFET sensitivity at different threshold voltage
levels. In the past six month, one RADFET dosimeter with the initialization voltage of
14 V was periodically calibrated in Varian 600C 6 MV photons under the established
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calibration setup. The dispersion of the measured sensitivity distribution around the
mean was computed to estimate the possible variation of the MOSFET response.

The OneDoseTM MOSFET detector is reported to be linear with dose from 2 to
400 cGy (Halvorsen 2005). For comparison purpose, the dose linearity was also
checked for OneDoseTM MOSFET detectors under the same setup conditions.

4.2.1.4. Dose rate dependence

The dose rate dependence was investigated for both the RADFET dosimeter and
the OneDoseTM MOSFET detector. For all the measurements, the MOSFET detector
was placed in the central beam axis at dmax in the RW3 slab phantom with the round
surface facing the beam.

Using Varian 600C 6 MV photons and the same calibration setup, the MOSFET
detectors were irradiated to a fixed dose (i.e. 20 cGy for the RADFET dosimeter and
100 cGy for the OneDoseTM MOSFET detector) at each of the following dose rates:
100 MU/min, 200 MU/min, 300 MU/min, and 400 MU/min. The sensitivity variation
of each type of MOSFET detectors was plotted with the given dose rates.

4.2.1.5. Angular effects

As shown in Figure 4.1 (a) and (b), both the azimuth axis angular dependence and
the polar axis angular dependence were evaluated for the RADFET dosimeter and the
OneDoseTM MOSFET detector, respectively.
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(a)

(b)

Figure 4.1 Cross-sectional view of experimental setup for angular dependence measurement. The
0° position corresponds to the gantry pointing straight down to the ground. (a) The azimuth axis
angular dependence; (b) The polar axis angular dependence.

The azimuth axis angular dependence was defined as the sensitivity variation
along the “cross-sectional axis” of the dosimeter. It was investigated in a cylindrical
PMMA phantom with a radius of 5 cm. Different inserts are available to help fix each
MOSFET detector in the central axis of the phantom. During the measurement, the
phantom was held on a PMMA stand 10 cm above the treatment couch and the
MOSFET detector was located at the isocenter. Using Varian 600C 6 MV photons
with 10×10 cm2 field size, the MOSFET detector was irradiated to a fixed dose (i.e.
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30 cGy for the RADFET dosimeter and 100 cGy for the OneDoseTM MOSFET
detector) at every 30° by rotating the insert around its central axis while keeping the
gantry at 0°. The average dosimeter readings for each angle were calculated and
normalized to the 0° average reading.

The polar axis angular dependence, referred to as the sensitivity variation along
the “longitudinal axis” of the dosimeter, was estimated in air with a custom-made
hemi-spherical buildup cap. The MOSFET detector with the buildup cap was held on
a PMMA stand at the isocenter and its longitudinal axis was aligned with the gantry
rotation plane. Using Varian 600C 6 MV photons and 10×10 cm2 field size, the
MOSFET detector was irradiated to a fixed dose (i.e. 20 cGy for the RADFET
dosimeter and 100 cGy for the OneDoseTM MOSFET detector) at every 30° from
270° to 90° by clockwise turning the gantry. The average dosimeter readings for each
angle were calculated and normalized to the 0° average reading.

4.2.2.

Treatment specific parameters

4.2.2.1. SSD effect

The influence of SSD to the dosimeter response was studied for different
MOSFET detectors in Varian 600C 6 MV photons with the field size of 10×10 cm2
defined at SSD=90, 100, and 110 cm, respectively. It was also assessed in Elekta
Precise 8 MeV electrons using the standard 14×14 cm2 applicator at SSD=95, 100,
and 105 cm, respectively. Since the standard applicator field size of 14×14 cm2 was
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defined at SSD=95 cm, different custom-made cutoffs were added to keep the field
size as 14×14 cm2 at SSD=100 and 105 cm.

During the measurements, the MOSFET detector was placed in the central beam
axis at dmax in the RW3 slab phantom with the round surface facing the incident beam.
20 monitor units were delivered each time for the RADEFT dosimeter and 100
monitor units for the OneDoseTM MOSFET detector. The corresponding doses at
various SSDs under the established setup conditions were computed using an ADAC
Pinnacle3 treatment planning system with data acquired by the Scanditronix Wellhofer
3D-beam analyzing system. The sensitivity variation of the MOSFET detectors with
SSD was thus analyzed for both photons and electrons.

4.2.2.2. Field size dependence

One RADFET dosimeter was calibrated against the NE-2571 Farmer type
ionization chamber using Varian 600C 6 MV photons at SSD=100 cm and dmax with
different field sizes (i.e. 5×5, 10×10, 20×20, 30×30, and 40×40 cm2, respectively). It
was also calibrated with the NACP-02 plane-parallel ionization chamber under Elekta
Precise 8 MeV electrons using the same setup conditions but different applicators (i.e.
6×6, 10×10, 14×14, and 20×20 cm2, respectively). All the measured data were
normalized to the standard 10×10 cm2 field value (for photons) or 10×10 cm2
applicator value (for electrons). The variation of MOSFET sensitivity with the field
size in high energy photon & electron beams was evaluated.
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As a comparison, the field size dependence was also investigated for OneDoseTM
MOSFET detectors using the setup conditions described above for both 6 MV
photons and 8 MeV electrons. Two dosimeters were irradiated to a fixed 100 monitor
units for each field size (or applicator size), and the averaged MOSFET readings were
compared with the known doses previously measured using the Farmer type
ionization chamber and the plane-parallel ionization chamber.

4.2.2.3. Wedge angle influence

Using 10×10 cm2 field size, SSD=100 cm, the wedge angle influence was
evaluated for both the RADFET dosimeter and the OneDoseTM MOSFET detector in
Varian 600C 6 MV photons.

The MOSFET detector was placed in the central beam axis at dmax in the RW3
slab phantom with the round surface facing the incident beam. An NE-2571 Farmer
type ionization chamber was also situated in the same phantom aligned with the field
center at a depth of 5 cm under the MOSFET detector. The ionization chamber was
exposed simultaneously with the MOSFET detector to determine the beam outputs in
each of the following wedge fields: 15°, 30°, 45°, and 60°. All the measurement data
were normalized to the 10×10 cm2 open field value.

4.3.

Results and Discussion

4.3.1.

Reproducibility
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The dose measurement reproducibility for the RADFET dosimeter at different
dose levels was shown in Table 4.2. From this Table, we can see that the MOSFET
reproducibility is closely correlated with the applied dose. This observation is
consistent with previous publications (Scalchi et al 2005, Ehringfeld et al 2005).

Table 4.2 The reproducibility of the RADFET dosimeter at different dose ranges.

Dose (cGy)

Reproducibility

5

6.5%

10

3.2%

20

1.5%

50

1.0%

100

0.5%

Because the MOSFET detector has limited lifetime, small applied doses are
preferred during calibration measurement to prolong the dosimeter’s life span.
However, too small dose may lead to an unacceptable error range. From our results,
the fractionation dose of 20 cGy was a good compromise between the measurement
uncertainty and the MOSFET lifetime. At this dose level, the RADFET dosimetry
system provided a dose measurement reproducibility of within 1.5%. Therefore, 20
cGy applied dose or equivalent was recommended here for MOSFET investigations.

For OneDoseTM MOSFET detectors, a fixed dose of 100 cGy was applied to five
dosimeters resulting in an average reading of 99.2 cGy for an accuracy of -0.8%. The
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coefficient of dispersion of these dosimeter readings was found to be 1.6% at the
applied dose of 100 cGy.

4.3.2.

Energy dependence

Table 4.3 gives the characteristics of the F34-I orthovoltage therapy unit. Five
x-ray beam energies ranging from 100 kVp to 210 kVp were used in this study. The
HVL values for these nominal energies were checked using a NE-2571 Farmer type
ionization chamber on the day of measurement, according to the IAEA Technical
Reports Series No.277 (1987).

Table 4.3 Characteristics of the F34-I orthovoltage therapy unit. The HVL values were verified
using a NE-2571 Farmer type ionization chamber on the day of measurement.

Potential
mA
(kVp)
100
120
140
160
180
210

Filter material and
thickness (mm)
Copper

12
12
12
12
12
12

Aluminum
0.86
1.25
1.14
1.48

0.11
0.27

HVL(mm)
2.86 Al
3.25 Al
5.14 Al
5.48 Al
0.36 Cu
0.52 Cu

The energy dependence of the RADFET dosimeter in orthovoltage x-rays was
presented in Table 4.4. The effective energies for each available beam were calculated

97

from HVL measurements. The dosimeter exhibited a non-linear response at x-ray
energies below 210 kVp, where the MOSFET sensitivity significantly increases with
the decrease of photon energy. A maximum dose enhancement of about 3.7 times
relative to the 6 MV photon value was observed at 100 kVp.

However, our results also show that there is no significant energy dependence for
the RADFET dosimeter in high energy photon & electron fields (see Figure 4.2). The
MOSFET sensitivities, with a positive gate bias of 5 V applied during irradiation,
nearly kept constant over this high energy ranges. The maximum deviation was found
to be less than 1% in high energy photons and within 2% in high energy electrons.

Table 4.4 The energy dependence of the RADFET dosimeter in orthovoltage x-rays. The
MOSFET response was normalized to 6 MV value.

Potential (kVp)

Effective energy (keV)

Relative response

100

32.4

3.67

120

34.5

3.48

140

43.7

3.22

160

45.4

2.93

180

54.2

2.54

210

62.0

2.21

The energy response of the RADFET dosimeter was further demonstrated in the
depth dose assessments. From Figure 4.3, we can conclude that the percentage depth
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doses measured by the RADFET dosimeter in Varian 600C 6 MV photons well agree
with the ionization chamber measurements to within ±2.5% for depths up to 15.5 cm
and within ±3.5% for depths from 16.5 to 19.5 cm. Clearly, the sensitivity variation of
the MOSFET detector with depth due to changes in the radiation energy spectrum is
minimal in high energy photon & electron beams.

Figure 4.2 The response variation of the RADFET dosimeter in high energy photons & electrons.
All the measurements were normalized to the 6 MV value. The uncertainty associated with
MOSFET measurements was within 1.5%.

Compared with the RADFET dosimeter, the OneDoseTM MOSFET detector also
showed a flat energy response in high energy photons (see Figure 4.4). Nevertheless,
the detector exhibited obvious energy dependence in high energy electrons. A
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maximum deviation of about 4% in MOSFET sensitivity relative to the 6 MV photon
value was found in this study. This may result from the fact that the OneDoseTM
MOSFET detector is designed in a passive mode and the enhanced electron-hole
recombination at different beam qualities will significantly influence the MOSFET
sensitivities. Therefore, appropriate energy dependence corrections are necessary for
OneDoseTM MOSFET detectors to obtain a good dosimetric result.

Figure 4.3 Depth dose measurement for a 10×10 cm2 field using the RADFET dosimeter and the
ionization chamber from depth of dmax to 19.5 cm. The uncertainty relevant to the MOSFET
measurements was within 1.5%.
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Figure 4.4 The energy dependence of OneDoseTM MOSFET detectors in high energy photon &
electron beams. The MOSFET response was normalized to the 6 MV value.

4.3.3.

Dose linearity

Both the RADFET dosimeter and the OneDoseTM MOSFET detector showed
good linearity of response (R2=1) with fractionation dose from 5 cGy up to 400 cGy
(see Figure 4.5 and 4.6). When comparing the measured doses with the expected
values at each applied dose, these two dosimeters both provided dose accuracy within
1% for doses above 10 cGy and within 0.5 cGy for dose less than 10 cGy down to 5
cGy.
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Figure 4.5 Dose linearity from 5 cGy up to 400 cGy for the RADFET dosimeter.

Figure 4.6 Dose linearity from 5 cGy up to 400 cGy for the OneDoseTM MOSFET detector.
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The OneDoseTM MOSFET detector is designed for single use only. The maximum
dose it can measure is no more than 5 Gy, according to the manufacturer’s
specification (Halvorsen 2005). The RADFET dosimeter, with a positive gate bias of
5 V applied during irradiation, has improved sensitivity and linearity thus providing a
much higher dose range (up to 24 V). However, some investigations have pointed out
that the radiation response of the R-type MOSFET may not be completely linear over
the whole voltage range (Zilio et al 2006). We herein calibrated one RADFET
dosimeter at different threshold voltage levels and results showed the coefficient of
dispersion of measured sensitivities was within 2.8% in the tested threshold voltage
range. This indicates that the RADFET dosimeter, once calibrated, can give a medium
accuracy level even without any sensitivity correction. For more accurate dose
measurements, periodic calibrations based on the weekly or monthly frequencies are
recommended.

4.3.4.

Dose rate dependence

Figure 4.7 presents the response variation of different MOSFET detectors with
the dose rate. No significant dose rate dependence was found for both the RADFET
dosimeter and the OneDoseTM MOSFET detector. The maximum deviation was less
than 0.5% for these two dosimeters.
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Figure 4.7 Dose rate dependence for different MOSFET detectors. The dosimeter response was
normalized to the 400 MU/min value. The measurement uncertainties associated with the
RADFET dosimeter and the OneDoseTM MOSFET detector were 1.5% and 1.6%, respectively.

4.3.5.

Angular effect

Figure 4.8 to 4.11 showed both the azimuth axis angular dependence and the
polar axis angular dependence for different MOSFET detectors.

(1) The azimuth axis angular dependence

Both the RADFET dosimeter and the OneDoseTM MOSFET detector exhibit
nearly isotropic responses for angles ranging from 270° to 90°, with maximum
deviation less than ±2%. However, due to the shape of the MOSFET that is not
designed with perfect cylindrical symmetry, large angular dependence of about 8% for
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the RADFET dosimeter and about 5% for the OneDoseTM MOSFET detector was
found when comparing the flat side response of the dosimeter with the round side (see
Figure 4.8 and 4.10). As a result, it is essential to keep these MOSFET detectors
during the measurement in the same position as they were situated in calibration
procedures. However, user may find it is rather difficult to manage the MOSFET
position with the same side always facing up to the incident beam for multi-beam
treatments, especially for routine IMRT dose verification. Therefore, new MOSFET
design with minimal angular dependence through full 360° is most expected in future.

Figure 4.8 The azimuth axis angular dependence for the RADFET dosimeter. The 0° position
corresponds to the gantry pointing straight down to the ground. All the measurements were
normalized to the 0° value.
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Figure 4.9 The polar axis angular dependence for the RADFET dosimeter. The 0° position
corresponds to the gantry pointing straight down to the ground. All the measurements were
normalized to the 0° value.

Figure 4.10 The azimuth axis angular dependence for the OneDoseTM MOSFET detector. The 0°
position corresponds to the gantry pointing straight down to the ground. All the measurements
were normalized to the 0° value.
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Figure 4.11 The polar axis angular dependence for the OneDoseTM MOSFET detector. The 0°
position corresponds to the gantry pointing straight down to the ground. All the measurements
were normalized to the 0° value.

(2) The polar axis angular dependence

The intrinsic MOSFET chip design results in an asymmetric structure along the
polar axis of the dosimeter. This leads to observable angular dependence (maximum
deviation 5%) over the evaluated angle ranges for both the RADFET dosimeter and
the OneDoseTM MOSFET detector (see Figure 4.9 and 4.11).

However, further comparison revealed that the polar axis angular dependence for
both dosimeters was better than 2.5% between ±60° (i.e. from 300° to 60°), and
within 3.5% between ±75° (i.e. from 285° to 75°). Since these beam incident angles
can satisfy most of the requirements of clinical setups, the polar axis angular
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dependence of current MOSFET designs has minimal influence in dosimetric
practice.

4.3.6.

SSD effect

Table 4.5 and 4.6 gave the SSD dependence for the RADFET dosimeter and the
OneDoseTM MOSFET detector, respectively, in high energy photon and electron
beams. No significant sensitivity variation with SSD was observed for both
dosimeters. The maximum deviation was better than 0.5% for the RADFET dosimeter
and less than 0.3% for the OneDoseTM MOSFET detector.

Table 4.5 SSD dependence for different MOSFET detectors in high energy photon beams. All the
measurements were normalized to the SSD=100 cm value.

SSD (cm)

90

100

110

RADFET

1.002

1.000

1.003

OneDoseTM

0.998

1.000

1.002

Table 4.6 SSD dependence for different MOSFET detectors in high energy electron beams. All the
measurements were normalized to the SSD=100 cm value.

SSD (cm)

95

100

105

RADFET

1.002

1.000

1.002

OneDoseTM

0.998

1.000

1.003

108

4.3.7.

Field size dependence

The field size dependence is a key feature for MOSFET detectors in IMRT
dosimetry since multiple beamlets with different field sizes are usually included in
IMRT fields. In this study, we investigated the field size dependence for different
MOSFET detectors in photon beams with field size up to 40×40 cm2, and in electron
beams with standard applicator field size up to 20×20 cm2 (see Figure 4.12 and 4.13).

As shown in Figure 4.12 and 4.13, the sensitivity variation was less than 2% for
the RADFET dosimeter over full photon field sizes and better than 1.0% over
different electron applicator field sizes. For OneDoseTM MOSFET detectors, the
sensitivity variation was kept within 1.5% over full electron applicator field sizes, but
significantly increased up to 3.7% in the large photon field sizes (≥ 30 cm2). However,
for NPC treatment, the field size is usually no more than 25×25 cm2. Thus, all these
MOSFET detectors, without further field size dependence correction, can still give
dose accuracy within measurement uncertainty. This may offer great convenience for
routine IMRT dose verification.
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Figure 4.12 Field size dependence for different MOSFET detectors in high energy photon beams.
All the measurements were normalized to the 10×10 cm2 value.

Figure 4.13 Field size dependence for different MOSFET detectors in high energy electron fields.
All the measurements were normalized to the 10×10 cm2 applicator value.
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4.3.8.

Wedge angle influence

Changing the wedge angle may alter the beam quality and so does the MOSFET
sensitivity. Nevertheless, our results showed that the response variation was less than
1.0% for the RADFET dosimeter and within 1.5% for the OneDoseTM MOSFET
detector for wedge angles ranging from 15° to 60° (see Figure 4.14). As a
consequence, no further wedge angle dependence correction was needed during
measurements.

Figure 4.14 Wedge angle dependence for different MOSFET detectors. All the measurements were
normalized to the 10×10 cm2 open field value.
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4.4.

Summary

Our experiments demonstrate that both the RADFET dosimeter and the
OneDoseTM MOSFET detector have good physical performance that are suitable for
in vivo dosimetry in external beam radiation therapy.

The OneDoseTM MOSFET detector is designed for single use only. There is no
need to apply a bias voltage to the MOS device during irradiation. This makes the
dosimetry system very convenient for clinical applications. The main limitations of
the OneDoseTM MOSFET detector are:
(1) Observable energy dependence in high energy electron beams;
(2) Short lifetime (0-5 Gy);
(3) Significant angular dependence;
(4) Relatively large physical size (failed to be held in a small-sized catheter).

The RADFET dosimeter, with a positive gate bias of 5 V applied during
irradiation, has improved sensitivity and linearity thus providing a much higher dose
range (up to 24 V). It can provide dose accuracy within measurement uncertainty for
applied doses above 20 cGy and within ±1 mV for small doses less than 10 cGy. The
dosimeter response nearly keeps constant across the tested range of energies and
modalities in both high energy photon and electron beams. Compared with the single
use OneDoseTM MOSFET, the RADFET dosimeter exhibits more attractive physical
characteristics and higher cost-effectiveness ratios. The main limitations that need to
be improved in future MOSFET designs are:
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(1) Angular dependence;
(2) Relatively large physical size (failed to be held in a small-sized catheter).

In a word, the above advantages of the MOSFET detector are among the reasons
that they are being used in routine in vivo dosimetry. New generation MOSFET
designs with smaller size that can be held in a 6F catheter are most expected. Also, the
dosimeter’s configuration needs to be further optimized so that the dosimeter can have
isotropic response through full 360°. It is clear that all these efforts will perfect
MOSFET features and help extend MOSFET applications in much more complicated
treatment situations such as in IMRT and HDR brachytherapy.
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CHAPTER 5
Dosimetric Evaluation of a New Miniature MOSFET for Quality
Assurance of High Dose Rate Brachytherapy

5.1.

Introduction

Recent technical advances in treatment planning and dose delivery systems have
significantly improved the accuracy of high dose rate (HDR) brachytherapy (Molloy
et al 1999, Ng 2005, Yamada et al 2006). Various optimization algorithms are widely
available that modulate the relative dwell times for each activated dwell position,
improving dose uniformity and target coverage (Jozsef et al 2003, Sumida et al
2006). Some advanced systems are even equipped with the inverse method of
treatment planning (Lessard et al 2001). Although greater degrees of freedom in the
optimization of the radiation dose distribution help achieve desired clinical outcomes,
this flexibility creates a number of quality assurance (QA) problems (AAPM 1997,
Kubo et al 1998]. Consequently, the accuracy of optimized calculations should be
checked independently to prevent potential dose errors.

Several authors have proposed mathematical methods for evaluating the stepping
source remote afterloading treatments (Ezzell et al 1995, Thomadsen et al 1995). In
essence, they evaluated characteristic parameters of the treatment plan, comparing
them to the expected values. However, these methods are insensitive to local dose
variations, reducing the capability of determining the dose at clinically relevant
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distances (Kubo et al 1998).

Unlike routine IMRT dose verification, where direct phantom measurements are
widely adopted, dose measurements in the vicinity of

192

Ir source are relatively

difficult (Tolli et al 1998). This is due to the extremely steep dose gradient near the
source. In the case of real in vivo dosimetry in brachytherapy, the dosimeters need to
be very small in size and have a very high spatial resolution. Thermoluminescent
dosimeters are often used to assess the accuracy of the planned dose for brachytherapy
(Mangold et al 2001, Anagnostopoulos et al 2003). They, in fact, are not suitable for
routine QA because they are very complex to handle and time consuming.
Semiconductor diodes are a good choice for dosimetry, but have a limited sensitivity
when manufactured with a sensitive volume small enough for use in steep dose
gradient applications such as in vivo measurement in brachytherapy (Waldhausl et al
2005).

Clearly, the dosimeter addressing the above-mentioned issues should have the
following characteristics:
(1) Small physical size that can be inserted into a 6F catheter;
(2) Good spatial resolution, preferably better than 0.1 mm;
(3) Ease of use and instant readout;
(4) Online measurement in a wide dynamic range of accumulated dose and dose rate.

In a recently published article, a Metal Oxide Semiconductor Field Effect
Transistor (MOSFET) was investigated by our group for its application in HDR
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brachytherapy (Zilio et al 2006). The preliminary results revealed that MOSFET
detectors could be used for absolute dose measurement, even in the vicinity of

192

Ir

source, with appropriate calibration and correction. The main limitation of this
MOSFET design for in vivo dosimetry of brachytherapy was its relatively large
volume. In the present study, we introduce a new miniature MOSFET detector that
can be inserted into a brachytherapy catheter. The dosimetric characteristics of the
detector, such as reproducibility, energy correction, angular effect and dose linearity,
were investigated for

192

Ir energy. The feasibility of this MOSFET dosimetry system

in routine pretreatment QA of the HDR brachytherapy treatment plan was evaluated.
The future use of miniature MOSFET detectors for HDR brachytherapy in vivo
measurement was also discussed.

5.2.

Materials and Methods

5.2.1.

Materials

5.2.1.1. HDR treatment units

A microSelectron HDR remote afterloader (Nucletron, The Netherlands), along
with a computerd tomography (CT)-based commercial brachytherapy treatment
planning system (Plato BPS, Nucletron, The Netherlands), was used for HDR
treatments. The source strength was verified using a well type chamber (HDR 1000
Plus, Standard Imaging, US) calibrated at the University of Wisconsin Accredited
Dosimetry

Calibration

Laboratory.

The

local

calibration

results

and

the
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vendor-supplied source strength were within 1% agreement.

5.2.1.2. MOSFET dosimetry system

The applied MOSFET dosimetry system includes the newly designed miniature
MOSFET detectors (MOSkinTM) and a microprocessor based reader.

The detector consists of a p-type MOSFET sensor with a gate oxide thickness of
0.55 µm. The sensor is dropped into a thin kapton layer, and hermetically sealed with
a 70-µm thick water-equivalent film. This thin-film encapsulating layer prevents
damage to the electronics caused by moisture, and acts as a carrier of the thin
aluminum contact leads that are connected to the MOSFET sensor from the top-side.
The entire MOSFET detector has small physical dimensions of about 4×1×0.5 mm3
(see Figure 5.1).

Figure 5.1 A photograph of a MOSkinTM detector.

The electrical signal used as the dosimetric parameter of the MOSFET detector is
the “threshold voltage”. This parameter exhibits a change when the device is
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irradiated and can be read by a portable reader. The CMRP dosimetry system is
capable of reading ten MOSFETs sequentially online in a short time and results are
sent to a PC via an RS232 link. The control software and internal microprocessor
corrects for any drift of the MOSFET threshold voltage induced during readout
(Rosenfeld et al 2001).

In this experiment, a positive gate bias of 5 V was applied during irradiation to
increase the MOSFET sensitivity and linearity. The readout was performed before and
after each irradiation by using a manual mode. For all the measurements, the
MOSFET detector was positioned with its surface of the silicon chip normal to the
incident beam. Such an orientation can provide the theoretical limit of resolution of
better than 1 µm (i.e. the thickness of the gate oxide) in the depth dose measurement
of the 192Ir source.

5.2.1.3. QA phantom

To facilitate the MOSFET calibration and routine plan verification, a
custom-made liquid water phantom was produced. A poly (methylmethacrylate)
(PMMA) support stand, by which the

192

Ir source can be positioned accurately with

respect to the detector, was centrally located in a 30×30×30 cm3 PMMA walled
phantom, as shown in Figure 5.2. The MOSFET detector and the ionization chamber
were fixed at the same height within the phantom. A series of source channels were
drilled between and around two detectors with a spacing of 1 cm. During the
measurement, the phantom was filled with water to obtain full scatter conditions.
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a

b

Figure 5.2 Schematic drawing of the phantom designed for in-water measurements. (a): Side view
of the phantom; (b): Plan view of the phantom.

120

5.2.2.

Methods

5.2.2.1. Ionization dosimetry for the 192Ir source

A NE-2571 0.6 cm3 Farmer-type ionization chamber (Nuclear Technology Ltd.,
Reading, UK) with calibration factors traceable to the national standard was used for
experimental determination of the absorbed dose in water around the

192

Ir source,

following a modified medium-energy x-ray dosimetry protocol (Reynaert et al 1998):

µ 
× PV × Pα
Dw = N k × M pt × Ps × Pst × Pe × Pd ×  en 
 ρ  w,air
where Nk is the chamber calibration factor for the average

192

obtained by interpolation of calibration factors between the

137

(Eq. 5.1)

Ir energy (397 keV),

Cs and the 250 kVcp

x-ray with an appropriate correction for wall attenuation;
Mpt is the field instrument reading corrected for ion recombination, polarity
effect, ambient pressure and temperature;
Ps and Pst are correction factors that take into account the non-water
equivalence of the PMMA sleeve and the stem scatter in water, respectively;
Pe modifies the absorbed dose deposited by electrons created in the water or in
the sleeve that enter the cavity so as to make the chamber as a photon dosimeter,
considering the high energy photons of the 192Ir;
Pd is the displacement factor which in fact is a correction for the photon
fluence perturbation;
(μen/ρ)w,air is the ratio of mass energy transfer coefficient between water and air,
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averaged over the photon spectrum at the specific depth and also over the volume of
cavity plus wall;
PV is the volume averaging correction factor that converts the kerma in a
volume equal to that of cavity plus wall (in the presence of a non-uniform photon
fluence) to the kerma in a point at the distance of interest;
Pα corrects for the angular dependence of the response of the ionization
chamber in water.
The associated factors for determination of the absorbed dose in water at the distance
of 5 cm from the 192Ir source were listed in Table 5.1.

The effective point of measurement of the ionization chamber for the 192Ir source
was taken as the center of the air cavity. During the measurements, the ionization
chamber was fixed in the phantom with its cavity center aligned horizontally to the
source center. Five consecutive measurements were performed after the stepping
source was driven to the predetermined calibration position. The average reading with
correction for source decay was used for calculation of the absorbed dose.

Table 5.1 The factors used in Eq.5.1 for determination of the absorbed dose in water at the
distance of 5 cm from the 192Ir source, introduced from Reynaert et al (1998).

d (cm)

Ps

Pst

Pe

Pd

(μen/ρ)w,air

Pv

Pα

5.0

1.000

0.999

1.000

0.995

1.108

1.017

0.993
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5.2.2.2. MOSFET calibration

Five miniature MOSFET detectors were calibrated against the NE-2571 0.6 cm3
Farmer type ionization chamber at a distance of 5 cm from the

192

Ir source in the

water phantom (Reynaert et al 1998).

For the purpose of accuracy, a single source position was used for MOSFET
calibration and investigation. The calibration position was determined by recording
the detector responses to a series of source dwell positions along the catheter with
minimum step size available (i.e., 2.5 mm in this case) and interpolating the source
position that corresponds to the maximum detector response.

Since the MOSFET readings were recorded using the internal timer of the remote
afterloader, the transit dose contribution needed to be corrected for to improve the
accuracy. The end effect for the afterloader was estimated using the graphical
extrapolation method (IAEA 2002), by which the graphical solution of zero exposure
on an exposure versus exposure timer plot yielded the end effect.

During calibration, the MOSFET detector was irradiated to a fixed dose of 20
cGy each time. The average of five repeated measures with correction for end effect
and source decay was used to determine the calibration factor.

5.2.2.3. Energy dependence correction

The photon spectrum in tissue of an 192Ir source is distance dependent (Meli et al
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1988, Zilio et al 2006), affecting the MOSFET sensitivity as a function of distance.
This sensitivity variation should be corrected for when using MOSFETs for HDR
brachytherapy dosimetry.

To independently check the planned dose, an EGS4 Monte Carlo code was used
to calculate the dose-rate distribution in water along the transverse axis of the
microSelectron HDR source. The photon cross section was generated by the code
PEGS4. The input source geometry and its characteristics were modeled using a
self-developed program (Chen et al 2006). Photons and electrons were transported
with a low energy cut-off of 10 keV, since most particles below 10 keV are secondary
electrons which are immediately absorbed. The primary energy spectra of the

192

Ir

source were taken from National Nuclear Data Center, Brookhaven National
Laboratory. The calculations were performed using the code DOSRZ. Many histories
were applied (109) to yield a statistical uncertainty lower than 1% at all scoring
locations.

The dwell times to deliver a fixed 20 cGy at five distances (1, 2, 3, 4, and 5 cm)
along the source transverse axis were calculated with the current source strength. The
MOSFET readings at each distance were recorded. The energy dependent correction
factors of the MOSFET detector, defined as the inverse of the MOSFET responses,
were obtained.

5.2.2.4. MOSFET performance investigation
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For accurate dosimetry, the features of each new MOSFET detector should be
well understood so as to utilize them properly and efficiently. Hence key
characteristics of the MOSFET detector in phantom measurements near the HDR 192Ir
source, such as the reproducibility, angular effect and dose linearity, were
investigated.

(1) Reproducibility

The reproducibility of the MOSFET detector response was determined by the
coefficient of dispersion of ten equal and successive irradiations at a distance of 5 cm
from the source in water.

The MOSFET detector was placed in the phantom with its sensitive surface (gate)
normal to the incident beam. A fixed dose of 20 cGy was irradiated each time. The
MOSFET readings, after correction for end effect and source decay, were used to
calculate the dose measurement reproducibility.

(2) Angular effect

The angular effect of the MOSFET detector was estimated for both the azimuth
axis and polar axis.

The azimuth angular dependence was measured using an

192

Ir source at 5 cm

source-to-detector distance in water, by rotating the MOSFET holder about the
longitudinal axis in 30° steps. The MOSFET detector was irradiated with a constant
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dose of 20 cGy at each angle and all the results were normalized to the 0° (i.e. normal
incidence) value.

The polar angular dependence was investigated under a

60

Co teletherapy unit,

where the MOSFET detector was inserted into the center of a custom-made spherical
phantom with its longitudinal axis aligned with the gantry rotation plane at the
isocenter. Using the constant dose setting and fixed 10×10 cm2 field size, the
sensitivity variation of the MOSFET detector about the polar axis was calculated from
270° to 90° clockwise by turning the gantry in 30° steps.

(3) Dose linearity

The linearity of MOSFET detector response was investigated in the water
phantom at a perpendicular distance of 2 cm from the 192Ir source.

Dose ranging from 5 cGy up to 200 cGy were measured with the established
calibration setup. The obtained MOSFET readings were plotted against the applied
doses and a best linear fit was used to estimate the expected MOSFET responses for
each given dose. The relative differences between the measured signals and their
expected values were calculated.

Also, the dose linear region of the MOSFET detector, beyond which the detector
becomes unusable for radiation dosimetry, was evaluated by comparing the variation
of MOSFET sensitivities at different accumulated dose levels. In the past several
months, one MOSFET detector was periodically calibrated with the accumulated dose
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up to 24 V. The dispersion of the measured sensitivity distribution around the mean
was computed.

5.2.2.5. Dosimetric verification of individual treatment plans

(1) Phantom plan creation

As a pretreatment QA program, the dosimetric accuracy of 30 single catheter
HDR intracavitary brachytherapy treatment plans was verified using the CMRP
MOSFET dosimetry system within the phantom. The treatment length varied from 1
cm to 4 cm, and the step size was 2.5 mm. The prescribed doses were given to the
minimum peripheral dose on the target surface. A geometric optimization was
performed, followed by a manual optimization to further improve the dose uniformity.

Following the completion of the treatment plan in Plato BPS, some dose points of
interest located at a perpendicular distance of 1-2 cm from the source train were set in
the plan as QA endpoints (see Figure 5.3). The doses at these points, which will be
measured in the phantom, were calculated. Since the MOSFET detector has a limited
lifetime, the prescription dose was modified to limit the doses (about 20 cGy) at the
dose points of interest. The quality assurance plan was then transferred to the
treatment control station.

127

Figure 5.3 Creation of a treatment QA plan for a nasopharyngeal carcinoma patient. The QA dose
points (blue spots) were placed at a perpendicular distance of 1 or 2 cm from the source train.

(2) Phantom measurements

The MOSFET detector and catheter were set up in the phantom according to the
geometry of the QA plan. To ensure position accuracy and reduce workload, the
MOSFET detector was fixed at the calibration point, while the dose points to be
measured were sequentially shifted to the position where the MOSFET detector was
located by adjusting the distance from the indexer to the first dwell position through
the console panel, as shown in Figure 5.4.
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Figure 5.4 Schematic drawing of the experiment setup. The MOSFET detector was fixed at the
calibration position in the phantom, while the dose points to be measured were sequentially moved
to the position where the detector was located by adjusting the distance from the indexer to the
first dwell position through the console.

Between four and five dose points were verified for each brachytherapy treatment
plan. The measured doses were compared to the planned doses for quality assurance
of the individual treatment plans.

5.3.

Results

5.3.1.

MOSFET Calibration and correction

Five MOSFET detectors from the same batch were independently calibrated. The
mean dose calibration factor between these MOSFETs was calculated to be 0.46±
0.012 cGy/mV. This indicated an intra-batch reproducibility of approximately 2.6%
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for the MOSkinTM detectors.

As illustrated in Figure 5.5, the MOSFET sensitivity varied as a function of the
distance from the source. The maximum sensitivity variation was found to be
approximately 7% in the given distance range. The associated correction factors,
calculated as the reciprocal of the normalized sensitivities, were tabulated in Table 5.2.
The correction factors for other positions between 1 and 5 cm can be determined
through interpolation.

Figure 5.5 The sensitivity variation curve of the MOSFET detector for the

192

Ir source. The error

bar represents one standard deviation.
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Table 5.2 Energy dependent correction factors at different distance from the 192Ir source in a water
phantom.

a

Distance (cm)

Mean energy (keV)a

Correction factor

1.0
2.0
3.0
4.0
5.0

323.55
293.91
269.47
250.23
340.32

1.07
1.04
1.02
1.01
1.00

The energy spectrum of the HDR 192Ir source was introduced from the published article (Zilio et

al 2006).

5.3.2.

MOSFET performance in HDR 192Ir source

(1) Reproducibility

The reproducibility of the detector response was evaluated for each individual
MOSFET detector. The delivered doses were corrected to compensate for end effect
and source decay. The coefficients of dispersion were below 2.5% for all the tested
MOSFET detectors.

(2) Angular effect

Both the azimuth axis angular dependence and the polar axis angular dependence
were evaluated. As shown in Figure 5.6, the azimuth axis angular dependence of the
MOSFET sensitivity varied less than 2% within 360°. The sensitivity about the polar
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axis varied within 2% for±60° (i.e. from 300° to 60°), and less than ±3% between
±75° (i.e. from 285° to 75°). A maximum decrease in MOSFET sensitivity of up to
5% was observed at the two longitudinal ends (see Figure 5.7).

Figure 5.6 The azimuth axis angular dependence for the MOSFET detector. The 0° position
corresponds to the gantry pointing straight down to the ground. All the measurements were
normalized to the 0° value.
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Figure 5.7 The polar axis angular dependence for the MOSFET detector. The 0° position
corresponds to the gantry pointing straight down to the ground. All the measurements were
normalized to the 0° value.

(3) Dose linearity

The MOSFET detector, with 5 V gate bias, has a linear dose response (R2=1.000)
versus the threshold voltage shift for doses from 5 cGy up to 200 cGy (see Figure
5.8).

Over the last several months, one MOSFET detector had been periodically
calibrated until the threshold voltage was accumulated up to 24 V. The coefficients of
dispersion of measured sensitivities were less than 3.5% within the tested threshold
voltage range. This suggested that the MOSFET detector, once calibrated, was able to
be used with medium accuracy throughout the entire lifetime (more than 100 Gy in
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this case). However, for more accurate dose measurements, periodic calibrations
based on the weekly or monthly frequencies are recommended.

Figure 5.8 Dose linearity of the MOSFET detector. The transit dose contribution was eliminated
from the MOSFET readings.

5.3.3.

Dosimetric verification of treatment plans

A total of 147 dose points for 30 single catheter HDR intracavitary brachytherapy
treatment plans were verified in the phantom using MOSFET detectors for quality
assurance.

Further comparisons of phantom measurements using MOSFET detectors with
dose calculations by Plato BPS showed that the mean relative deviation was 2.2±0.2%
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for dose points 1 cm away from the source and 2.0±0.1% for dose points located 2 cm
away. The relative deviations between the measured doses and the planned doses were
below 5% for all the measurements. No significant difference was found for the
different treatment lengths. A summary of the measurement results is listed in Table
5.3.

Table 5.3 Comparison of phantom measurements using MOSFET detectors with dose calculations
by Plato BPS for HDR intracavitary brachytherapy treatment plans of various treatment lengths.
The mean and the standard deviation (1σ) of the ratios are specified as percentages. The range of
percentage deviations are also listed in parentheses.

Dose points
of interest
1 cm away

2 cm away

Treatment length (cm)
1

2

3

4

2.0±1.8

2.1±2.0

2.4±1.7

2.2±2.1

(-1.2 to 4.5)

(-1.4 to 4.2)

(-0.9 to 4.4 )

(-2.1 to 4.6)

1.9±1.8

2.1±1.8

2.1±1.7

2.0±2.0

(-0.9 to 4.3)

(-1.9 to 3.9)

(-1.0 to 4.0)

(-1.2 to 4.1)

During a regularly scheduled pretreatment check, the time consumed for phantom
setup was about 5 minutes. The following treatment plan verification takes between 5
and 10 minutes, depending on the source strength, the dose prescription, and the
number of points measured.

135

5.4.

Discussion

A successful HDR treatment plan requires a reliance on many factors, including
accuracy in catheter reconstruction, reliability of treatment planning system software
data and algorithms, and consistency of information transfer. Understanding the
process behind these actions and functions becomes increasingly difficult. This may
cause a situation that errors are prone to occur. Since the HDR treatment procedure
usually proceeds very quickly, it is extremely difficult for users to verify each
treatment in such a short time. Potential errors in the treatment plan or treatment unit
operation overlooked by quality reviews will occur without detection. Therefore, the
QA for HDR treatment planning presents a great challenge. It is desirable that the
computed absorbed dose can be verified with independent dosimetric systems (Tolli et
al 1998).

In our cancer center we defined the QA process for HDR treatment planning on
three levels. The first level is to investigate the performance of the BPS during the
system commissioning. The second level is to verify the accuracy of the planned
doses for each patient on a routine basis. The third level is to measure the in vivo dose
during the HDR treatment. The direct phantom verification of the planned dose
introduces a comprehensive quality assurance program, covering not only the
treatment planning, but other factors including the source position accuracy and timer
consistency. Since the phantom verification is performed at a small distance from the
source, it is very sensitive to errors such as source position inaccuracies, data transfer
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errors or source strength discrepancies. Potential errors in dose computation &
optimization as well as in source decay compensation can be detected in time during
the phantom measurement, which may otherwise be unnoticed. According to the
report of AAPM Task Group 24 (1984), an uncertainty of ±5% for positions less than
2 cm from the source is a reasonable goal for the absorbed dose calculation. This
value is taken as our tolerance level.

The MOSFET detector, with its advantages of small size and instant readout, is
very suitable for routine phantom measurements in HDR brachytherapy where the
dose gradient is steep. Careful handling of the detector is essential to achieve accurate
dosimetric results (Gladstone et al 1994, Kron et al 1998, Kinhikar et al 2006). Each
MOSFET detector, regardless of the batch, requires individual calibration. The energy
dependent correction factors needs to be applied for accurate dose measurements,
especially for the measurements performed within 2 cm of the source.

To some extent, the reproducibility of the MOSFET detectors seems less than that
of diodes (Jornet et al 2004). This is partially due to the small fractionation dose
applied for MOSFET measurements. Ehringfeld et al reported that the error range for
commercial MOSFET detectors with “standard” bias sensitivity was closely
correlated with the dose used. For applied doses smaller than or equal to 1 Gy the
largest deviation can reach ±7.4%, and for doses between 1.5 and 2 Gy, these
maximum deviations decreased to±2.5% (Ehringfeld et al 2005). Nevertheless, the
uncertainty was not so great in small dose measurements for the tested CMRP
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MOSFET dosimetry system. The reproducibility of MOSFET detectors is still
acceptable and the reusability is similar to that of diodes. Our results were in good
agreement with previous observations of Cheung et al (2005) using a similar
dosimetry system.

At present, direct dose measurement in phantom with the CMRP MOSFET
dosimetry system has been taken as a standard QA program in our center for CT-based
single catheter HDR intracavitary brachytherapy treatments. After the usual
pretreatment checks were completed, the water phantom was assembled and the plan
QA was performed. This process can offer an additional opportunity for the
prevention of human errors and system malfunctions, and for users to become familiar
with the treatment procedures. The phantom measurement helps build confidence for
users to proceed with future in vivo dosimetry using MOSFET detectors.

As stated in ICRU report 24 (1976), an ultimate check of the actual treatment
given can only be made by using in vivo dosimetry. One of the major advantages of
MOSFET detectors is their extremely small physical size which can be easily inserted
into to a brachytherapy catheter. This provides a potentially useful tool for in vivo
dosimetry. In an ongoing project, we inserted a MOSFET detector into a
nasopharyngeal catheter, monitoring the actual dose variation during the HDR
treatment for nasopharyngeal carcinoma. Currently, dose variation has been assessed
in 11 cases, and the mean deviation of the measured dose versus the planned doses
was about 3.7%, with the maximum deviation less than 7%. The preliminary results
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revealed that the MOSFET detector was useful for in vivo dosimetry as a safeguard
against erroneous treatment.

5.5.

Conclusion

The newly developed miniature MOSFET detector has several advantages over
the previously used RADFET dosimeter:
(1) Very small physical dimensions that can be held in a 6F catheter;
(2) Improved angular dependence (within ±2% over full 360°);
(3) Much longer lifetime (more than 100 Gy).
It has proven to our satisfaction that it can provide a reliable tool for confidence
checks of HDR brachytherapy treatments.

Pretreatment QA of the brachytherapy treatment plan with MOSFET detectors
has been demonstrated to be useful in preventing human errors and system
malfunctions. The phantom verification method described here is universal and can be
applied to all HDR brachytherapy treatments. Future work will focus on in vivo
dosimetry using MOSFET detectors to improve the accuracy of HDR treatments.
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CHAPTER 6
In vivo verification of superficial dose for head and neck treatments
using intensity-modulated techniques

6.1.

Introduction

Accurate knowledge of superficial dose is generally important in radiation
therapy (RT), especially when patient skin is a part of dose limiting critical tissue or a
part of the treatment target in some cases of advanced diseases. An overexposure of
the skin to radiation may lead to acute skin reactions or delayed effects (Turesson et al
1989, Denham et al 1995, Denham et al 1999). Although improved treatment
techniques such as intensity modulated RT (IMRT) may help reduce normal tissue
complications (Ling et al 1996, Nutting et al 2000, Xia et al 2000, Huang et al 2003),
adverse skin reactions are still common. A significant increase in acute skin toxicity
has been clinically observed in the neck region for nasopharyngeal carcinoma (NPC)
patients receiving extended-field IMRT (Lee et al 2002). The possible causes of the
observed skin reactions may be due in part to the increased skin doses from the “bolus
effect” of the thermoplastic mask, the use of multiple tangential beams, and the
inclusion of the skin as part of the target volume. These high doses, and subsequent
skin reactions, can be avoided during the treatment planning by setting the dose
objectives to the clinical target volume (CTV) to higher importance (Thomas et al
2003) or by designating the skin a sensitive structure and giving it a low dose
objective (Lee et al 2002 ).
However, a number of phantom investigations have demonstrated that accurately
predicting superficial doses in commercially available treatment planning systems
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(TPS) is generally problematic (Mutic et al 2000, Chung et al 2005, Chow et al 2006,
Higgins et al 2007). Megavoltage x-ray dose delivered in the first few millimeters is
dominated by electron contamination and depends largely on beam setup parameters
(e.g., source to skin distance, field size) and patient-specific geometry. The planning
systems are normally unable to accurately calculate the patient skin dose because of
the complexity of head scatter associated with patient-specific treatments, particularly
with IMRT (Chow et al 2006). A previously published study has revealed that TPS
can overestimate the skin dose by up to 18.5% (Chung et al 2005). In recent years, it
has been shown that the Monte Carlo methods, such as EGS4/BEAM, are capable of
accurately calculating the dose in the build-up region (Rogers et al 1995, Liu et al
1997, Scalchi et al 2005). However, the use of Monte Carlo systems is restrained in
routine clinical practice due to the expensive computing power required. Therefore, in
vivo measurements are frequently needed to verify the skin dose calculations,
especially when a critical equivalent dose volume lies close to the surface.
Skin dose measurement is a challenging task as there is a major difficulty in
reproducing the equivalent depth of the small distance to superficial layers. The whole
skin, consisting of the epidermis and the dermis, is typically 3 mm in thickness
(Whitton et al 1973). The radiosensitive basal layer, the innermost layer of the
epidermis, is an average depth of 0.07 mm and varies throughout the human body
(e.g., from 0.05 mm for the eyelid to 1.5 mm for sole of the foot) (ICRP 1975).
Beneath the epidermis lies the dermis that can extend to a depth of 0.5 mm on the
eyelid to 3.0 mm on the back. Blood vessels and nerves course through this layer,
which supplies the skin with nutrition and transmits sensations of pain, itch, and
temperature (Williams et al 1989). The clinically relevant depth for skin dose
determination depends on the biological effect considered. For skin erythema the
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basal cell layer is of interest, while at higher doses the damage is related to deeper
layers of the skin (ICRP 1978). Previous clinical research has found that late skin
reactions such as hypoxia and telangiectasis occur when the dermis is exposed to a
large dose (Pointon 1991). Hence the measurement depth of concern in this study is
ranging from 0.05 mm to the first few millimeters for the head and neck radiation
treatments.

Traditionally entrance and build-up region doses are best measured with
extrapolation chambers (Velkley et al 1975), but few institutions have these
instruments at their disposal. Due to the thin entrance window, fixed-separation
plane-parallel ionization chambers, with appropriate corrections, are most commonly
used in the clinic for this purpose (Rawlinson et al 1992, Gerbi et al 1993).
Unfortunately, these ionization chambers are only suitable for phantom measurements
because of their large size and rigid geometry. Application of radiochromic film and
TLD extrapolation method for skin dosimetry has been described earlier (Kron et al
1993, Butson et al 1998, Devic et al 2006). Recently, there has been a great interest in
using MOSFET detectors for measuring the patient skin dose (Butson et al 1996,
Quach et al 2000, Scalchi et al 2005). The major advantages of this detector include
its small physical size, immediate readout and its ability to record dose history.
Nonetheless, several investigations have also revealed that the MOSFET detectors
may produce incorrect skin surface dose readings due to the intrinsic build-up of
MOSFET encapsulation (Rosenfeld et al 1995, Butson et al 1996, Xiang et al 2007).
As a consequence, the build-up thickness of the MOSFET detector should be taken
into account for accurate skin dosimetry.

143

Current commercially available standard MOSFET detector (TN-502, Thomson
and Nielson Ltd, Ottawa, Canada) has been known to have an intrinsic build-up equal
to a water equivalent depth (WED) of 0.8 or 1.8 mm depending on sensor orientation
(Scalchi et al 1998). As to the improved Thomson and Nielson’s microMOSFET
(TN-502RDM, Thomson and Nielson Ltd, Ottawa, Canada), Ramaseshan et al found
the WED for the microMOSFET to be dependent on photon beam energy and in a 6
MV photon beam, the calculated WED values were 0.89 mm for the epoxy side and
1.48 mm for the flat side (Ramaseshan et al 2004). Xiang et al (2007) reported the
microMOSFET had a WED of 0.72 mm for 6 MV x-ray beams from the epoxy side,
and a WED of 0.87 mm from the flat side. They further suggested that this
microMOSFET was best used to estimate superficial doses at a depth equal to or
deeper than 1 mm. For dose measurements with micro-MOSFETs directly placed at
the phantom surface, appropriate corrections must be applied to give reasonable
estimations of phantom skin doses. More recently, Cherpak et al (2008) estimated the
WED of the micoMOSFET using the manufacturer-recommended orientation with the
flat side of the detector facing the beam and obtained an average WED value of 0.53
mm in 6 MV photon beams. They have applied this MOSFET device in quality
assurance of tomothetapy treatments and results proved the MOSFET detector can
provide valuable skin dose information in areas where the treatment planning system
may not be accurate. Clearly the microMOSFET detector when corrected for the
WED can be used to measure build-up doses. However, lack of ability to provide
direct measurement of the total radiation dose deposited in the very shallow skin
layers (e.g. 0.05 to 0.5 mm in this case) has sparked new interest in designing a
MOSFET with minimal intrinsic build-up for in vivo skin dosimetry.
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To develop a proper patient skin dosimeter, Scalchi and his co-workers (2005)
introduced a new MOSFET detector configuration. They removed part of epoxy
coating from a commercially available MOSFET detector, resulting in an intrinsic
build-up equal to a WED of 0.09 mm on average (from 0.04 to 0.15 mm). Due to
extremely thin WEDs, which are close to the epidermis thickness, the modified
MOSFET sensors have been proved suitable for in vivo skin dosimetry in their total
body irradiation (TBI) setup.

For the use of the MOSFET as a skin dosimeter in a complicated treatment
condition, particularly for tomotherapy IMRT, the angular dependence of the
MOSFET detector is a key issue. The quoted uncertainties for current MOSFET
designs are usually within ±2～3% in a full-buildup setup (like the detector placed at
the center of a spherical or cylindrical phantom) (Ramaseshan et al 2004, Qi et al
2007, Cherpak et al 2008). As charged particle equilibrium (CPE) conditions do not
exist in the build-up region and a full-buildup setup may give better results than a
surface setup (Scalchi et al 2005), the angular dependence should be re-evaluated for
the MOSFET detectors in skin dosimetry applications.

The main aim of the present study was to assess the use of an alternative
MOSFET detector in verifying the superficial dose calculations for a commercial
inverse TPS both in phantom and in vivo. This device was recently introduced for
brachytherapy dosimetry purposes (Qi et al 2007). To yield a minimal but
reproducible intrinsic build-up, the sensor surface was specially coated with a
polyimide thin film rather than conventional epoxy bubble. The feasibility of this
MOSFET detector for accurate skin dosimetry was firstly evaluated in a
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water-equivalent slab phantom by comparison with a thin-window plane parallel
ionization chamber and radiochromic films. The WED value of the MOSFET build-up
material was determined accordingly and the angular dependence was assessed with
the MOSFET detector positioned at the phantom surface. The uncertainties of a
commercial inverse TPS in skin dose calculations were then investigated using these
MOSFET detectors in an anthropomorphic phantom. The preliminary results of in
vivo skin dosimetry for IMRT treatment of NPC patients were also presented.

6.2.

Materials and Methods

6.2.1.

Phantom and irradiation conditions

Central axis percentage depth dose (PDD) in the build-up region was measured in
a water-equivalent RW3 slab phantom (SP34, PTW-Freiburg, Freiburg, Germany).
The use of water-equivalent solid phantom rather than liquid water was assumed to
introduce a negligible uncertainty (Tello et al 1995). In addition, the solid phantom
helps minimize the uncertainties in depth positioning near the surface. The RW3 slab
phantom has a physical density of 1.045 g·cm-3 and consists of 30×30 cm2 slabs of
various thickness ranging from 1 mm to 5 cm. The equivalent depth was herein
referred to the equivalent mass depth and the detector readings in the slab phantom
had to be corrected by a scaling factor which was defined as the ratio of the ionization
readings in liquid water to that in the RW3 phantom at the same equivalent mass
depth in the user beams.

The build-up region measurements were carried out with four different
dosimeters, including the Attix plane parallel ionization chamber (RMI Model 449,
Middleton, WI), EBT GAFCHROMIC® film (ISP, Wayne, NJ), a commercial
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MOSFET (OneDoseTM, Sicel Technologies, Morrisville, NC) and our newly
developed miniature MOSFET detector. All the dosimeters were irradiated at the
phantom surface and at various depths in a SSD setup with a 6 MV photon beam
using a Varian 600C linear accelerator (Varian, Palo Alto, CA). The results represent
the average of five continuous readings for each measurement.
For ease of understanding, throughout this chapter, the term “surface dose” was
used to refer to the real zero-depth dose and the term “dose measured at the phantom
surface” denotes the dose measured with a dosimeter placed at the phantom surface
with its external surface levelled with the phantom surface.

6.2.2.

MOSFET dosimetry system

The newly designed miniature MOSFET detector (MOSkinTM) and a CMRP
microprocessor based reader were used in this experiment.
Unlike most other MOSFET detectors, the MOSkinTM does not incorporate an
epoxy bubble to encapsulate and protect the radiosensitive MOSFET sensor. Special
packaging technology has been used that allows the MOSFET to be hermetically
sealed with a tissue equivalent flexible overlayer of reproducible thickness. Figure 6.1
shows schematic comparison of this MOSFET detector with the traditional MOSFET
design in their encapsulation.

The MOSFET detector was used in an active mode with a positive gate bias of 5
V to increase the sensitivity and linearity of its dosimetric characteristics. This
corresponds to a sensitivity of about 2.0 mV·cGy-1 for measurements at a depth of 1.5
cm in the water phantom under a 6 MV photon beam from a medical linac.
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Figure 6.1 A schematic comparison of the packaging between a typical MOSFET detector
(Left) and a MOSkinTM (Right). To yield a minimal but reproducible intrinsic build-up, the
MOSkinTM surface is specially coated with a polyimide thin film rather than conventional
epoxy bubble, which also avoids wire bonding.

The radiation-induced threshold voltage shift is measured by the reader using a
selected current for a thermostable point on the MOSFET current versus voltage (I-V)
characteristic, which minimizes the temperature sensitivity of the MOSFET readings
(Rosenfeld et al 2001). Thus standard calibrations performed at room temperature can
be directly used for in vivo dose assessments conducted at near body temperature
without a temperature correction function (Cheung et al 2004). The stated uncertainty
associated with this readout equipment is lower than ±1 mV before and after the
irradiation (Zilio et al 2006). Recently published study has reported that the MOSFET
detector is able to be used with sufficient accuracy until the threshold voltage reached
approximately 24 V (Qi et al 2007). More details on this MOSFET dosimetry system
are given in Rosenfeld et al (2001).

6.2.3.

Comparison of surface and build-up region dose measurements

6.2.3.1. Reference ionization chamber dosimetry

Thin-window Attix parallel plate ionization chambers are often used to measure
surface doses and doses in the build-up region. The over-response of the Attix
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chamber in measured PDDs was reported to be less than 1% for normally incident 6
MV photon beams (Rawlinson et al 1992, Gerbi et al 1993) as such no corrections to
data were required. For obliquely incident photon beams, however, the Attix chamber
was observed to have limited angular dependence (Gerbi et al 1993) and thus proper
corrections were used according to the published over-response factors given by Gerbi
et al (1993). In this study, the Attix chamber was our standard of comparison for all
measurements.

To better reconstruct the PDD curve of normally incident photon beams within
the build-up region, the depth dose measurements were conducted from the phantom
surface with 1 mm increments to a depth of 1.6 cm extending up to one millimeter
from dmax. The effective point of measurement of the Attix chamber was taken to be at
the center of the front surface of the air cavity, which corresponds to a reference depth
of 4.8×10-3 g/cm2 (Devic et al 2006). In a fixed SSD setup, 100 Monitor Unit (MU)
was delivered each time and all results were normalized to the dmax value. Different
field sizes were investigated ranging from 5×5 to 30×30 cm2.

To evaluate the MOSFET response to obliquely incident beams, the Attix
chamber was taken as a reference and thus the PDDs were also measured with the
Attix chamber at the slab phantom surface for beam angles of 30°, 60°and 75°,
respectively, using a 10×10 cm2 radiation field.

For dose measurements in the build-up region, signals for both positive and
negative chamber polarities were measured with the ionization chamber and the
average chamber reading between the two polarities was recorded. This can
effectively eliminate the so-called “Compton current” that is caused by the photon
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interactions in the chamber measuring electrode and can lead to increased reading for
positive chamber polarity and decreased reading for negative chamber polarity
(Podgorsak 2003).

6.2.3.2. Film dosimetry

For comparison, the surface and build-up region doses of normally incident 6 MV
photon beams were also measured with EBT GAFCHROMIC® films (Lot no.
34016-3BX2, International Specialty Products, Wayne, NJ). The EBT film has two
sensitive layers, each with a thickness of 17 µm and separated by a surface layer of 6
µm, all sandwiched between two 97-µm-thick polyester sheets. The effective point of
measurement was reported to be at a depth of 1.53×10－2 g/cm2 underneath the surface
(Devic et al 2006).
For the measurements, the EBT film was cut into small pieces of 2×2 cm2 in size.
Because response of the EBT film is sensitive to orientation, the direction of each
small film piece was recorded and the same orientation was maintained during
irradiation and readout. To optimize the film response, different number of MUs was
given, depending on depths and field sizes used, to keep a delivered dose of 100 cGy
for all the measurements. Background (un-irradiated) film pieces were also obtained
at the start and completion of each run.
After a period of 6 hours post-irradiation, all exposed films were digitized using
an Epson 1680 flatbed scanner (Epson Seiko Corporation, Nagano, Japan) with a
red-light filter. Film pieces grouped within an area of 10×10 cm2 were scanned
together. The pixel resolution was set to 0.2×0.2 mm2 and the average reading of
optical densities (OD) over a central area of 10×10 mm2 for each film piece was
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acquired and processed using a commercial software (OmniProTM I’mRT, Standard
Imaging Inc, USA).
The net OD of each irradiated film piece was obtained by subtracting the average
background OD. These readings were then corrected to a fixed irradiation of 100 MU.
Using pre-determined calibration curve, the net ODs were converted to the dose and
all results were normalized to the dmax value.

6.2.3.3. MOSFET dosimetry
Four MOSkinTM detectors and six OneDoseTM MOSFETs were investigated in
this study. The MOSkinTM detectors were calibrated against a NE 2571 0.6 cm3 Farmer
type ionization chamber (Nuclear Enterprises, U.K.) at a depth of 1.5 cm in a water
phantom using 100 cm SSD and 10×10 cm2 field size under Varian 600C 6 MV
photon beams. The OneDoseTM MOSFETs were pre-calibrated by the manufacturer
and were re-verified in the user beam for each batch under the above calibration
conditions.
For surface and build-up region dose measurements, the MOSFET detectors were
embedded into a 1 cm thick phantom slab with a round epoxy bubble surface facing
the beam in case of the OneDoseTM MOSFET and with the sensitive surface (gate)
facing the beam in case of the MOSkinTM detector. The surface of these detectors was
leveled with the surface of the slab.

Using a fixed SSD=100 cm and normally incident 6 MV photon beams, the
measurements were performed at the phantom surface and at different depths ranging
from 1 mm to dmax for the following field sizes: 5×5, 10×10, 20×20, and 30×30 cm2.
To keep the MOSFET signal (i.e. the change of the threshold voltage) at a reasonable
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level (about 100 mV), different MUs were administered depending on the depths and
the field sizes used. The readings were corrected to a fixed irradiation of 100 MU and
were then normalized to the dmax value. Each measurement was repeated five times.
The reproducibility of MOSFET readings, defined as the coefficient of dispersion of
repeated measurements from individual detectors, was evaluated at the phantom
surface and at the dmax, respectively.
To assess the angular response of the MOSkinTM detector at a surface setup, the
PDD was also measured at the slab phantom surface with oblique incident beam
angles of 30° , 60° and 75°, respectively, using SSD=100 cm and 10×10 cm2 field size.
To account for the surface dose variation with the obliquely incident beams, the
angular dependence of the MOSFET was determined by taking the ratio of the
MOSFET measurements to the corresponding Attix chamber results.
The MOSFET measured surface PDDs for both the MOSkinTM detector and the
OneDoseTM MOSFET were then compared to a polynomial fit of the ionization
chamber measurements in the build-up region. The WED of each MOSFET detector
was thus acquired (Scalchi et al 1998, Scalchi et al 2005). The coefficient of
dispersion of WED values between four MOSkinTM detectors was further calculated to
evaluate the manufacturing reproducibility of detector encapsulation.

The MOSFET measurement depths were shifted downstream accordingly and the
corrected PDDs of MOSFET measurements were compared with reference Attix
chamber results and EBT film data, whereby the feasibility of using different
MOSFET detectors for surface and build-up region dose measurements was
evaluated.

152

6.2.4.

Evaluation of a commercial treatment planning system for surface and

build-up region dose calculations

6.2.4.1. Anthropomorphic phantom and CT simulation
An average-man Rando® Phantom (The Phantom Laboratory, NY, USA) was
used to simulate the radiotherapy treatments. The head and neck part of the phantom
was immobilized in the supine position with a thermoplastic mask. The MOSkinTM
detectors were placed on the head and neck surface through the interstice of the mask
at the following hypothetic locations: (1) right and left parotids with a deep seated
primary tumour volume of nasopharyngeal carcinoma; and (2) right and left sides of
the necks with a shallow depth target of lymph nodes.
A CT scout scan was firstly acquired, from which the setup isocenter was
determined. Fiducial markers were attached to the phantom and lined up with the CT
lasers to identify the setup position. The Rando phantom with the MOSFET detectors
in place was then scanned using the parameters that clinically selected for a NPC
treatment (i.e. 3-mm-slice thickness and 3-mm spacing). The acquired CT images
were transferred to a commercial TPS (Corvus 6.2, North American Scientific, CA).
To evaluate the build-up region dose calculations at different depths, a 0.5 cm
thick bolus and a 1 cm thick bolus were placed over the MOSFET detectors,
respectively. The associated CT images of the phantom with boluses were also
acquired for treatment planning.
6.2.4.2. Treatment planning
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A serial tomotherapy IMRT system, namely Peacock System (North American
Scientific, CA), has been in use in our department since 2000. The system includes an
inverse TPS (Corvus 6.2) and MIMiC MLC, which delivers IMRT in an arc mode.
Once the CT images were registered in the Corvus TPS, the phantom outline was
generated by defining a window and level that includes the skin but not the
surrounding air. A hypothetical primary tumor target and neck lymph nodes were
contoured on all the involved CT images. Three critical structures (brainstem and two
parotid glands) were also considered.
A total dose of 68 Gy in 30 fractions over 42 days was prescribed to the GTV.
The planning goals, transferred from a real patient plan, were assigned not only to the
tumor target, but also to the non-target tissue and critical structures. Since the so
called partial volume effect is particularly significant near the air-surface interface and
finest grid size is expected to minimize this problem for the head and neck treatment
(Cherpak et al 2008), the calculating matrix was set as 1×1 mm2. Tissue heterogeneity
correction was applied with the specified density calibration curve during the
optimization and dose calculation process. A Varian 600C 6 MV photon beam was
chosen with MIMiC setting in 2-cm mode. The gantry rotation arc was set as
105-255°, and the beamlet patterns changed every 5°.
The dose distribution was calculated and optimized. The planned doses to the
locations where the MOSFET detectors were situated were obtained, and the
treatment delivery reports were transferred to the Varian 600C linac.
6.2.4.3. Surface and build-up region dose measurements
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Once the Rando Phantom was set up on the treatment couch, the MOSFET
detectors were connected to the reader via a 20-meter cable.
Three treatment plans were sequentially delivered, and measurements were
performed with MOSFET detectors at the phantom surface, under the 0.5 cm thick
bolus, and under the 1.0 cm thick bolus, respectively. The corresponding threshold
voltage shifts of these detectors were recorded and converted to doses based on the
known calibration factors. By comparison of measured doses with planned doses, the
capability of the inverse TPS in accurately predicting the surface and build-up region
doses was assessed.
6.2.5.

In vivo measurement of patient skin dose

Following the phantom assessment, the MOSkinTM detector was used to verify
skin dosimetry in vivo for NPC patients undergoing serial IMRT treatments.
During patient simulation, 2 or 3 MOSFETs were placed on the surface of
patient’s head and neck. These radiopaque detectors were identified on the CT images
in the planning system, and doses delivered to the MOSFET detectors were
determined.
In vivo dosimetry with the MOSFET detector was performed in the first IMRT
treatment session. The positioning accuracy of the treatment setup with the detector
was verified by portal film each time. Following the completion of the IMRT
treatment, the measured threshold voltage shift of each MOSFET detector was
converted to dose which was then compared with the planned dose.
To date, IMRT in vivo skin dosimetry has been performed for a total of 16
measurements of 6 NPC patients. The preliminary results are presented in this study.
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6.3.

Results

6.3.1.

Comparison of surface and build-up region dose measurements

Table 6.1 and Table 6.2 give the PDDs obtained with an Attix chamber and EBT
films, respectively, at the phantom surface and in the build-up region for various field
sizes ranging from 5×5 to 30×30 cm2. The specified measurement depths in the slab
phantom were converted to the corresponding depths of the effective points of
measurement in water. The percentage uncertainties relevant to the Attix chamber
measurements and EBT film results, in terms of one standard deviation (SD) around
the mean, are on average 0.03% and 1.02%, respectively.

Table 6.1 Percentage depth doses (PDD) obtained with an Attix chamber in a water-equivalent
RW3 phantom for normally incident 6 MV photon beams from a Varian 600C linac. Different
field sizes ranging from 5×5 to 30×30 cm2 were investigated using a fixed SSD=100 cm. The
coefficients of dispersion relevant to the Attix chamber measurements were on average
0.03%.

Phantom
depth
(cm)

Effective point
of measurement
(g/cm2)

5×5

10×10

20×20

30×30

Surface

0.0048

12.90

18.95

29.12

37.89

0.1

0.1093

39.58

44.75

52.85

59.22

0.2

0.2138

59.50

63.17

69.12

74.18

0.5

0.5273

88.56

89.63

92.74

94.44

1.0

1.0498

97.82

98.10

98.49

98.71

1.4

1.4678

100.00

100.00

100.00

100.00

PDD (%)
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The PDDs measured with the MOSkinTM detector at the phantom surface and in
the build-up region are listed in Table 6.3. The measurements are reported at depths
scaled by physical density. These PDD data are compared to a four-order polynomial
fit of the ionization chamber measurements in the build-up region. The resulting
WEDs for each field size are given in Table 6.4.

Table 6.2 Percentage depth doses (PDD) obtained with EBT films in a water-equivalent RW3
phantom for normally incident 6 MV photon beams from a Varian 600C linac. At SSD=100
cm, different field sizes ranging from 5×5 to 30×30 cm2 were investigated. The coefficients of
dispersion in EBT film measurements were on average 1.02%.

Phantom
depth
(cm)

Effective point
of measurement
(g/cm2)

5×5

10×10

20×20

30×30

Surface

0.0153

13.48

23.52

33.68

41.97

0.1

0.1198

41.74

49.12

56.78

62.28

0.2

0.2243

61.82

64.17

70.86

74.89

0.5

0.5378

89.31

89.64

93.47

95.96

1.0

1.0603

97.79

98.22

98.67

98.84

1.4

1.4783

100.00

100.00

100.00

100.00

PDD (%)

As shown by our measurements, the encapsulation of the MOSkinTM results in an
intrinsic build-up thickness equal to the WED of 0.08±0.01 mm for radiation field
sizes ranging from 5×5 to 30×30 cm2. The observed insignificant WED variation with
radiation fields may be due in part to the field-size dependence of the MOSFET
sensitivity. Considering the MIMiC IMRT delivers a beam with size no more than 20×
4 cm2, the MOSkinTM detector can provide an effective WED of about 0.07 mm.
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Table 6.3 Percentage depth doses (PDD) obtained with a MOSkinTM detector at the slab
phantom surface and in the build-up region for normally incident 6 MV photon beams.
Different field sizes ranging from 5×5 to 30×30 cm2 were investigated using a fixed SSD=100
cm. The equivalent depth was herein referred to the equivalent mass depth from the phantom
surface to the detector surface. The coefficients of dispersion relevant to the MOSkinTM
measurements were also listed.

Phantom
depth
(cm)

Equivalent
depth
(g/cm2)

5×5

10×10

20×20

30×30

Surface

0.0000

13.48±1.8%

19.49±1.7%*

30.13±1.7%

39.08±1.7%

0.1

0.1045

40.60±1.6%

45.99±1.5%

52.71±1.7%

60.20±1.7%

0.2

0.2090

58.84±1.6%

62.92±1.6%

68.63±1.6%

74.12±1.6%

0.5

0.5225

88.09±1.7%

88.77±1.7%

92.27±1.5%

94.28±1.7%

1.0

1.0450

97.06±1.4%

97.68±1.2%

98.61±1.4%

98.46±1.4%

1.4

1.4630

100.00±1.3%

100.00±1.2%

100.00±1.3%

100.00±1.4%

PDD (%)

Note: For 10 x 10 cm2 the reported surface value (*) comes from the mean detector response
of four MOSkinTM detectors, as given in Table 6.5.

Table 6.4 Water equivalent depth (WED) of the MOSkinTM detector for each field size under 6
MV photon beams. The coefficients of dispersion associated with MOSkinTM measurements at
the phantom surface were on average 1.7%.

Field Size
(cm)

WED value
(mm)

5×5

0.07

10×10

0.07

20×20

0.08

30×30

0.10

AVE

0.08±0.010
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For the sensor reproducibility, the coefficient of dispersion of repeated
measurements from individual MOSkinTM detectors is calculated to be on average
1.7% and 1.3%, respectively, for detectors placed at the phantom surface and at the
dmax. There is no statistically significant difference in the sensor reproducibility among
various field sizes.
As to the manufacturing reproducibility of detector encapsulation, a total of four
MOSkinTM detectors were investigated using a 10×10 cm2 radiation field. The global
average dose from all the mean detector responses is 19.49% of the dmax value, with a
coefficient of dispersion less than 0.4%. This corresponds to an average WED of 0.07
mm with a small standard deviation of 0.002 mm between the MOSFETs (see Table
6.5). Our results indicate that the encapsulation techniques used for the MOSkinTM
detector is highly reproducible to be better than 3.5% in terms of WED values.
Figure 6.2 presents comparisons of the MOSkinTM detector with the Attix
chamber and EBT films in the build-up region dosimetry for different field sizes. The
MOSkinTM measured PDDs were corrected for the intrinsic build-up thickness by
shifting the measurement depths downstream accordingly. The results show that the
MOSkinTM measurements, when considering the intrinsic build-up thickness, provide
an improved agreement with the PDDs obtained using the Attix chamber and EBT
films in all field sizes.
Table 6.6 gives PDDs measured with the MOSkinTM detector and the Attix
chamber, respectively, at the slab phantom surface for both normally and obliquely
incident beams. The MOSkinTM data are normalized to the dmax value of normal
incident-beam angle and so do the Attix chamber results. The ratios of MOSkinTM

159

measurements vs. Attix chamber results, which reflect the sensitivity variation of the
MOSFET detector with incident-beam angles, are also listed in Table 6.6. All the
ratios are normalized to the 0° value.

Table 6.5 Percentage depth doses (PDD) measured at the phantom surface using four
MOSkinTM detectors from the same batch for the 6 MV photon beam of 10×10 cm2 field size.
Each measurement was repeated five times and the average values were reported. The
coefficients of dispersion relevant to MOSkinTM measurements at the phantom surface were
on average 1.7%. The WED values associated with each individual MOSkin detector were
also given.

MOSFET

Relative Surface
Doses (%)

According WED
(mm)

No.1

19.55

0.069

No.2

19.45

0.066

No.3

19.55

0.069

No.4

19.43

0.065

AVE

0.067±0.002

As shown in Figure 6.3, the MOSkinTM measurements are consistent with the
Attix chamber results within 0.1% when the beam is incident at 30°, but exhibit slight
over-response at beam angles of 60° and 75° (i.e. 3.1% and 2.8%, respectively).
The PDDs obtained at the phantom surface and at the 0.5-cm depth using the
OneDoseTM MOSFET detector were 47% and 92%, respectively, for the 10x10 cm2
radiation field. This implies that the intrinsic build-up of the OneDoseTM MOSFET
detector due to epoxy encapsulation yields a WED of 1.2 mm (see Figure 6.4).
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5×5 cm2 field

a

10×10 cm2 field

b
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20×20 cm2 field

c

30×30 cm2 field

d
Figure 6.2 Percentage depth doses (PDD) for normally incident 6-MV photon beams.
Measurements were performed with different detectors in a water-equivalent RW3 slab
phantom. At a fixed SSD=100 cm, the following field sizes were investigated: 5×5 cm2 (a),
10×10 cm2 (b), 20×20 cm2 (c), and 30×30 cm2 (d). The MOSkinTM measured PDDs, as given
in Table 6.3, were corrected for the intrinsic build-up thickness. The error bars represent the
coefficient of dispersion of five measurements.
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Table 6.6 Percentage depth doses (PDD) measured with the MOSkinTM detector and the Attix
chamber, respectively, at the phantom surface for both normal and oblique incident beams.
The coefficients of dispersion of each assessment were also reported.

Incident angle (°)

0

30

60

75

MOSkin (%)

19.49±1.7%

21.42±1.6%

28.51±1.7%

37.98±1.7%

Attix chamber (%)

18.95±0.03%

20.82±0.03%

26.88±0.03%

35.92±0.02%

Normalized ratio

1.000

1.000

1.031

1.028

Figure 6.3 Sensitivity variation of the MOSkinTM detector with incident-beam angles for dose
measurements at the phantom surface. The radiation field size was set to be 10×10 cm2 at
SSD=100 cm. The error bars represent the coefficient of dispersion of five measurements.
Results were normalized to the 0° value.
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Figure 6.4 Determination of water equivalent depth (WED) for the OneDoseTM MOSFET
detector. The percentage depth doses (PDD) obtained with the OneDoseTM MOSFET at the
phantom surface and at the 0.5-cm depth for the 6 MV photon beam of 10×10 cm2 field size
were compared to a polynomial fit of the Attix chamber measurements in the build-up region.

6.3.2.

Evaluation of a commercial treatment planning system for surface and

build-up region dose calculations
Table 6.7 shows comparisons of doses measured using MOSkinTM detectors with
doses calculated by the Corvus 6.2 TPS for various locations of clinical interest.
Comparisons were performed at the surface of the anthropomorphic phantom and at
the depths of 0.5 and 1.0 cm, respectively.
From Table 6.7, it is clear that the planning system may overestimate the skin
dose by an average of 7.8%, ranging from 7.1% to 8.5%. However, at the depths of
0.5 cm and 1.0 cm, the dose difference between MOSkinTM measurements and TPS
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calculations was within measurement uncertainty. No statistically significant
difference was found for various locations.

Table 6.7 Comparison of doses measured using the MOSkinTM detector with doses calculated
by the Corvus TPS at different depths for various locations of clinical interest in an
anthropomorphic phantom. The coefficients of dispersion of MOSkinTM measurements were
also listed.

Structures

Parotid(L)

Parotid(R)

Neck(L)

Neck(R)

Depth
(cm)

Calculated
(cGy)

Measured
(cGy)

Deviation
(%)

Surface

50.9

46.9±1.7%

-7.9

0.5-cm

67.5

68.8±1.6%

1.9

1.0-cm

79.9

81.6±1.3%

2.1

Surface

57.9

53.0±1.7%

-8.5

0.5-cm

70.3

72.4±1.5%

3.0

1.0-cm

77.2

79.1±1.3%

2.5

Surface

170.9

158.1±1.5%

-7.5

0.5-cm

198.4

204.7±1.2%

3.2

1.0-cm

213.6

216.8±1.0%

1.5

Surface

166.7

154.8±1.5%

-7.1

0.5-cm

194.3

198.5±1.2%

2.2

1.0-cm

212.2

211.4±0.9%

-0.4

Note: The deviation (%) = (Dose measured–Dose calculated) / Dose calculated×100

6.3.3.

In vivo measurement of patient skin dose

The in vivo skin doses, measured using MOSkinTM detectors during the first
IMRT treatment fraction for 6 NPC patients, are plotted in histograms as deviation
from the calculated doses (see Figure 6.5). The observed dose difference between
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MOSFET measurements and TPS calculations was on average -7.2%, ranging from
-4.3% to -9.2%. This reveals that much attention should be paid to the skin dose
calculations in the planning system.

Figure 6.5 Relative deviation of MOSkinTM measured skin doses from TPS calculated skin
doses as percentage for a total of 16 measurements of 6 NPC patients. The negative deviation,
defined as (Dose measured-Dose calculated)/Dose calculated×100, indicates that the
measured skin doses are lower than the calculated values.

6.4.

Discussion
The radiation-induced skin reactions were most frequently observed during the

days of orthovoltage radiotherapy. In the era of megavoltage radiotherapy, the
build-up of absorbed dose is responsible for the skin sparing effect, representing an
important advantage of megavoltage beams in skin protection during the irradiation of
deep-seated tumors. However, even when optimal conditions of megavoltage
irradiation are met, about 25% of the patients undergoing external radiotherapy using

166

parallel opposed lateral fields will still have observable skin reactions (Lee et al 2002).
Skin reddening is quite common, while slight oedema, blisters, increased
pigmentation and dry desquamation can sometimes eventuate. Less common, but
more severe, effects include oedema of subcutaneous tissues, moist desquamation,
epithelialization, erosion, ulceration, ischemia and tissue necrosis (Paelinck et al
2005). Hence the patient’s skin should be treated with care, especially when critical
equivalent dose volume lies close to the surface.
Currently the definition of “skin dose” has not been clearly introduced in
radiotherapy, despite the fact that the equivalent dose Hp (0.07) as given in the ICRP
Report 60 (1991) is an acceptable parameter for radiation protection purposes. The
clinically concerned depth for skin dose measurement, when considering the
biological effects of skin reactions, ranges from the basal cell layer to the first few
millimeters. Radiation dose deposited in this region is generally contributed from
several factors including (Butson et al 1996, Paelinck et al 2005): (1) photon and
electron scatter from the collimators, flattening filter and air, (2) backscatters from the
patient, and (3) high-energy electrons produced by photon interactions in air and any
shielding structures in the vicinity of the patient. Due to lack of CPE, there exits a
large dose gradient in the build-up region where central axis PDD can increase by up
to about 60% within the first 5 mm depth (Xiang et al 2007). This makes dose
measurements at the surface very sensitive to the thickness of the build-up materials
around the sensitive volume of the dosimeter, such as in the case of MOSFET. As
shown in the present work, the PDD measured with the standard-sized OneDoseTM
MOSFET detector at the phantom surface is 47.0% of the dmax value for a 10x10 cm2
radiation field, which is equal to a depth dose at the WED of 1.2 mm. While this kind
of MOSFET detector, with proper correction for the intrinsic build-up thickness, is
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proved suitable to measure a dose at a relatively deep depth, they fail to provide a
direct measurement at the superficial 1-mm thick layer. To extend the range of
measurements to shallower depths, any suitable dosimeter should have a minimal
intrinsic build-up thickness, allowing the required WED of measurements to be
reproduced corresponding to the definition of skin dose.
In a previously published study, Butson et al (1996) proposed an
“unencapsulated” MOSFET design for surface dosimetry by removing the Nickel
casing leaving the bare crystal intact and exposed. Although the unencapsulated
configuration has proved its ability to accurately estimate the surface dose in the
phantom, it is not reliable for clinical use on a patient since the uncovered sensors are
subject to damage. Recently, some other authors recommended the use of the
microMOSFET in surface and build-up region dose measurement (Ramaseshan et al
2004, Xiang et al 2007, Cherpak et al 2008). These microMOSFET detectors have a
thin build-up thickness, but not yet so thin to be closest to the epidermis thickness. To
address the above-mentioned concerns, a “skin” MOSFET configuration was
developed by Scalchi et al (2005) with small WED of about 0.09 mm on average,
which corresponded to the depth of the basal cell layer. This would provide a possible
solution for in vivo skin dosimetry in their TBI treatment. In our current MOSFET
design, a different packaging technology was introduced to produce an ultra-thin
surface overlayer above the sensitive area of the detector so as to diversify the use of
MOSFET for skin dosimetry in radiotherapy and radiation protection. Phantom results
have showed that this new packaging can yield a build-up thickness of 7mg·cm-2
corresponding to the requirement of personal surface dose equivalent Hp (0.07).
Compared with the often used skin dosimeter of EBT film which has an effective
point of measurement of about 15.3 mg·cm-2 underneath the surface (Devic et al
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2006), the newly developed MOSFET detector results in an even smaller WED value.
From this point of view, the developed system can fulfill most of the clinical
requirements for in vivo skin dosimetry. In addition, benefiting from the extremely
thin dosimetric volume (i.e. 0.55 µm), this miniature detector has a high spatial
resolution in rapidly changing dose regions. This offers an additional advantage in
surface and build-up dose measurements. It has been observed in our phantom
investigations that the MOSkinTM measured PDDs, with the WED correction, agrees
well with the Attix chamber measurements and EBT film results for all radiation field
sizes.
As to the reproducibility of MOSkinTM measurements, we evaluated this quantity
both at the phantom surface and at the dmax. Because the MOSFET readout
reproducibility is closely correlated with the applied dose, different MUs were
administered to keep the sensor signal at a level of about 100 mV for each
investigation. The 100-mV voltage shift considered here for the reproducibility
assessment is relevant to the typical patient dosimetry in our skin dosimetry
applications. The new MOSFET detector, with a positive gate bias of 5 V, produces
reproducibility of dose measurement within 2% at the phantom surface. Clearly, in
vivo skin dosimetry with the MOSkinTM detector is possible to achieve recommended
levels of accuracy in radiotherapeutic dose delivery.
The use of a new packaging technology as a replacement for epoxy bubble
encapsulation minimises the variability in the build-up material thickness between
individual MOSkinTM detectors. The observed manufacturing reproducibility of this
detector is better than 3.5%. However, for the purpose of accuracy, we suggest that the
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build-up thickness should be investigated for each MOSFET detector even within the
same batch.
The angular dependence is one of the major concerns for applying the MOSFET
in complicated treatment conditions where obliquely incident beams are often
assigned. Currently designed MOSFET detector, owing to the reduction in the
thickness of the silicon substrate layer, will minimize the angular dependence (Scalchi
et al 1998). Recently published data have shown the MOSkinTM has an isotropic
response within 2% over full 360° in a CPE condition (Qi et al 2007). For dose
determination at the skin surface with lateral electron disequilibrium, this detector
also exhibits minimal angular dependence (<3.2%) even for an incident beam with a
large oblique angle. As a result, skin dose can be measured with MOSkinTM detectors
in much more complicated treatment conditions, such as oblique IMRT fields. This is
particularly applicable to our tomotherapeutic IMRT delivery.
Several studies have revealed that current treatment planning dose calculation
algorithms can not accurately model the superficial dose distribution (Mutic et al
2000, Chung et al 2005, Chow et al 2006, Higgins et al 2007)[10-13]. As shown in
this study, the evaluated planning system may overestimate the skin dose by an
average of 7.8%, ranging from 7.1% to 8.5%, for both deep and shallow seated target
cases. This observation is in agreement with previous findings (Chung et al 2005,
Higgins et al 2007). However, in the neck region where the planning target volume
(PTV) of the neck lymph nodes for a typical NPC treatment usually extends to just 2
or 3 mm underneath the surface, a much higher dose has been delivered to the patient
skin compared with the head surface dose. Moreover, as it has been reported by Lee et
al (2002), the head-neck-shoulder mask has a “bolus” effect on the skin surface
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especially over the neck and shoulder regions where the mask is generally the thickest.
Consequently, it is strongly recommended that the users should investigate and
understand how their planning systems calculate the skin dose, with special attention
to the neck region.
Due to large uncertainties in surface and superficial dose calculations induced by
the TPS, in vivo skin dosimetry using MOSFET detectors is recommended as an
additional means for IMRT QA in our department when patient skin dose is of
concern. In vivo measurements are performed during the first IMRT fraction and once
a week thereafter. Several MOSFET detectors are placed on the patient head and neck
surface area at locations of clinical interest, for instance, the junction region of two
treatment slices. The recorded skin dose, which reflects the real dose absorbed by the
patient’s skin, helps our doctors to better analyze IMRT treatment plans, especially in
cases where a compromise between tumor coverage and skin toxicity should be made.
Based on our phantom investigations and in vivo measurements, we confirm that
the newly developed MOSkinTM detector, with its advantages of an instant readout,
ease of use and a capability of providing real time dosimetry, is ideal for routine
IMRT QA and accurate in vivo skin dosimetry.
6.5.

Conclusion
The patient skin dose is a critical issue for radiation protection and clinical

dosimetry. However due to technical limitations, current treatment planning systems
cannot correctly estimate the skin dose, indicating that the calculated skin dose should
be verified using in vivo dosimetry.
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The major difficulty in accurate skin dosimetry with the current in vivo
dosimeters is to reproduce the equivalent depth of the small distance to superficial
layers, as well as the extremely thin dosimetric volume required to measure the dose
in a radiation field with a high dose gradient. The newly developed MOSkinTM
detector, which is encapsulated into a thin water protective film, has a minimal
reproducible intrinsic build-up recommended for skin dosimetry. Also due to
extremely thin dosimetric volume, this detector has a high spatial resolution for depth
dose measurements where a steep dose gradient exits. The data presented demonstrate
that the MOSkinTM detector can accurately and reliably determine the skin dose in the
clinic, providing a suitable tool for routine IMRT QA and accurate in vivo skin
dosimetry.
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CHAPTER 7
Real-Time In Vivo Dosimetry with MOSFET detectors for High Dose
Rate Intracavitary Brachytherapy of Nasopharyngeal Carcinoma

7.1.

Introduction

The recent evolution of computed tomography (CT)-based implant planning and
dosimetry has sparked renewed interest in using high-dose rate (HDR) intracavitary
brachytherapy for the treatment of nasopharyngeal carcinoma (NPC) (Levendag et al
1998, Levendag et al 2002, Ng et al 2005). The CT-based techniques have accurately
reconstructed the position of all intracavitary applicators with respect to the patient’s
anatomy, thereby demonstrating the spatial dose distributions to the tumor volume and
neighboring structures. By optimizing the relative dwell times for each activated
dwell position, the radiation doses are best conformed to the NPC whilst sparing more
of the normal tissues like brain stem, spiral cord, temporary lobes, visual apparatus
and pituitary gland (Levendag et al 1998, Levendag et al 2002, Ng et al 2005).

However, when HDR brachytherapy is used, the treatments must be executed very
carefully. A number of factors could potentially lead to substantial dose deviations
from the prescription in the chain of HDR treatment (Kubo et al 1998). This is mainly
due to the fact that the planning and treatment systems tend to be relatively
complicated and the treatment procedures tend to proceed rapidly. Significant errors
in treatment dose can result from the use of incorrect calculation parameters and
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incorrect applicator diameters as well as from machine malfunction (Alecu et al 1997,
Kubo et al 1998, Duan et al 2001, Wan et al 2005). As it has been pointed out
recently (Alecu et al 1997), these potential errors are quite difficult to be identified
and even though all the quality assurance (QA) checks recommended have been
implemented, mistakes can happen without detection. This may result in severe
radiation injury to patients since HDR brachytherapy delivers very high doses within
a short time period. To avoid therapy misadministration as well as to verify the actual
doses delivered to the tumor during a HDR treatment, the development of an in vivo
dosimetry method as a supplement to existing QA programs is thus very desirable.

Several studies have explored the feasibility of in vivo dosimetry with
thermoluminescent dosimeters (TLDs) and semiconductor diodes for HDR
brachytherapy (Alecu et al 1997, Alecu et al 1999, Brezovich et al 2000,
Anagnostopoulos et al 2003). While TLDs are often used in clinical dosimetry due to
their small size, they are also known to be tedious to use (Izewska et al 2007, Ho et al
2008). The fact that acquiring moderately accurate, reproducible results using TLDs
requires stringent calibration, handling and annealing procedures suggests that in vivo
thermoluminescence dosimetry would be difficult to implement on a daily basis. Also
TLDs are not real time dosimeters so that they are incompetent to provide on-line
monitoring of operational mistakes and their immediate corrections. Semiconductor
diodes are simpler to use than TLDs. The major disadvantages of diodes are their
relatively large size, which makes them unable to be held in a small nasopharyngeal
applicator. In addition, some investigations have revealed that diode measurements
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may need several correction factors for even simple application in clinical
radiotherapy (Zhu 2000, Saini et al 2004).

The mental-oxide-semiconductor field-effect transistor (MOSFET) detector is the
most recent development for in vivo dosimetry compared with TLDs and diodes.
Incorporating many of the advantages of TLDs and diodes such as small physical size,
ease of use and immediate readout, the MOSFET detector has been well-established
as a useful dosimeter in external beam radiotherapy (Quach et al 2000, Chuang et al
2002, Best et al 2005, Cherpak et al 2008). However, only a few experiments relevant
to the potential use of MOSFET detectors in HDR brachytherapy have been reported
(Zilio et al 2006, Qi et al 2007, Fagerstrom et al 2008). In a previously published
study, Zilio and his coworkers (2006) demonstrated that the MOSFET detector, with
appropriate calibration and correction, could also be used for absolute dosimetry in
the context of a microSelectron HDR

192

Ir source, even for situations where photon

energy spectra were different from the reference location. More recently, our group
has successfully exploited an improved micro-MOSFET design with reduced external
dimensions for use in brachytehrapy catheters as a means of routine QA to verify
brachytherapy dose calculations (Qi et al 2007). These pilot MOSFET dosimetry
studies, basically, are limited to the integral dose measurements, in which results are
obtained only after a treatment has been delivered. As reported by Gladstone et al
(1991) and others (Kaplan et al 2000, Rosenfeld et al 2001), the MOSFET detector
has an advantage over many other dosimeters in its ability to provide real-time dose
information. This will offer extra benefits for treatment monitoring in that it may
175

allow dose errors to be detected at a much earlier stage.

The main purpose of the present study is to evaluate the efficiency of a real time
MOSFET dosimetry system in avoiding therapy misadministration for HDR
intracavitary brachytherapy. Some special features relevant to real time data
acquisition such as measurement reproducibility and drift effects were investigated.
With the detector placed inside a custom-made nasopharyngeal applicator, the
radiation dose delivered to the tumor was verified in vivo for NPC patients receiving
HDR treatments. The preliminary results of real-time in vivo measurements with
MOSFET detectors for 70 treatment fractions in 11 NPC patients are presented and
compared to dose calculations using a commercial brachytherapy planning system
(BPS).

7.2.

Materials and Methods

7.2.1.

Materials

7.2.1.1. Brachytherapy equipment

A microSelectron-HDR remote afterloader (Nucletron, The Netherlands)
containing a single

192

Ir stepping source was used to deliver HDR treatments. The

equipments are maintained under strict QA, according to the report of AAPM Task
Group 59 (1998). The source strength was calibrated in the clinic by a well-type
ionization chamber (HDR 1000 Plus, Standard Imaging, US) with calibration factors
traceable to the national standards. The source positioning accuracy is verified to be
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within ±0.5 mm, and the timer accuracy and linearity are estimated to be consistent
with regulatory requirements.

The HDR treatment plan was generated by a CT-based commercial brachytherapy
treatment planning system (Plato BPS, Nucletron, The Netherlands) using the AAPM
TG-43 dose calculation formalism (AAPM 1995). The required input data consisting
of air kerma strength, dose rate constant, geometry factor, radial dose function and
anisotropy function that depend on the specific source geometry have been worked
out using Monte Carlo calculations and measurements (Daskalov et al 1998). Various
optimization algorithms are also available that modulate the relative dwell times of
each activated dwell position to provide better dose uniformity and target coverage.

7.2.1.2. Nasopharyngeal applicator

Due to the steep dose gradient near the

192

Ir source, slight inaccuracies of

applicator positioning may result in considerable deviations of the dose distribution
from the plan. To ensure reproducible treatment delivery, a custom-made
nasopharyngeal applicator was used for individual patient treatments.

The nasopharyngeal applicator, see Figure 7.1, is a thermoplastic resin tube with
a curvature of about 20° at 1 cm from the distal blind end. It has an outer diameter of
12 French and an inner diameter of 9 French, which can accommodate standard 6
French afterloading catheters. The applicator can be reshaped for each individual
patient, when heated, to conform to the superoposterior wall of the nasopharynx. Thus
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the HDR

192

Ir stepping source can be positioned closer to the target mucosa as

compared with the traditional intraluminal stabilizing devices which place the source
in the middle of the cavity and hence up to 1-2 cm from the target mucosa (Ng et al
2005).

The customization process for the nasopharyngeal applicator is performed under
topical anesthesia using nebulized 4% lidocaine hydrochloride applied to the patient’s
nasal cavity, nasopharynx, and oropharynx. With the guidance of a nasopharyngeal
speculum, the applicator is introduced transnasally into the nasopharynx and is
custom formed to be optimally positioned against the region of the primary disease.
The nasopharyngeal applicator is then secured to the nose by a thermoplastic mask.
The inserted length and orientation to the nasopharyngeal cavity are recorded
accordingly from graduations and angles imprinted on the applicator to allow the
applicator position to be reproduced in the subsequent treatments.

Figure 7.1 A custom-made nasopharyngeal applicator. The imprinted lengths and angles on
the applicator are used for daily applicator positioning.
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7.2.1.3. MOSFET dosimetry system

The applied MOSFET dosimetry system, including the newly developed
miniature MOSFET detectors (MOSkinTM) and a microprocessor based reader, has
been previously introduced (Qi et al 2007, Qi et al 2009, Kwan et al 2009). One of
the major characteristics of this miniature MOSFET detector is its packaging
technology, by which the sensor chip is hermetically sealed with a 70-µm thick
water-equivalent film. The thin-film encapsulating layer prevents damage to the
electronics, and acts as a carrier of the thin aluminum contact leads that are connected
to the MOSFET sensor from the top-side.

In this experiment, dose measurements were performed in a real time mode with
a positive bias voltage of 5 V applied to the MOSFET during irradiation. This
required a connection to a laptop computer and utilization of the “MosPlot” software.
The computer DAQ system measured periodically the instantaneous voltage signal
with the user-defined period (one second in this case). The software MosPlot 4.1
allowed for the online graphical presentation of the change in Vth (i.e. accumulated
dose variation) or increments of ⊿Vth for consecutive readouts (i.e. differential dose
rate).

7.2.2.

Methods

7.2.2.1. MOSFET calibration and correction

Five MOSFET detectors were independently calibrated against a NE-2571 0.6
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cm3 Farmer-type ionization chamber at a perpendicular distance of 5 cm from the
source in a water phantom. This is essentially a two-step process: calibration in a
standard set-up to determine the reference calibration factor and subsequently the
establishment of a series of correction factors for irradiation conditions deviating from
the reference conditions. A detailed description of this calibration procedure has been
given in Chapter 5. The derived energy dependent correction factors were compared
with the published data for a previously used RADFET dosimeter.

7.2.2.2. The reproducibility of real-time MOSFET dosimetry system

The readout reproducibility of the CMRP dosimetry system was investigated for
both the absolute voltage response (proportional to the accumulated dose) and the
voltage increment between two consecutive readouts (proportional to the dose rate).

The dose-rate measurements were conducted with a MOSFET detector at a
clinically relevant distance of 1 cm from the source in the water phantom. To avoid
the influence of the transit dose, the readout was triggered after the stepping source
had reached the calibration position. Thirty consecutive readings were recorded using
the automatic mode with the sampling period of 1 second. The associated standard
deviation was calculated.

Next, the MOSFET detector was irradiated ten times for each of the following
integrated doses: 20, 30, and 50 cGy at 5-cm source-to-detector distance (SDD). The
threshold voltage change before and after each irradiation was measured using both

180

the real-time mode and the manual mode, respectively, for comparison purposes. The
corresponding coefficients of dispersion of repeated measurements were computed for
different applied doses.

7.2.2.3. Signal drift after irradiation

The CMRP dosimetry system is designed with special efforts to reduce the drift
of the MOSFET threshold voltage induced during readout (Rosenfeld et al 2001).
This was verified by computing the coefficient of dispersion of a set of detector
readings after the radiation.

During the measurements, the MOSFET detector was fixed in the water phantom
at a perpendicular distance of 5 cm from the source. The readout was performed
immediately after irradiation and every second thereafter up to 3 minute
post-irradiation. The signal drifts of the MOSFET detector with time were hence
analyzed.

7.2.2.4. CT-based HDR intracavitary brachytherapy

HDR intracavitary brachytherapy provided an attractive method of boosting dose
to NPC whilst sparing sensitive normal tissues. Treatments were generally delivered
with two nasopharyngeal applicators at our institutions, one in each naris, with a
separation of 1.2-1.5 cm according to the size of the tumor target. Prior to the CT
simulation, the nasopharyngeal applicators were brought into the nasopharynx under
the direct guidance of the nasopharyngeal speculum and remained in situ for the
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duration of the treatment. The patient then lay on the simulator table, immobilized
with a head and neck mask in the supine position (see Figure 7.2). Three radiopaque
markers were attached to the mask in alignment with the CT lasers, which served as
benchmarks for daily radiographs to verify the applicator localization. After insertion
of standard afterloading catheters with dummy sources into the nasopharyngeal
applicator, the patient was CT scanned with 1-mm slice thickness and 1-mm pitch.
The acquired CT images were subsequently transferred to the Plato BPS.

Figure 7.2 The patient lay on the simulator table, immobilized with a head and neck mask in
the supine position. After insertion of standard afterloading catheters with dummy sources
into the nasopharyngeal applicator, the patient was CT scanned with 1 mm slice thickness and
1 mm pitch.
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The primary tumor target and critical structures such as brainstem, spine and
bilateral parotid glands were contoured on all the involved CT scans. The two
applicators were sequentially reconstructed by the BPS with the source step of 2.5
mm. A catheter offset value, which was predetermined in the CT scout view, was used
for correctly placing the center of the first dwell position with respect to the
reconstructed catheter. This can provide a higher positional accuracy than half the CT
slice spacing. The minimal peripheral dose (MPD), typically 3-5 Gy per fraction, was
prescribed to cover the target surface. A geometrical optimization was performed,
followed by manually adjusting dwell weights and times to further improve the target
dose uniformity. The planned doses to the measurement points where the MOSFET
detectors were located during the in vivo measurement were specially calculated in
terms of dose rates of the 192Ir source from each individual source dwell position. The
accumulated dose variation with treatment time at the measurement point was thus
predicted as a baseline for in vivo MOSFET dosimetry in real-time monitoring the
performance of HDR treatment delivery.

The HDR treatments were delivered on an outpatient basis once per day for 2 to 4
days. The applicator localization was verified with fluoroscopy each time and
orthogonal radiographs were taken for document (see Figure 7.3).
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a

b

Figure 7.3 Orthogonal radiographs for a NPC patient. a: anterior photography; b: lateral
photography. The applicator localization was verified from fluoroscopy.

7.2.2.5. In vivo dosimetric verification
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After accurate positioning of the nasopharyngeal applicators has been confirmed,
the MOSFET detector was inserted into one applicator when other one was being
connected to the afterloader via a transluminal catheter for treatment delivery. The
MOSFET was fixed to the distal source dwell position with each fraction for
measurements in the left applicator and was kept at the proximate source dwell
position in the right applicator.

The in vivo measurements were started as soon as the

192

Ir stepping source was

driven out of the container. The accumulated threshold voltage of the MOSFET
detector was recorded with the controlled software MosPlot 4.1 every second. By
using a lookup table, the measured threshold voltage shift was converted to the
absorbed dose, which was then compared with the calculated values by the TPS.

To date, real-time in vivo dosimetry with MOSFET detectors has been performed
for a total of 70 measurements of 11 NPC patients. The preliminary results are
presented in this work.

7.3.

Results

7.3.1.

MOSFET calibration and correction

Five MOSFET detectors were independently calibrated in the water tank,
resulting in a mean dose calibration factor of 0.46±0.012 cGy/mV for the

192

Ir

source.
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Figure 7.4 was a comparison of the energy dependent correction factors between
the new MOSFET detector and a previously used RADFET dosimeter. The correction
factors were plotted against the source axis distances. The RADFET data were
derived from the published data (Zilio et al 2006), which were re-normalized to the
5-cm value. The newly developed MOSFET detector showed a relatively flat energy
response in the low energy spectrum of the

192

Ir source compared with the RADFET

dosimeter. The maximum sensitivity variation was found to be no more than 7% in
the given distance range.

Figure 7.4 Comparison of energy-dependent correction factors between the new MOSkinTM
and a previously used RADFET dosimeter. The RADFET data were derived from the
published data (Zilio et al 2006), which were re-normalized to the 5-cm value.
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7.3.2.

The reproducibility of real-time MOSFET dosimetry system

The reproducibility of the dose-rate measurements, as shown in Figure 7.5, was
estimated at a clinically relevant distance of 1 cm from the source. At the current
source strength, the dose rate at the above distance in water was calculated to be 10.1
cGy/s. This yielded a MOSFET threshold voltage change of 20.5±1.2 mV/s in our
experiment. The observed standard deviation was within the specification limits
(lower than ±2 mV in real time mode).

Figure 7.5 The MOSFET readout reproducibility in dose-rate measurements at a clinically
relevant distance of 1 cm from the source.

Table 7.1 showed the reproducibility of the accumulated dose assessments at
quoted dose levels. It was found that the MOSFET readout reproducibility was
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closely correlated with the applied dose. As the dose was increased, the
reproducibility of the dosimetry system was improved from 2.3% to 1.2% for the
manual mode and from 4.1% to 1.7% for the real-time mode. A relatively large
deviation in reproducibility tests associated with real-time data acquisition may be
partially owing to the computer making random noise. However, for irradiated dose
levels of more than 30 cGy, the real-time mode can also give a reasonable
reproducibility of measurements better than 3%.

Table 7.1 The MOSFET readout reproducibility in integral dose measurements and real-time
accumulated dose assessments, respectively, at given dose levels.

7.3.3.

MOSFET readout reproducibility

Dose level
(cGy)

Manual mode

Real time mode

20

2.3%

4.1%

30

1.8%

2.8%

50

1.2%

1.7%

Signal drift after irradiation

The drift of the MOSFET threshold voltage induced during readout was observed
from immediately after the radiation till to 3-minitue post-irradiation.

A total of 181 detector readings were acquired. The coefficient of dispersion of
these readings was calculated to be within 0.5‰. No significant drift effect was found
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for the CMRP dosimetry system after irradiation.

7.3.4.

In vivo dosimetric verification

In vivo dosimetric verification was performed for 70 measurements of 11 NPC
patients. For all the patients, measurements were followed through the whole
treatment sessions. The mean position deviation of the nasopharyngeal applicators,
observed from the verification films, was 1.6±0.6 mm in the right-left direction,
0.7±0.3 mm in the cranial-caudal direction, and 0.8±0.3 mm in the anterior-posterior
direction.

Figure 7.6 was an example of real-time comparison of in vivo measurements with
calculated accumulated dose variations for a given treatment fraction. The transit
doses were included in the measurements. As shown in the figure, the MOSFET
measurements coincided with the calculated values within ±5% throughout the
treatment delivery. The total radiation dose was also compared with the planned dose
after the irradiation. In this case, the dose discrepancy between in vivo measurements
and TPS calculations was found to be 1.1%.

Figure 7a and 7b showed the frequencies of measurements with discrepancies in
percentage between measured and calculated values for right and left side
measurements, respectively. The observed dose differences within a single treatment
fraction were on average 0.3±4.6% (right side) and 0.4±4.3% (left side) accordingly.
83% of right side measurements and 86% of left side assessments have deviations
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within the range of -5% to 7%. The maximum dose discrepancy was 11.3%.

Figure 7.6 An example of real-time comparison of in vivo measurements with calculated
accumulated dose variations for a given treatment fraction. The MOSFET measurements
coincided with the calculated values within ±5% throughout the treatment delivery.

The corresponding dose measurements with MOSFET detectors in each fraction
of a particular patient were then averaged and compared with the expected TPS
calculated dose at each measurement point. As plotted in Figure 7.8, the mean
discrepancies between planned and measured doses averaged over all fractions of a
patient was 0.3±4.0% (right side) and 0.4±3.8% (left side), respectively. Less than
±7% deviation from the planned dose was measured in all patients.
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a

b

Figure 7.7 The frequencies of measurements with discrepancies in percentage between
measured and calculated values for right and left side measurements, respectively. a: right
side; b: left side.
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Figure 7.8 The mean discrepancies between planned and measured doses averaged over all
fractions of a patient. The error bar represents one standard deviation.

7.4.

Discussions

Intracavitary brachytherapy, due to its advantage of the rapid dose fall-off with
distance, is conceptually an attractive method of boosting dose to NPC whilst sparing
sensitive normal tissues. The treatment is most commonly performed using a HDR
192

Ir source by means of intranasal devices like the Rotterdam nasopharynx applicator

(Levendag et al 1997) and the customized brachytherapy catheter (Ng et al 2005).

Among kinds of QA problems for HDR brachytherapy, the accurate placement of
the applicator is crucial for reliable dose distribution and treatment outcome. Kremer
et al (1999) developed a computer-assisted device for three-dimensional placement of
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afterloading probes based on CT scans. With this device, target points have been
reached with a mean accuracy of 0.6 mm (maximum deviation was 2.6 mm). At our
institution, we treated NPC patients using a customized nasopharyngeal applicator on
an individual basis as introduced by Ng et al (2005). By improving the applicator
design with the indicated lengths and angles as well as immobilizing the patient head
and the applicator with the face mask, the inaccuracy of applicator positioning can be
minimized to the same level as the complex computer-assisted system. However, such
small displacement is quite difficult to be adjusted in pretreatment QA reviews.

In vivo dosimetry with MOSFET detectors provides an estimate of the overall
error in a HDR treatment besides separate QA checks for each component of the
treatment process. The MOSFET detector has a very small sensitive volume of
typically 200×200×1 µm3. This property makes it attractive for measurements in the
high gradient radiation field，like the vicinity of the

192

Ir source. Before use each

MOSFET detector should be calibrated individually against a 0.6 cm3 ionization
chamber in the water phantom for the purpose of accuracy. There are some reports
that the radiation response of the MOSFETs may not completely linear over the whole
voltage range (Zilio et al 2006, Fagerstrom et al 2008). As a result, a recalibration of
the device was performed periodically for every 5-V increment in our experiments.

The MOSFET detectors are known to have photon energy dependence in the low
energy range of the

192

Ir spectrum (Kron et al 1998). The previously published data

showed that a correction factor of about 1.27 times greater than the 5-cm value was
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required in absolute depth dose determination at 1-cm distance from the source for a
conventional MOSFET design from CMRP (Zilio et al 2006). In this updated
generation products, the energy response of the MOSFET detector in the

192

Ir

spectrum has been significantly improved by using special encapsulation techniques
that avoid high Z materials close to the dosimetric volume. The sensitivity variation,
as shown by our results, was minimized to be within 7% in the clinically relevant
distance range of 1-5 cm. This will help acquire a good in vivo dosimetry result for
HDR brachytherapy.

The reproducibility of MOSFET measurements in the manual mode was found to
be 1.2% at the threshold voltage shift of about 100 mV. This result was consistent
with previous findings (Cheung et al 2005). While the real time data acquisition mode
associates with a relatively large deviation in reproducibility tests (i.e. 1.7%), it is
practically within the measurement uncertainty. Considering HDR brachytherapy
techniques deliver a very high dose over a few fractions, real time dosimetry is most
valuable in detecting a dose error at the onset of treatment that otherwise would be
unnoticed leading to clinical adverse effects.

Some investigations have revealed the so-called drift effects for the MOSFET
detector (Ramaseshan et al 1997, Verellen et al 2010) and therefore suggest not
performing the readout until one minute post-irradiation. This is impossible for real
time data acquisition which measures the instantaneous voltage signal. To count-act
this problem, the CMRP dosimetry system has specially designed circuits that can
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correct for any drift of the MOSFET threshold voltage between consecutive read
cycles (Rosenfeld et al 2001). As a consequence, the MOSFET readout can be
performed immediately after irradiation with sufficient accuracy.

Due to the small physical size, the MOSFET detector can be inserted into the 6F
nasopharyngeal applicator. By this means, the MOSFET detector was conveniently
introduced to the nasopharynx near the target volume during in vivo treatment
verification. To date, 11 NPC patients have been evaluated with real time MOSFET
dosimetry as an in vivo method for brachytherapy QA. The preliminary results from a
total of 70 measurements show good agreement between theory and experiment. The
observed mean differences between the planned and the actually delivered dose
within a single treatment fraction were 0.3±4.6% and 0.4±4.3%, respectively, for
right and left side assessments. The only two measurements that exceeded a deviation
of ±10% might be the result of relatively large inter-fraction displacement of the
nasopharyngeal applicator in a rotary direction. More research is warranted.

According to the previously published document (Alecu et al 1997), more than
20% total dose deviation from prescription was taken as the action level in our
experiments. However, for a treatment with measurable 10%～20% dose difference, a
retrospective QA review was required. With verification films, the variation of the
applicator position was analyzed and proper adjustment may be made in the following
fractions, if necessary, based on the in vivo dosimetry results. Consequently, the
measured average dose over all fractions of a patient differed from the calculated
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value within ±7%, ensuring the validity of HDR intracavitary brachytehrapy.

The presented study has major focus on the development of a simple point dose
method for in vivo monitoring and verification of HDR treatments. Hence only a
single MOSFET detector was evaluated in our phantom measurements and in vivo
applications. Price and his coworkers (2004) have recently presented a new linear
MOSFET-array dosimeter configuration that can provide a one-dimensional dose
profile across the target volume. As the detector array may better serve the purpose of
in vivo patient dosimetry, it is now under research by ours and other groups. In future
developments the external dimensions of the array dosimeter will be significantly
reduced so as to permit its use in brachytherapy catheters. Anyhow, we feel that even
with currently designed MOSFETs, the proposed method is capable of detecting
errors of major clinical significance.

7.5.

Conclusion

In vivo measurement using the real-time MOSFET dosimetry system provides a
means of overall dosimetry check for the HDR treatment. With detectors placed
within the patients’ nasopharynx, it is possible to evaluate and document, in real time,
the actual dose to the tumor received by the patient during a treatment fraction.
Through an online comparison between the measured dose and the calculated value,
the dosimetry system offers another line of security to detect and prevent large errors.
The method we presented here is universal and can be applied in any other cases of
clinical interest.
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CHAPTER 8
Online In Vivo Dosimetry with MOSFET detectors for Serial
Tomotherapy of Head and Neck Patients

8.1.

Introduction

Intensity modulated radiation therapy is the most recent and advanced form of
three-dimensional conformal radiotherapy (Nutting et al 2000, IMRT Collaborative
Working Group 2001). It uses sophisticated software and hardware to design multiple
segments per field that provide a varying intensity of radiation fluence in each beam.
Combining these beams allows achieving a much higher degree of target conformity
and normal tissue sparing than most other treatment techniques, especially for target
volumes at risk with complex shapes and concave regions such as head-and-neck
cancer (Xia et al 2000, Huang et al 2003). The efficiency of IMRT in the treatment of
nasopharyngeal carcinoma (NPC) has been well documented (Sultanem et al 2000,
Hunt et al 2001, Lee et al 2002, Lu et al 2002).

While a correctly delivered IMRT plan has many potential benefits, a poorly
delivered plan may lead to the opposite outcome, either by failing to destroy tumor
cells or by causing unnecessary damage to normal tissues (AAPM 2003). It is widely
accepted that the clinical implementation of IMRT necessitates high standards of
treatment verification since the risk of error increases with increasing complexity of
the delivery method (Boehmer et al 2004, Agazaryan et al 2003, Jones et al 2003).
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This is particularly applicable to tomotherapeutic IMRT delivery (Carol 1995). Unlike
conventional treatment modalities, serial tomotherapy IMRT is delivered with a
dynamic multileaf collimator (MIMiC, NOMOS Corporation, Pittsburgh, PA) that
modulates “slices” through sequential treated volumes while the gantry is rotating,
providing up to 40 individual intensity-modulated beams per every 5 degrees of
rotation. Owing to the complexity of treatment planning and delivery, many
techniques developed for dosimetric verification of conventional external beam
therapy cannot be used for serial tomotherapy IMRT.

The dosimetric accuracy of serial tomotherapy IMRT treatment has been
evaluated by Low at al (1998) using homogeneous cubic phantoms. To date, phantom
measurement is still the most reliable and practical technique used for patient-specific
IMRT dose delivery verification (Dong et al 2003, Leybovich et al 2003, Bouchard et
al 2004). This process usually involves the generation of a so-called “hybrid phantom
plan”, which transfers the beam fluence distribution of the patient plan to the CT
images of a QA phantom. The phantom is subsequently irradiated, and the absolute
doses at several points or the relative dose distributions in selected planes are verified
in the phantom using an ionization chamber or film dosimetry. The main limitation of
this verification method in homogenous phantoms is that it is still an indirect process.

To solve this problem, the ideal method would be to do true in vivo measurement
on the patient during serial IMRT treatments. Unfortunately, current detectors
available for in vivo dosimetry, such as thermoluminescent dosimetry (TLD) and
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silicon diodes, all have their shortcomings (Kron et al 1996, Wilkins et al 1997,
ESTRO 2001). Interesting developments have been made using electronic portal
imaging devices for in vivo verification of IMRT delivered dose (McDermott et al
2006, McDermott et al 2007). However, these devices are not specifically designed
for dosimetry and there is still a requirement for introduction of a new detector that
can offer sufficient accuracy for in vivo measurement.

A new in vivo dosimeter, Metal Oxide Semiconductor Field Effect Transistor
(MOSFET), has been recently put forward as an alternative device for clinical
radiation dosimetry (Quach et al 2000, Chuang et al 2002, Ramaseshan et al 2004,
Best et al 2005). In a pilot study, Marcie and his coworkers (2005) develop a
custom-made oral plate by means of which they can perform in vivo measurements
with MOSFET detectors directly in oropharynx and nasopharynx, thus providing a
useful QA tool for step and shoot IMRT. As it has been demonstrated by our group
and others, MOSFETs also have an advantage over many other dosimeters in their
ability to provide real-time dose information (Gladstone et al 1991, Rosenfeld et al
2001). This may offer extra benefits for monitoring the progress of the treatment
during dynamic IMRT deliveries.

The main purpose of this work is to explore the applicability of a recently
developed real-time in vivo MOSFET dosimetry system in patient-specific QA of
serial tomotherapy. Treatment parameters that may affect the accuracy of MOSFET
measurements such as SSD, field size, and radiation energy spectrum were
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investigated. The feasibility of this real-time dosimetry system in IMRT dose
verification was estimated in phantom with comparison to ionization chamber
measurements. The initial results of real-time in vivo measurements during serial
tomotherapy IMRT treatment of NPC patients are also reported.

8.2.

Materials and Methods

8.2.1.

IMRT treatment system

The IMRT plans are generated using a commercial planning system (Corvus 6.2,
NOMOS Corp.), and the treatments are delivered using the serial tomotherapy
technique via a binary MLC (MIMiC, NOMOS Corp.).

The MIMiC, attached to the treatment head of a Varian 600C linear accelerator,
consists of 2 rows of 20 leaves. Each leaf projects a nominal beam length of 1 cm at
isocenter in the 1-cm treatment mode and a nominal 2-cm beam length in the 2-cm
treatment mode. During the rotation, the MIMiC is driven open and closed, depending
on the gantry position, to produce varying beam intensity across the field.

Since the serial tomotherapy treatment requires the abutment of contiguous slices
in a precise manner to minimize dose nonuniformity at the slice junction, the
treatment couch position is determined using a digitally programmed driven
mechanism (Auto-crane, NOMOS Corp.). This device is attached to the side of the
treatment couch and latched to the handrail, positioning the treatment table in
0.01-mm accuracy.
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8.2.2.

MOSFET dosimetry system

The miniature MOSFET detector, namely MOSkinTM, is specially designed for
measurement in regions of steep dose gradient, such as the one encountered at an
air-tissue “surface” interface. Recently published research has demonstrated the
azimuth angular response of this MOSFET detector is isotropic within 2% over full
360° (Kwan et al 2008).

The MOSFET detector was used in a real-time mode with a positive gate bias of
5V applied during irradiation to increase its sensitivity and linearity. Online dose
measurements were made with the readout system connected to a lap-top computer
(powered by battery only). With the aid of control software (MosPlot 4.1), the
dosimetry system measured the instantaneous voltage signal from the designated
probes every one second in this experiment. The uncertainty associated with real time
data acquisition applications was stated to be lower than ±2 mV (Zilio et al 2006). By
selecting the readout current corresponding to a thermostable point, the temperature
sensitivity of the MOSFET readings was minimized (Cheung et al 2004).

8.2.3.

QA phantom and ionization chamber

The IMRT QA phantom (IMRT Head & Torso Freepoint Phantom, CIRS Tissue
Simulation Technology) used is manufactured from water-equivalent materials that
can mimic water within 1% from 50 KeV to 25 MeV. Optional rod inserts are
available to accommodate a variety of dose measurement devices such as ionization
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chambers, diodes, and MOSFETs in the same location within the phantom. In this
work, we removed the outer phantom body part leaving only the center cylinder to
simulate head and neck setups.

Two kinds of Farmer type ionization chambers were used in this study (i.e. 0.6
cm3 NE-2571, Nuclear Enterprises U.K and 0.125 cm3 CC13, Scanditronix Wellhofer
North America). Both the ionization chambers and their corresponding electrometers
are calibrated at national standard laboratory every year with calibration factors
traceable to the national standard.

8.2.4.

Influence of treatment specific parameters on MOSFET sensitivity

8.2.4.1. SSD effect

The SSD may vary with different incident beam angles during serial
tomotherapy delivery, resulting from the fact that the body surface of a patient is
curved or irregular in shape. The influence of SSD to the detector response was
studied in Varian 600C 6 MV photons with 10×10 cm2 field size at different SSDs (90,
100, and 110 cm).

During the measurement, the MOSFET detector was placed in the central beam
axis at the depth of maximum dose (dmax) in a RW3 water equivalent slab phantom
(SP34, IBA) with the sensitive surface (gate) facing the beam. To save MOSFET
lifetime while keeping a reasonable signal, 20 cGy was delivered each time. All
measurements were repeated five times and the average reading was used for analysis.
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8.2.4.2. Field size dependence

The field size dependence is a key feature for MOSFET detectors in IMRT
dosimetry since multiple beamlets with different field sizes are usually included in
IMRT fields.

The MOSFET detectors were calibrated against the NE-2571 Farmer type
ionization chamber in the RW3 slab phantom using Varian 600C 6 MV photons at
SSD=100 cm and dmax with different field sizes (i.e. 5×5, 10×10, 20×20, 30×30, and
40×40 cm2). The results were normalized to the 10×10 cm2 value.

8.2.4.3. Energy response

The MOSFET detector was usually calibrated at dmax while being used at different
depths in routine IMRT dosimetry. Because both dose rate and the radiation energy
spectrum change with the thickness of materials it passes through, the depth dose
dependence of the MOSFET detector was checked in this study.

Using a field size of 10×10 cm2 at SSD=100 cm, the percentage depth dose (PDD)
curve was measured in the 30×30×30 cm3 RW3 slab phantom for a 6 MV photon
beam from dmax up to 20 cm in 1 cm increments under electron equilibrium conditions.
To keep the MOSFET signal at a reasonable level, different monitor units were
delivered for different depths. The recorded readings, corrected to a fixed irradiation
of 100 monitor units, were normalized to the dmax value.
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The measured depth dose curve was compared with a known PDD acquired by a
3D-beam analyzing system. The agreement of MOSFET measurements with
ionization chamber data was estimated.

8.2.5.

Phantom study: Feasibility of MOSFET in IMRT phantom plan

verification

8.2.5.1. Patient plan selection

Eight serial tomotherapy plans for NPC treatment were selected for dose
verification in the phantom using both MOSFET detectors and ionization chambers.
These treatment plans were clinically approved. The dose calculating matrix was all
chosen to be 1×1×1 mm3.

8.2.5.2. Hybrid patient-phantom plan generation

To generate the phantom QA plan, the IMRT QA phantom with the detector in
place was scanned in a CT scanner. The phantom was set up in the measurement
position and aligned with lasers at isocenter. By using different rod inserts, the
ionization chamber and the MOSFET detector were accommodated in the center
position of the phantom, respectively. Three radio-opaque markers were placed on the
phantom as setup reference in the left, right, and anterior directions. A 1-mm slice
thickness and 1-mm pitch were used to scan through the detector location for better
spatial resolution, while the rest of the phantom was scanned with 5-mm slice
thickness and 5-mm pitch.
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A hybrid patient-phantom plan was then created by re-computing the dose
distribution with the QA phantom geometry using the same beam parameters of the
patient plan. Since the ionization chamber measurement can only provide an average
value throughout the chamber’s sensitive volume, the following measures were taken
to avoid significant errors.
(1) The measurement setup was carefully selected to locate the ionization chamber in
a relatively homogeneous dose region in the plan. Considering the relatively large
sensitive volume, the 0.6 cm3 ionization chamber was only used to verify the accuracy
of dose delivery within the high-dose target region. The 0.125 cm3 chamber was used
to measure the radiation dose in the regions with higher dose gradient (e.g. brainstem
dose).
(2) The air cavity of the chamber which was considered as the measurement volume
was carefully outlined in the CT images as the target volume. Consequently, the mean
dose planned to this volume can be calculated in the hybrid plan. This
volume-averaging method can significantly reduce measurement uncertainties,
especially for relatively large chambers (Leybovich et al 2003).

Opposite to the ionization chamber, the MOSFET detector, owing to its small
physical dimensions, was not only used to verify the planned dose in high-dose target
regions, but also used to measure the delivered dose to the surroundings where a
larger dose-gradient usually existed.

8.2.5.3. IMRT phantom plan verification
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After a daily linac output check had been completed, the hybrid plan was
delivered to the IMRT QA phantom. The dose difference between measurement and
calculation was computed for both ionization chambers and MOSFET detectors.

A Statistical t test was performed using the SigmaPlot 10.0 software (Systat
Software Inc) to estimate the correlation between MOSFET measurements and
ionization chamber results. The reliability of the MOSFET dosimetry system in IMRT
dose verification was hence evaluated.

8.2.6.

Clinical study: Real-time in vivo dose verification of serial IMRT

treatments

8.2.6.1. Patient and treatment characteristics

Taste dysfunction and oral mucous reaction are major radiation sequels in NPC
patients receiving radiotherapy. To improve quality of life, currently a clinical trial is
ongoing at our institution to explore the role of a molded oral plate in sparing the
normal oral tissues during radiotherapy for some NPC cases with oropharynx
extension.

The oral plate is made of tissue equivalent materials (see Figure 8.1). It can push
the tongue and a part of oral mucous membrane away from the radiation fields, thus
decreasing the irradiation dose and volume of the tongue. To ensure the positioning
accuracy, the oral plate is specially designed for each patient. Prior to the patient
simulation, a dentist takes impression of the patient teeth and prepares the oral plate.
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Three lead seeds are embedded in the oral plate, which are visible on CT slices and on
verification films.

For dosimetric analysis, in vivo measurements of the radiation dose delivered to
one or two points of the tongue and oral cavity by serial tomotherapy have been
conducted using MOSFET detectors. Measurements were usually performed during
the first treatment fraction and once a week thereafter. A total of 8 NPC patients and
48 dose points have been currently measured in vivo.

a

b
Figure 8.1 The custom-made oral plate for in vivo dosimetry. a: top view ; b: bottom view.
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8.2.6.2. In vivo MOSFET dosimetry during serial IMRT delivery

The MOSFET detectors were well fitted with the oral plate at the plate-tongue
interface with the sensitive surface (gate) facing the oral plate. These detectors were
identified on the patient CT images in the process of treatment planning. Dose points
of interest were set to the location where MOSFET detectors were situated.

A radiation dose of 68 Gy in 30 fractions was administrated to the gross tumor
volume (GTV), with the planning goals assigned not only to the tumor target but also
to the critical structures. The calculating matrix was chosen as 1×1×1 mm3 and
inhomogeneity corrections were included in the plan calculation. The planned doses
to the corresponding points of interest were then obtained (see Figure 8.2).

Positioning accuracy of the oral plate and the MOSFET detector was verified
using lateral portal films (see Figure 8.3). These films were compared with previous
films and digitally-reconstructed radiographs (DRRs) from the planning system. Any
shift of the lead markers correlated with bony anatomy was thus analyzed and
corrected.

The threshold voltage shift of the MOSFET detector was recorded every second
during the irradiation using MosPlot 4.1 control software. The integral threshold
voltage shift was then converted to dose in cGy immediately after the treatment
fraction using the pre-determined calibration factor. The measured doses were, in turn,
compared with the expected values calculated by the planning system.
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a

b

Figure 8.2 Example of a Corvus IMRT treatment plan. The MOSFET detector can be
identified on the patient CT images as shown by white arrow. a: cross-section view; b: sagittal
view.
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Figure 8.3 Example of a verification film for NPC patient setup with the molded oral plate.
Lead seeds embedded in the oral plate, shown by white arrow, are identified on the film.

8.3.

Results

8.3.1.

Influence of treatment specific parameters on MOSFET sensitivity

8.3.1.1. SSD effect

Table 8.1 shows the SSD dependence of the MOSFET detector in high energy
photon beams. No significant sensitivity variation with SSD was observed for the
detector (maximum deviation<0.5%).
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Table 8.1 SSD dependence of the MOSFET detector in high energy photon beams. All the
measurements were normalized to the SSD=100 cm value.

SSD (cm)

90

100

110

MOSFET

1.004

1.000

1.002

8.3.1.2. Field size dependence

The MOSFET sensitivity varied less than 2.5% over all photon field sizes and
less than 1.0% for the field sizes smaller than 20×20 cm2 that are usually included in
IMRT fields for NPC treatments (see Table 8.2).

Table 8.2 Field size dependence for MOSFET detectors in high energy photon beams. All the
measurements were normalized to 10×10 cm2 value.

Field size (cm)

5×5

10×10

20×20

30×30

40×40

MOSFET

1.004

1.000

1.009

1.023

1.019

8.3.1.3. Energy response

The PDD measurement differences between MOSFETs and ionization chambers
were within 2.5% for depth up to 15.5 cm and within 3.5% for depths from 16.5 cm to
19.5 cm, respectively (see Figure 8.4).
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Figure 8.4 Depth dose measurement for a 10×10 cm2 field using MOSFET detector and
ionization chamber, respectively, from depth of dmax to 19.5 cm.

8.3.2.

Feasibility of MOSFET detectors for IMRT plan verification in phantom

Table 8.3 shows a comparison of MOSFET measurements with 0.6 cm3
ionization chamber results at the target region for eight serial tomotherapy plans. The
percentage deviation between MOSFET measurements and TPS calculations was on
the average 0.77±1.50%, while the mean deviation between ionization chamber
measurements and TPS calculations was 0.54±1.56%. No significant difference was
found between these two detectors (P>0.05), indicating that the MOSFET detector is
comparable to the ionization chamber for dose verification of IMRT QA plan.
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Table 8.3 In-phantom verification of IMRT target dose using both MOSFET detector and 0.6
cm3 ionization chamber (Unit: Gy).

NPC
patient
1
2
3
4
5
6
7
8
AVE
t test

Ionization chamber

MOSFET

Calc

Meas

Diff(%)

Calc

Meas

Diff(%)

1.98
2.05
2.06
1.89
2.10
2.08
2.12
2.08

2.03
2.08
2.04
1.91
2.11
2.05
2.17
2.06

2.53
1.46
-0.97
-1.06
0.48
-1.44
2.35
0.96
0.54±1.56

2.07
2.06
2.08
1.84
2.13
2.09
2.10
2.10

2.12
2.10
2.06
1.83
2.16
2.06
2.14
2.13

2.42
1.94
-0.96
-0.54
1.41
-1.43
1.90
1.43
0.77±1.50
P=0.18

Table 8.4 In-phantom verification of IMRT in high dose gradient region using both MOSFET
detector and 0.125 cm3 ionization chamber (Unit: Gy).

NPC
patient
1
2
3
4
5
6
7
8
AVE
t test

Ionization chamber

MOSFET

Calc

Meas

Diff(%)

Calc

Meas

Diff(%)

0.72
0.78
0.70
0.69
0.72
0.71
0.78
0.81

0.75
0.80
0.71
0.72
0.71
0.72
0.80
0.78

4.16
2.56
1.43
4.35
1.39
1.40
2.56
-3.70
1.77±2.51

0.85
0.77
0.71
0.76
0.71
0.68
0.75
0.75

0.87
0.76
0.72
0.79
0.69
0.69
0.76
0.74

2.35
-1.30
1.41
3.95
2.81
1.47
1.33
-1.33
1.34±1.86
P=0.55

In table 8.4, the mean dose deviation measured in the relatively high-dose
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gradient region by MOSFETs was 1.34±1.86%, while it was 1.77±2.51% by the 0.125
cm3 ionization chamber. The t-test showed that there was no statistically significant
difference between MOSFET measurements and ionization chamber results (P>0.05).
Compared with the ionization chamber, a smaller standard deviation was associated
with MOSFET measurements, implying that the MOSFET detector might be more
suitable for measurement in regions with steep dose gradient.

8.3.3.

Clinical results of MOSFET real-time in vivo measurements

After ensuring accurate positioning of the oral plate with MOSFET detectors by
portal films, the deliveried doses of serial tomotherapy for 8 NPC patients were
measured in vivo.

Figure 8.5 shows a sample of real-time in vivo measurements for a single
treatment arc during the MIMiC IMRT delivery. The measured integral dose deviated
from the planned dose by about 2.21% in this case.

In a total of 48 in vivo verification measurements, the overall deviation of
delivered doses was on average 3.33%, ranging from -2.20% to 7.89%. Less than 5%
deviation from the planned dose was measured in 92% of all cases (see Figure 8.6).

The dose difference between the MOSFET measurements, averaged over all
measurement days for individual patients, and the planned values varied from -0.93%
to 5.52% (see Figure 8.7). The observed standard deviation of day to day MOSFET
measurements of each patient was all less than 1.5%, indicating that this measurement
setup is highly reproducible.
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Figure 8.5 A sample measurement of IMRT in vivo doses during a treatment fraction for a
NPC patient using a real time MOSFET dosimetry system.

Figure 8.6 Frequency of measurements with discrepancies (in percentages) between measured
and calculated values for IMRT treatments.
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Figure 8.7 The dose difference between the MOSFET measurements, averaged over all

measurement days for individual patients, and the planned values. The error bars
correspond to one standard deviation.

8.4.

Discussion

The complexity of serial tomotherapy IMRT has enhanced the need for more
extensive and more frequent diagnostic testing than is the case for traditional
three-dimensional radiation therapy. A rigorous quality assurance program is therefore
essential to identify errors before treatment starts, and to ensure accurate treatment
delivery. In addition to the standard quality assurance methods via point
measurements (Dong et al 2003, Leybovich et al, Bouchard et al 2004) and film
dosimetry (Winkler et al 2005, Fiandra et al 2006, Sankar et al 2006), in vivo
measurements offer a unique treatment monitoring technique for IMRT delivery
especially in the treatment process.
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The use of MOSFET as an in vivo dosimeter has several advantages, such as
small detector size, ease of use, real time readout and negligible perturbation of the
radiation (Quach et al 2000, Chuang et al 2002, Ramaseshan et al 2004). Our
investigations show that the MOSFET sensitivity does not change with SSD.
Considering that the IMRT field size is usually smaller than 20×20 cm2 for NPC
treatment, the MOSFET detector, even without further field size dependence
correction, can still give dose accuracy within measurement uncertainty. As for the
energy response, the sensitivity variation of the MOSFET detector with depth due to
changes in the radiation energy spectrum is negligible in high energy photon fields.
These dosimetric characteristics suit the requirements of routine in vivo measurement
for serial IMRT delivery. In addition, the fact that a small standard deviation is
associated with our in-phantom MOSFET measurements in the high gradient dose
region supports that the MOSFET detector is a good candidate for IMRT dose
assessment not only in the homogeneous area but also in the rapid dose fall-off
region.

Importantly, the used MOSFET dosimetry system is able to give a real time
response in terms of accumulated dose variation or instantaneous dose rate, making it
particularly attractive for online validation of dynamic IMRT. As shown in the present
study, MOSFETs are convenient to be used in meaningful locations in head and neck
IMRT to monitor the daily intrafraction variation of the delivered dose to critical
organs. Since MOSFET detectors are positioned inside the treated volume, this in vivo
dosimetry method is sensitive to significant errors due to human errors or system
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malfunction and breakdown. By this means, it is possible to duly terminate incorrect
treatment delivery in case of gross error occurring so as to avoid severe injury to the
patient.

We currently use this MOSFET in vivo dosimetry method as the final stage of our
QA procedures in serial tomotherapy IMRT treatments for NPC. Online
measurements are usually performed on a routine basis. With the patient still in the
treatment position, the MOSFET detects a total dose error which may have many
components such as interfraction setup error, plan computation inaccuracy,
physiologic organ motion, and etc. Following the recommendations of the ICRU
report 50 (1993), a tolerance range of -5 to +7% has been taken as our action levels
for in vivo dose verification on individual patient. Whenever a MOSFET signal falls
outside this dose deviation window, the treatment is suspended and a detailed review
of the whole treatment process is required. Appropriate adjustment, if necessary, can
then be made to the treatment parameters for the following fractions in order to bring
the overall treatment back in-line with expectations.

During the in vivo measurements, we find that an important prerequisite for
accurate MOSFET dosimetry is accurate and reproducible detector positioning. To
facilitate MOSFET use, we make use of a special molded oral plate, similar like the
method introduced by Marcie et al (2005) that allows detector positions to be
reproduced in the mouth. An improvement in our measurements is to fix the MOSFET
detectors in the flat, relatively rigid body of the oral plate. This can avoid the possible
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distortion of the catheter and offers better positioning accuracy for MOSFETs against
the tongue surface. A good reproducibility with small standard deviation has been
observed in our repeat in vivo measurements throughout the 6-week course of IMRT
treatment. Meanwhile, it is evident from our investigations that the use of the
MOSFET detector and the oral plate do not produce any visible reaction and
noticeable discomfort to the patients.

8.5.

Conclusion

In vivo dosimetry has been demonstrated to be a valuable technique among the
standard quality assurance methods used in a radiotherapy department. Due to the
small physical size, ease of use and real time readout, the newly developed in vivo
MOSFET detector can be easily positioned inside a critical organ to verify the true
delivered dose relative to predictions for NPC patients undergoing serial IMRT
treatments.
Since in vivo dosimetry measurements are performed in a region with relatively
steep dose gradients, the positioning accuracy of the MOSFET detector is a key issue
for accurate in vivo dosimetry. The special molded oral plate, custom-made for each
patient, can allow positions to be reproduced in the mouth during the whole treatment
course.
The developed MOSFET Dosimetry system has undergone rigorous development
and calibration protocols. The use of this MOSFET detector and the oral plate do not
produce any visible reaction and noticeable discomfort to the patients. The method we
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presented here is universal and can be applied in all cases for which the
nasopharyngeal dose is of concern.
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CHAPTER 9
Conclusion and Future Work

9.1.

Thesis Conclusions

9.1.1.

Advantages and disadvantages of traditional MOSFET designs

In this thesis, the physical performance of some commercial MOSFET detectors
has been fully investigated, including the active mode RADFET dosimeter and the
passive mode OneDoseTM MOSFET detector. With proper calibration and correction,
both of these detectors have shown their suitability for dosimetry in high energy
photon and electron fields.

The RADFET dosimeter, with a positive gate bias of 5 V applied during
irradiation, has improved sensitivity and linearity than the zero-biased OneDoseTM
MOSFET detector. It can provide a much higher dose range up to 24 V. Although the
radiation response of the MOSFET detector may not be completely linear over the
whole voltage range, this effect can be simply minimized by periodic calibrations on
weekly or monthly frequencies. Compared with the passive mode MOSFET, the
RADFET dosimeter exhibits more attractive physical characteristics and higher
cost-effectiveness ratios.

The main limitations of these two MOSFET designs are their relatively large size
and obvious angular dependence. In order to place the MOSFET detector inside the
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patient for in vivo dosimetry, a miniature-size dosimeter is preferred. Also the angular
dependence of the MOSFET detector prevents it from being used in more complicated
treatment conditions such as in IMRT and HDR brachytherapy.

9.1.2.

Characteristics and performance of the new MOSFET detector

Recently at CMRP we have developed a miniature MOSFET detector (MOSkinTM)
utilizing a novel packaging technology that yields a minimal but highly reproducible
intrinsic buildup suitable for dose measurements in rapidly changing dose gradients.

The new MOSFET detector carries many advantages as expected. It can provide
dose accuracy within measurement uncertainty for applied doses above 20 cGy and
within ±1 mV for small doses less than 10 cGy. The detector response nearly keeps
constant across the tested range of energies and modalities in both high energy photon
and electron beams. With a positive gate bias of 5 V applied during irradiation, the
MOSFET detector presents a linear response (R2=1) for a measured dose range of 5
cGy to 200 cGy.

Unlike semiconductor diodes, the MOSFET detector is dose-rate independent and
its sensitivity dose not change with SSD. For field sizes smaller than 20×20 cm2, the
sensitivity variation of the MOSFET detector was found to be within 1.0%. By
selecting the readout current corresponding to a thermostable point, the temperature
sensitivity of the MOSFET readings is minimized.

More importantly, the new MOSFET detector has an isotropic response with
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variations of less than 2% over full 360° measured in a cylindrical phantom of 10-cm
diameter. The detector size has also been well controlled so that the detector can be
held in a small brachytherapy catheter. These advantages are among the reasons that
this new MOSFET detector is a good candidate not only for routine in vivo dosimetry,
but also for more advanced techniques such as IMRT and HDR brachytherapy.

9.1.3.

Clinical applications

(1) Verification of the plan dosimetry for HDR brachytherapy

The feasibility of the new CMPR MOSFET dosimetry system for dose
verification of HDR brachytherapy treatment planning has been investigated.

As above mentioned, one of the major difficulties in measuring the absolute dose
rate in the vicinity of the
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Ir source is dosimeter energy dependence. Like the

RADFET and many other dosimeters, the new miniature MOSFET also over-responds
to low energy photons. To overcome this problem, a simple method has been used to
characterize the dosimeter’s energy response in the
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Ir energy spectrum and

determine the proper correction factors. It has proven to our satisfaction that the new
CMRP MOSFET detector can provide a reliable tool for confidence checks of HDR
brachytherapy treatments.

At present, direct dose measurement in phantom with the miniature MOSFET
detector has been taken as a standard QA program in our center for CT-based HDR
intracavitary brachytherapy. This process offers an additional opportunity for the
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prevention of human errors and system malfunctions. In addition, the phantom
measurement helps build confidence for users to proceed with future in vivo
dosimetry using MOSFET detectors.

(2) In vivo verification of superficial dose for head and neck treatments

Skin dose is one of the key issues for clinical dosimetry in radiation therapy.
Currently planning computer systems are unable to accurately predict dose in the
buildup region, leaving ambiguity as to the dose levels actually received by the
patient’s skin during radiotherapy. This is one of the prime reasons why in vivo
measurements are necessary to estimate the dose in the buildup region.

The new miniature MOSFET detector, which is encapsulated into a thin water
equivalent film, has a minimal but high reproducible intrinsic buildup of 7mg/cm2
recommended for skin dosimetry. Phantom investigations have demonstrated the
MOSFET detector agrees well with the Attix chamber and the EBT Gafchromic®
film in terms of surface and buildup region dose measurements at the same mass
equivalent depth, even for oblique incident beams.

To date, in vivo skin dosimetry with miniature MOSFET detectors has been
performed for a total of 16 measurements of 6 NPC patients receiving serial
tomotherapy IMRT treatments. The dose difference between MOSFET measurements
and TPS calculations is on average −7.2%, ranging from −4.3% to −9.2%. It has been
recognized that in vivo skin dosimetry can help our doctors to better analyze IMRT
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treatment plans, especially in cases where a compromise between tumor coverage and
skin toxicity should be made.

(3) Real-Time in vivo dosimetry for HDR intracavitary brachytherapy

The new MOSFET dosimetry system has an advantage over many other
dosimeters in its ability to provide real-time dose information. This feature has been
utilized to avoid therapy misadministration for HDR intracavitary brachytherapy.

Due to the small physical size, the miniature MOSFET detector can be easily
placed within the patient’s nasopharynx through a brachytherapy catheter. It is thus
possible to evaluate and document, in real time, the actual dose to the tumor received
by the patient during a treatment fraction. Through an online comparison between the
measured dose and the calculated value, significant dose errors resulting from either
human errors or machine malfunction can be detected at the onset of treatment that
otherwise would be unnoticed.

A total of 70 in vivo measurements in 11 NPC patients have been performed
during this project. The preliminary results confirm that this new MOSFET dosimetry
system, with advantages of small detector size, ease of use and real time readout,
offers another line of security to detect and prevent large errors. The developed
method is universal and can be applied in any other cases of clinical interest.

(4) Online in vivo dosimetry for serial tomotherapy of head and neck patients
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Currently most of in vivo dosimetric measurements performed in the clinic serve
the purpose of measuring either the entrance or exit dose, and detectors are typically
placed at a surface site. However, in IMRT, beam fluence is not uniform, in which
case those entrance or exit measurements are not well correlated with the dose at
depth. Therefore, in this project, we developed an oral plate by means of which the
miniature MOSFET detector can be directly placed inside the oropharynx to verify the
true delivered dose relative to predictions for NPC patients undergoing IMRT
treatments.

Our in phantom study and in vivo measurement results have demonstrated the
suitability and efficiency of this new MOSFET dosimetry system in avoiding therapy
misadministration as well as in evaluating the actual dose within individual patients
during the IMRT treatment. The new MOSFET detector, due to its small size, is
convenient to be used in meaningful locations in head and neck IMRT. The special
molded oral plate, custom-made for each patient, can allow positions to be reproduced
in the oropharynx during the whole treatment course.

9.1.4.

Research contributions

More than five years have passed since we initiated this MOSFET dosimetry
project under the bilateral CMRP/SYSUCC collaboration. The pilot studies described
in this thesis have resulted in a broad application of MOSFET in vivo dosimetry in
routine clinical practice at SYSUCC.
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The research has contributed to the field of radiation therapy in the following
ways:
(1) We have provided a detailed description of the calibration procedure for the
MOSFET detector. This can be taken as a general guideline to assist clinical
physicists in performing reliable dose measurements using MOSFETs in daily
practice.
(2) We have developed a new miniature MOSFET detector using a special packaging
technology. The characteristics and performance of this detector has been well
documented. This provides a useful tool not only for routine QA but also for in vivo
assessment of radiation dose to organs at risk.
(3) We have introduced a simple method to characterize the dosimeter’s energy
response in the 192Ir energy spectrum. The MOSFET detector, with proper corrections,
has proven to be suitable for absolute dosimetry in the context of HDR brachytherapy.
This extends the use of MOSFET detectors to the low-energy kV x-ray range.
(4) We have demonstrated that the new MOSFET detector, with a minimal but high
reproducible intrinsic buildup of 7mg/cm2, is a good candidate for skin dosimetry.
This diversifies the use of MOSFET detectors for dosimetry in radiotherapy and
radiation protection fields.
(5) We have explored novel methods to perform real-time in vivo dosimetry with
miniature MOSFET detectors for HDR brachytherapy as well as for serial
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tomotherapy IMRT. These in vivo dosimetry practices help improve the safety and
efficiency of radiation treatment of cancer patients.

9.2.

Future Works

9.2.1.

Developing a linear MOSFET-array dosimeter

In this thesis, we have a major focus on the development of a simple point dose
method for in vivo monitoring and verification of HDR treatment and serial
tomotherapy IMRT. Hence only a single MOSFET detector has been used in our
phantom measurements and in vivo applications.

It is known that a linear array dosimeter, consisting of a chain of MOSFETs, can
provide a one-dimensional dose profile across the target volume. This would offer an
advantage over point dosimeters that a single measurement may yield sufficient
information for patient dose assessment. As such a detector array may better serve the
purpose of in vivo dosimetry, it is now under research by ours and other groups.

Future work will include a comprehensive investigation on its dosimetric
characteristics for both HDR brachytherapy and serial tomotherapy IMRT. Also, in
future development, the external dimensions of the array dosimeter will be
significantly reduced to permit its use in brachytherapy catheters.

9.2.2.

Extending the MOSFET applications

The current research has resulted in a broad implementation of MOSFET in vivo
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dosimetry in routine IMRT treatment and HDR brachytherapy at SYSUCC. However,
in recent years, there have been a number of new techniques being introduced to the
clinic such as image guided radiation therapy (IGRT) and large bore CT scanner.
Although these advanced imaging modalities bring improved treatment accuracy, the
increasing imaging procedures may result in an additional significant dose to the
patient.

Future work will extend the use of MOSFETs to the diagnostic imaging field.
This may relate to point estimates of organ dose within an anthropomorphic physical
phantom or in vivo measurement of entrance surface dose at diagnostic x-ray energies.
Also, for these low dose measurements, the sensitivity and the bias voltage of the
MOSFET detector may need to be re-optimized to achieve sufficient accuracy.
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